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Abstract 
The data presented in this thesis has been organized in three parts: First part included the development 
and validation of a quantitative HPLC-DAD analytical method of mephedrone after extraction from 
spiked whole blood and serum samples, alone and with methcathinone. The second part included in 
vitro metabolism of mephedrone and other NPS, which are methoxetamine and methcathinone, using 
an in-house prepared in vitro metabolic system, namely liver microsomes, followed by performing 
analysis for the drugs and their proposed metabolites utilizing LC-MS. Third part included in vitro 
studies of selected NPS using purchased HepaRG and hepatocytes. In vitro study included in vitro 
cytotoxicity studies of 4-fluoromethamphetamine, mephedrone, methoxetamine and methcathinone, 
and analytical studies of these drugs of abuse and their potentially produced metabolites using GC-
MS. 
In the first part of this thesis, a HPLC method for the analysis of mephedrone after LLE from blood 
matrix was developed and validated and shown to be linear with R2> 0.995, precise with intraday 
and interday RSD values of 4.36 and 4.77% respectively and LOD and LOQ of 0.025 and 0.082 
µg/mL respectively. Recovery percentages were low and ranged between 28-37%. Emulsion 
formation was the major problem effaced which negatively affected recovery and precision values. 
The previously developed method was optimised and fully validated for the simultaneous analysis 
of mephedrone and methcathinone after liquid-liquid extraction (LLE) from whole blood and serum 
samples. The LLE method was optimised through selection of extraction solvent and adjustment of 
pH values achieving the best validation parameters and minimal emulsion formation. The LLE 
protocol involved extraction with a mixture of dichloromethane: n-butanol (80:20 v: v) after 
buffering the sample with borate buffer pH=9.2 and using aniline as internal standard. The HPLC-
DAD method was optimized, using reverse mode chromatography and buffered mobile phase of 
(acetate buffer pH 4.1: ACN – 85:15) for qualitative and quantitative analysis of these drugs in less 
than 10 minutes under isocratic elution and ambient temperature. The method was fully validated for 
both drugs and showed to be linear over the specified range of 0.1-10 µg/mL with R2 > 0.99 for both 
drugs. The accuracy was assessed by calculating percentage recovery at different concentrations for 
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both drugs, and retained recovery percent between 84-110%. For repeatability and intermediate 
precision tests, RSD values were ≤ 6.73%. Specificity was assessed by good resolution between the 
peaks and by checking peak purities. Limit of detection and limit of quantification, calculated 
mathematically for both drugs either extracted from whole blood or serum samples, were 0.010- 
0.013 µg/ml and 0.032 - 0.043 µg/mL, respectively. 
In the second part, in vitro studies on the metabolism of the selected NPS using pig liver microsomes 
and liquid chromatography-mass spectrometry (LC-MS) analysis were performed. Microsomes were 
prepared by a conventional ultracentrifugation method. In brief, pig liver was brought freshly from 
local abattoir, sliced into small pieces, homogenised and ultra-centrifuged to produce microsomes 
and S9 fractions. Produced microsomes were incubated with the drugs of interest under optimised 
conditions and followed by analysis utilizing LC-MS for the detection of the drugs and the potentially 
produced metabolites. It was possible to detect two metabolites of the drug mephedrone, 
hydroxytolyl-mephedrone and nor-dihydro mephedrone. For MXE, one metabolite produced by the 
O-demethylation was detected and it identity confirmed by MS/MS study to be o-desmethyl-MXE.  
Another metabolite was detected is suggestively produced by the reduction of the ketone moiety to 
produce dihydro-MXE or by two steps of O-demethylation and hydroxylation to produce O-
desmethyl –hydroxy-MXE. However, due to low intensity signal recorded, MS/MS study was not 
conclusive for the identity of the molecule 
In the third part, two types of hepatocytes were used for the study of the metabolism and cytotoxicity 
of the selected NPS - Mephedrone, Methoxetamine, Methcathinone and 4-Fluoromethamphetamine. 
Studying the metabolism of selected NPS followed utilizing HepaRG™ followed by GC-MS 
analysis, it was possible to detect new peaks in the chromatograms of mephedrone and methcathinone 
which is suggestively the product of N-demethylation.  However, it was not possible to detect any 
new peaks in the chromatograms of methoxetamine nor 4-flouromethamphetamine.  The cytotoxicity 
study utilizing HepaRG cell line showed that these drugs have cytotoxic effects causing in vitro cell 
death, within the specified range of 4.0x10-2-1.6x101 mM. These drugs were able to cause 43-83% 
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cell death, and EC50 values were 0.2323-0.6297 mM. The most potent drug was 4-
fluoromethamphetamine, while mephedrone showed the least biological effect to produce. 
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Chapter 1  Introduction 
1.1.  Aims and objectives 
A huge number of novel psychoactive substances (NPS) have appeared recently on the market. Those 
NPS are being easily obtained via Internet websites or through so-called ‘headshops’ or ‘smart 
shops’. These substances are sold labelled ‘not for human consumption’. However, they are 
purposefully marketed as replacements for illegal drugs. In fact, in most cases these NPS are very 
closely structurally related to controlled psychoactive molecules in order to create alternative 
psychoactive compounds. Due to this structural relationship, these NPS may show similar clinical 
and toxic effects similar to controlled ones. The misleading idea of being ‘safe’ drugs because of 
their legality in many countries, strongly increased the use of these substances, especially among 
young age groups of 15-64 years old. Cathinone derivatives, along with synthetic cannabinoids, 
represent currently about two-thirds of all substances notified since 2005 (Kelly, 2011; Araújo et al., 
2014).  The abuse of novel psychoactive substances (NPS) have been a matter of concern for public 
health, many cases of death because of intoxication with these chemicals have been recently reported. 
However, this phenomenon is undervalued in the EU because the outdated toxicological screening 
tests do not cover the wide range of these novel molecules. The rapidly increasing number of 
constantly varying NPS makes their identification and the study of their analytical and toxicological 
profile an extremely difficult task, especially when standards are not available (Rosner et al., 2005; 
Kelly, 2011; Favretto et al., 2013; Araújo et al., 2014). 
Due to these restrictions, the aims of the current work were developing novel approaches for the 
analysis of drugs of abuse that keep in pace with rapidly appearing ‘NPS’ and able to provide real 
time information about the toxicity and risks associated with these drugs. 
The availability of HPLC instruments and DAD type of detectors is advantageous as a preliminary 
quantification tool for NPS. HPLC-DAD methods are quiet easy to develop, specific and robust for 
identification and quantification NPS. The aim of the first part of this thesis research was to develop 
validated methods for the analysis of only mephedrone, with other drugs, in presence of adulterants 
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and related cathinones after extraction from biological samples. This method can be helpful for future 
analysis of other appearing NPS both qualitatively and quantitatively. 
The limited data about metabolic studies of NPS is another concern while researching NPS. The 
second part of this thesis research started with limited data available about the previously studied 
mephedrone and another emerging NPS, MXE. Due to ethical limitation of researching these NPS 
in vivo, either in clinical setup or using animal models, in vitro approaches were selected for 
metabolic studies of NPS. Though in vitro studies are well established in medicinal drugs industry, 
the use of in vitro models is limited in the field of forensic study of drugs of abuse in general. In vitro 
biological studies have many advantages over in vivo studies, such as relatively lower cost, effort 
and time. Additionally, it fulfils the ethical requirements with minimal harm to animals. 
Consequently, the aim at this stage of study was to develop a satisfactory in vitro metabolizing model, 
by preparing microsomes from slaughtered pig liver cells and using these microsomes for 
metabolizing the selected NPS. This in vitro studies are followed by developing an analytical method 
applying the power of the modern instruments of chromatography coupled to mass spectrometry in 
order to detect these drugs and their potential metabolites. 
In the third part of the work, the aim was to develop another in vitro model using human cells for a 
metabolizing system, hepatocytes. The aim was to research any variation between metabolising 
capacity of different in vitro system of different sources. In vitro studies using hepatocytes was 
followed by analysis of the selected NPS using GC-MS together with cytotoxicity studies about the 
impact of this selected NPS on the cell viability and if any relation existed between the type and 
amount of produced metabolites and any toxic effects observed. 
To the best of knowledge, limited data are still available about metabolism of the selected NPS, 
namely Mephedrone, Methoxetamine, Methcathinone and 4-Fluoromethamphetamine, and other 
traded NPS. The currently available data do not fulfil the critical need for analysis of these significant 
drugs of abuse. 
  
  Introduction 
3 
 
1.2.  Epidemiology of drug abuse 
Drug abuse can be defined as the use of a pharmacologically active substances for non-medical 
purposes. The cultural problem of drugs abuse is not a modern dilemma; as the history of drug intake 
can be traced from the days of ancient Greece, where from that time to the present, religious and 
legal attempts have been performed in order to control drug abuse and trade (Lambert, 1998; 
Compton et al., 2005; Sloboda, 2005). 
Drug abuse is worldwide problem, though there are variable trends between regions, age groups and 
genders. In general, men are at least two times more likely than women to have drugs of abuse. 
Worldwide, about 5% (243 million) of the population of the age group 15-64 years had used, at least 
once, one or more of drugs of abuse, as being estimated in 2012. However, about 27 million of the 
world population regularly use drugs of abuse (UNODC, 2014). 
Drugs of abuse are of critical concern for the public and the authorities because of the devastating 
effect they have, where drug related death is the most dangerous effect. Worldwide, it is estimated 
that in 2012 drugs were the cause of death of about 183,000 people in the 15-64 years’ age group 
(UNODC, 2014). 
The National Program on Substance Abuse Deaths (NPSAD) publish an annual report about drug 
related deaths all over UK and islands. The data collected are reported by coroners, police forces, 
statistic and research agencies. There are minor differences in the inclusion criteria for the drug 
related deaths between geographical areas. In general , for the 2013 annual report, a death fell within 
the NPSAD criteria for drug related deaths when: one or more psychoactive substance directly 
associated with death: history of abuse or dependence : presence of controlled substances in post-
mortem samples or when the death is directly caused by drugs but with no investigation According 
to the NPSAD drugs were the cause of death in at least 2478 cases in 2012 compared to at least 2952 
cases in 2011 all over the UK and islands  (Ghodse et al., 2013). According to study conducted by 
Bargagli et al. during 1990-1998 about the estimated mortality rates of opiate users in Amsterdam, 
Dublin, Barcelona, Lisbon, Rome, Vienna, Denmark and London, opiates were the cause of death in 
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10-20% of mortalities in the 15-49 years old age group in these eight European countries. The study 
showed that mortality rate within opiate users is 5-54 times higher than general population (Bargagli 
et al., 2006). 
Non-fatal cases of drug abuse are also important. It is estimated that in Europe, for each one fatal 
drugs related death there are another 20-25 non-fatal cases of overdose. The importance of these non-
fatal cases is that they contribute to morbidity that may need hospitalization due to different side 
effects of drugs of abuse. In more serious cases they may end with some sort of disability, mainly 
due to brain damage. In addition, drug abuse is negatively affecting the quality of life and it is a 
major cause of either long or short term health impairment. For example, the prevalence of 
transmitted infection, mainly HIV, is estimated to be 22-50 higher between drug abusers compared 
to the general population (UNODC, 2014). 
The adverse effects of drug abuse involve not only the individuals who abuse drugs, but also their 
families and friends, government resources and the whole society. Families will be affected by the 
feeling of guilt and stigmatization by the community as well as financial impacts in terms of cost. 
The attempt by drug abusers to manage their drugs costs by stealing from families is an example of 
financial cost. The social impact relies on the cost to cover the care and rehabilitation costs. Drug 
users need extensive medical treatment; some may abuse or neglect their families; some may commit 
crimes including domestic violence, assault, and theft. As an example, the economic cost of illicit 
drug use on American Society in the year 2007 was about $193.1bilion. In comparison to other 
societal costs, it is more than the estimated costs of diabetes in the year 2008 which were estimated 
more than $174 billion, and more than the medical costs associated with obesity in the year 2008 
which were estimated more than $147 billion (National Drug Intelligence Centre, 2011). 
In UK, the ‘Misuse of Drugs Act 1971’ governs the legal status of drugs. The ‘Misuse of Drugs Act 
1971’ categorizes controlled drugs into three classes, A, B and C. Under the force of this act the 
importation, exportation, production, possession and supply of controlled drugs is completely 
restricted (Parliament of the United Kingdom, 1971). Although the primary act was implemented in 
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1971, the Advisory Council on the Misuse of Drugs regularly updates the legal framework in 
response to national and worldwide drug threats. 
1.3.  Novel Psychoactive substances 
Novel Psychoactive Substances (NPS) are a variable class of compounds, rapidly appearing in the 
illicit drug market that show significant psychoactive effects. These substances often have no 
limitations on commercial delivery as they claim to contain ‘non-illegal’ compounds. It is estimated 
that 20 or more NPS appear annually, either through the internet or through what is known as ‘smart 
shops.’ 
In general, NPS can be considered into four categories: substances available under trade names 
without indication of their contents, related medicinal chemicals, natural herbal extracts or fungal 
products and substances specifically designed with minor alterations to simulate the effect and/or the 
chemical structure of known controlled drugs (ACMD, 2011). 
The term ‘Designer Drugs’ is mainly used to describe one category of NPS, which is produced by 
performing minor alterations to one or more functional group of a chemical with known 
pharmacological activity, to avoid the legal regulations and to produce more effective substances 
(Henderson, 1988; Christophersen, 2000; Camilleri et al., 2010). ‘Designer drugs’ are usually 
synthesized, distributed and used in low levels and within small sub-populations, which makes their 
detection and control challenging for authorities and scientists (Wills, 2005; EMCDDA, 2010). 
Characteristic examples of NPS are synthetic derivatives of cathinones and synthetic cannabinoids. 
The expressions ‘Designer Drugs’ or ‘legal Highs’ were used in literature interchangeably to refer to 
NPS, while the term NPS is an expansive descriptive term for these versatile groups of drugs. In fact, 
it is advised not to use the term ‘Legal Highs’ in order to avoid confusing the public as this term may 
reflect positive euphoric effects in addition to the legality of these substances. Also, the use of the 
term ‘legal highs’ to describe these groups of drugs, can give a false impression about the safety of 
these drugs.  Legal Highs are usually traded as research chemicals, bath salts or plant food, with 
some mentioning clearly the contents. However, it has been reported that legal highs available on the 
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internet do not always contain the labelled drug, but caffeine or any other controlled drug 
(EMCDDA, 2011; Baron et al., 2011; Prosser and Nelson, 2012; Favretto et al., 2013). 
During 2009, 24 new synthetic substances were reported for the first time in European Union (EU), 
and by mid of July 2010; another 15 new synthetic substances were added to the list.  In 2014, 
additional 101 novel designer drugs were reported, of which 31 drugs were cathinones. Therefore, 
the entire number of designer drugs examined by the European Monitoring Centre for Drugs and 
Drug Addiction has exceeded 450 (EMCDDA, 2015). Due to this rapidly appearance of NPS, and 
mainly the lack of standard references, the development of new analytical methods to detect 
‘Designer Drugs’ is a significant challenge for the forensic scientists. 
The synthetic cathinones are one of the major groups of designer drugs. Synthetic cathinones are 
central nervous system stimulants, and are abused for their stimulant Amphetamine-like effects 
including enhanced energy and increased libido. They are chemically similar to Cathinone ((S)-2-
amino-1-phenyl-1-propanone), a naturally occurring stimulant alkaloid with beta-ketone skeleton 
found in the fresh leaves of the Catha edulis (Khat) plant. Leaves of Khat have been chewed since 
the tenth century in some African countries and very widely in Yemen.  In UK, cathinone is classified 
C drug in Schedule 1 of the UK 1971 Misuse of Drugs Act. Bupropion is the only synthesized 
cathinone-derivative that was approved for therapeutic purposes in Europe; and it is medically 
indicated now as an antidepressant and as an aid in smoking-cessation (Gibbons and Zloh, 2010; 
Winstock and Wilkins, 2011; Kavanagh et al., 2013). 
Synthetic cathinones are sold mainly as blends of white powder, crystalline salts and liquid forms, 
though oral tablet and capsules preparation are also available. Current studies show that the main 
mechanism of action of synthetic cathinones is the dysfunction of central monoamine systems that 
apparently cause their interactive properties (Prosser and Nelson, 2012). 
The beta-ketoamphetamines, with methcathinone and mephedrone as better-known members of this 
family, as examples of synthetic cathinones, have rapidly entered the drug market in the last few 
decades (EMCDDA, 2010; Grueninger and Englert, 2011). Methcathinone and mephedrone were 
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reported to be synthesized in 1929. Their abuse started in the early 1990s for Methcathinone and the 
early 2000s in the case of mephedrone. Though little data are available on the clinical and 
toxicological profiles of the synthetic cathinone derivatives, the reported side effects of these 
derivatives are similar to those related to cathinone intake: elevated blood pressure, increased heart 
rate, probable risk of myocardial infarction and duodenal ulcers (Gebissa, 2010; Al-Motarreb et al., 
2010). In general, synthetic cathinones have nearly similar clinical and toxicological effects to each 
other and naturally occurring cathinone and amphetamines, which can be explained by the structural 
similarity of these drugs (Figure 1) 
 
Figure 1: Structural similarity of amphetamine, cathinone, methcathinone and mephedrone 
 
 
1.3.1.  Mephedrone 
Mephedrone, (4-methylmethcathinone, IUPAC: 2-Methylamino-1-p-tolyl-propan-1-one) is a 
synthetic cathinone derivative (see Figure 1 above), where the history of mephedrone synthesis dates 
back to 1929, when it was reported by Saem de Burnaga Sanchez (Europol-EMCDDA, 2010). No 
much data is available about the clinical or toxic effects of mephedrone, and it has never been 
licensed as a medicine anytime since its first appearance in the illicit drug market in 2007 (WHO, 
2014). 
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Mephedrone started to appear online and become available in 2007 (Schifano et al., 2010), and it 
was traded and consumed legally in many countries. It was late April 2010 when mephedrone was 
added to the list of the illegal drugs of abuse in UK, after some fatalities were related to the drug. By 
the end of July 2010, mephedrone was also identified in at least 38 drug-related fatalities, whereby 
in two cases mephedrone was the only detected drug (Morris, 2010) 
Mephedrone comes in forms of powder, tablets or capsules. It may be swallowed, injected, snorted, 
smoked or even taken rectally. The most common effects reported with mephedrone intake include 
euphoria, tachycardia, agitation, anxiety and tremor. These effects are similar to the typical effects 
of cathinone, which have similar effects to the amphetamines group which include also elevated 
blood pressure, increased heart rate, probable risk of myocardial infarction and duodenal ulcers 
(Bentur et al., 2008; James et al., 2010; Gebissa, 2010; Al-Motarreb et al., 2010; Grueninger and 
Englert, 2011). 
Since its appearance in 2007, work concerning mephedrone has been related to developing analytical 
methods for the identification of the drug and its metabolites in biological samples utilizing different 
analytical instrumentation. For example, these methods mainly utilized LC-MS/MS, GC-MS (Baron 
et al., 2011; Jankovics et al., 2011; Sorensen, 2011) while some utilized HPLC-DAD for qualitative 
and quantitative studies (Singh et al., 2010; Santali et al., 2011). 
1.3.2.  Methcathinone 
Methcathinone (IUPAC: 2-Methylamino-1-phenyl-propan-1-one) is a methyl derivative of cathinone 
which has related chemical structure, and hence similar clinical effects, to amphetamine, to 
mephedrone and to cathinone, with comparable sympathomimetic effects (see Figure 1 above). 
History of synthesis of methcathinone dates back, similar to mephedrone, to the 1920s. The first case 
of methcathinone intoxication was described more than 20 years ago, but nowadays, there have been 
significant increases in both the number of people who use this drug and the total number of cases 
of intoxication. As in the administration of other synthetic cathinones, the most reported route of 
methcathinone intake is through snorting, though oral and intravenous injection are also used. 
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Clinical effects are also similar to cathinones, amphetamine and related drug and include euphoria, 
increased alertness, increased heart rate and blood pressure (Baumann et al., 2013). There are 
publications dealing with analysis of methcathinone utilizing, for example, HPLC-DAD (Golasik et 
al., 2014) or GC-MS (Beyer et al., 2007; Sorensen, 2011). 
1.3.3.  4-Fluoromethamphetamine 
4-Fluoromethamphetamine (4-FMA, IUPAC: [2-(4-Fluoro-phenyl)-1-methyl-ethyl]-methyl-amine), 
is a central nervous system stimulant related to methamphetamine (Figure 2). It is found to increase 
the effectiveness and duration of action of methamphetamine by being an inhibitor of the enzyme 
CYP450, so it reduces its metabolism. Generally, the replacement of a hydrogen atom by fluorine 
increases the lipophilicity, and so increases the drug absorption into biological membranes and its 
passing through the blood brain barrier of central nervous system. Additionally, small covalent radius 
of fluorine assists binding with biological receptors. Rosner et al., 2005; Taniguchi et al., 2010; 
Taniguchi et al., 2013). There is no sufficient data yet known about the metabolism, toxicity and 
clinical effects of 4-FMA. 
 
Figure 2: Chemical structure of methamphetamine and 4-fluoromethamphetamine 
 
 
1.3.4.  Methoxetamine 
Methoxetamine (MXE, IUPAC: 2-Ethylamino-2-(3-methoxy-phenyl)-cyclohexanone) is a 
dissociative anaesthetic that has been traded as a designer drug. It is distributed as a white powder 
under different names, such as Kmax, M-ket and Mexxy. MXE is synthetically derived from 
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ketamine, and shares the same mechanisms of action and clinical effects, with even stronger and 
longer psychoactive effects than ketamine. The first case of methoxetamine abuse that is analytically 
confirmed was reported in 2012. MXE can be administrated sublingually, nasally or parentally, and 
the reported symptoms of MXE include tachycardia, hypertension, confusion, agitation, 
hallucinations, mydriasis, and nystagmus. (Hofer et al., 2012; Coppola and Mondola, 2012). 
 
Figure 3: Chemical structure of Ketamine and methoxetamine 
 
 
As with all other NPS, limited data has been found on the metabolic profile of MXE, though some 
clinical data has been reported in the literature in the last couple of years (Shields, Dargan et al. 2012, 
Hofer, Grager et al. 2012). Little information is available about the study of the metabolism of MXE 
from an analytical point of view. To the best of knowledge, only two recent papers on in vitro and in 
vivo studies (Meyer et al., 2013; Menzies et al., 2013). The in vivo study by Meyer et al. investigated 
the metabolism of MXE using male rats by administration of single dose MXE through gastric route 
and then collecting urine and faeces separately over 24 hours, in addition to urine samples received 
by the authors’ laboratory for toxicological analysis, and the prepared samples were then analysed 
utilizing GC-MS and LC-MS (Meyer et al., 2013). A recent literature review also yielded another 
published work about analytical findings after acute MXE intoxication (Imbert et al., 2014). There 
are no other available data about the acute effects of MXE exposure, and only two more available 
studies about the chronic effects of MXE exposure using animal models (Wood et al., 2012; Yew et 
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al., 2013). The restricted information about the toxicological profile of MXE acted as an incentive to 
developing approaches for the production and identification of its metabolites. 
1.4.  Biotransformation of drugs 
The biotransformation of exogenous chemicals is a main mechanism for drug elimination, and the 
products of the biotransformation mechanism - the metabolites - are generally more polar and water 
soluble than the parent chemical which makes their excretion easier, and so prevents the build-up of 
these exogenous, usually toxic, chemicals in the body. However, sometimes biotransformation does 
not detoxify these exogenous chemicals but produce metabolites that are more toxic than the parent 
molecule. Almost every chemical entering the body undergoes biotransformation reactions catalysed 
by one or, most of the time, more than one enzymatic system.  The type of the catalysing enzymatic 
system and the metabolic pathway the chemical will go through are highly dependent on its chemical 
structure. Chemicals that are structurally similar tend to share the general metabolic pathway and the 
enzymatic group that catalyses their biotransformation. 
Typically, after absorption (A) of any chemical through one or more of the body systems, it will go 
into a detoxification process. The detoxification process starts by distribution (D) of the chemical in 
blood, body fluids and target organs followed by the metabolism (M) of the chemical in different 
body organs. The last stage is the elimination (E) of the chemical and/or its metabolites as body waste 
products. This is known as ADME model, a very important concept in the drug industry, 
pharmacokinetic and toxicological studies. Metabolism, the (M) part of ADME model, is a major 
pathway for detoxification of the chemicals in the body, where it is responsible for about 75% of the 
whole process, either partially or completely. In general, the aim of toxicokinetics and 
pharmacokinetics studies of a chemical is the identification of its ADME parameters (Figure 4). 
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Figure 4:ADME model of the biotransformation of drugs 
 
1.4.1.  Metabolism 
Chemicals entering the body, mainly through gastrointestinal system are metabolized by enzymes, 
which may decrease, increase or totally change their action.  Toxic materials can be detoxified while 
nontoxic drugs can be converted into toxic metabolites.  
Classically, drug metabolism includes two phases; phase I in which nonpolar molecules are changed 
to polar ones, and phase II (conjugation) where glucuronic acid, sulfate, methyl or acetyl moieties 
are added to drugs molecules (Asha and Vidyavathi, 2010). However, Phase III is now added to the 
classical description of chemicals metabolism which is responsible for the transportation of the 
molecules produced from metabolic process from the extracellular into the extracellular space 
utilizing energy and specific transport system (Coleman, 2010).  
Metabolism takes place anywhere in the body, e.g. in the intestines, in the liver and in the kidney. 
However, liver is the major organ responsible for the metabolism of exogenous compounds, greatly 
reinforced by its anatomical position between systemic circulation and the gastrointestinal tract and 
its rich content of metabolizing enzymes, mainly the cytochrome P450 enzymatic system (CYP450). 
Liver is the second largest organ in the body, weighing in an adult human in average 1500 gm, which 
is about 2% of the total body weight. In addition to its major function as a detoxifying organ, liver 
has other important functions, which include: protein synthesis, bile production and hormone 
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production. Chemicals entering the body through the gastro intestinal tract are transported directly 
into the liver via the hepatic portal vein, a major vein in the body, which drains venous blood from 
the gastro intestinal organs. The main function of metabolism is to change the physicochemical 
properties of the exogenous compounds from less water-soluble to more water-soluble to be easily 
excreted in urine. 
Usually metabolism goes in order from Phase I-III, but some chemicals may go through one phase 
without being preceded or followed by the other. Phase I is mainly an oxidative reaction catalysed 
by the CYP450 enzyme family group, though other reduction and hydrolysis reactions are catalysed 
by other enzyme families, and are included in 'Phase I' reactions.  
Phase II reactions are mainly conjugative processes, where sugars, amino acids or salts are 
conjugated to the chemical, again with the aim to make the chemical more water soluble and easy to 
eliminate. Phase III is about the removal of the hydrophilic conjugates produced from phase II 
metabolism from inside the metabolizing cells through the lipophilic cell membrane to the 
extracellular fluid and then back to the bloodstream until they reach kidneys to be excreted (Coleman, 
2010).  
1.4.1.1.  Phase I Metabolism 
The aim of phase I metabolism is to add polar reactive groups into the structure of the xenobiotic, 
that may be performed by oxidation, hydrolysis, reduction, cyclization or decyclization. After phase 
I, if the generated metabolites are adequately polar, they can be excreted without undergoing phase 
II metabolism. Oxidation reactions are mainly catalysed by Cytochrome P450 monooxygenases. 
However, Flavin monoxygenase enzymatic system (FMOs), alcohol and aldehyde dehydrogenases, 
Monoamine oxidases and peroxidases can catalyse these oxidation reactions. The NADPH-
cytochrome P450 reductase is the enzyme mainly responsible for reduction reactions. Hydrolysis 
reactions are catalysed by amidase, epoxide hydrolases or esterase enzymes. The physicochemical 
properties of xenobiotic compounds are changed after metabolism, and the new chemicals – 
metabolites – will have different structure after undergoing metabolic reactions. This is a very 
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important process as it is producing metabolites with target effects (i.e.: activation) or producing 
metabolites with no, less or benign effects; i.e.: detoxification (Woolf, 1999; Guengerich, 2001; Foye 
et al., 2012).  
The start of the research with CYP450 dates back to the 1940s, through in vitro studies on the 
metabolism of drugs. Spectral observation, the role as oxidase in the electron transport system, 
separation and purification of the P450 enzymes were the major Followed by several studies 
including biochemical and biophysical work with different species of the P450 enzymatic systems 
(Guengerich, 2001; Guengerich, 2007; Coleman, 2010).  
CYP450 are a group of enzymes with approximate molecular Weight of 50000 Da that share the core 
structure and mode of action, and they are responsible for more than 75% of chemicals metabolism, 
making them a principal player in the metabolism in living bodies (Woolf, 1999; Foye et al., 2012). 
So far, more than 7700 CYP450 enzymes have been identified, out of which about 57 are human and 
only 15 out of these human CYP450 are known to be responsible for metabolism of chemicals 
(Coleman, 2010). 
The general structure of the CYP450 is a central haem iron group supported by a protein frame known 
as ferriprotoporphyrin-9 (Figure 3).  This is a common core structure of CYP450 and the active site 
of its enzymatic oxidative function, and it is a common supportive structure in other enzymes 
containing the haem core (e.g.: haemoglobin, myoglobin). Through and over the core structure of the 
haem and F9 support, helices run as covering structures and help to add flexibility to the core active 
site. The active site of the CYP450 enzyme is the area where the chemicals are catalysed. However, 
though CYP450 enzymes share a common structure and general function, there is an extreme 
difference in the specificity for the chemicals between them, even within the same family member 
(Coleman, 2010).  
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Figure 5: General structure of ferriprotoporphyrin-9 support 
 
Cytochromes P450 are systematically classified into families, where CYP450 of the same family 
share 40% of the amino acid structure and each family is sub classified into sub families where the 
CYP450 of the same subfamily share 55% of the amino acid structure. The CYP450 nomenclature 
is of four parts: the prefix (CYP) followed by number in reference to the family, letter in reference 
to the subfamily and ends by a number in reference to the isoform of the same enzyme. Despite the 
various numbers of CYP450 and their isoforms, mainly CYP1, CYP2 and CYP3 families are 
involved in chemicals metabolism in humans, and it is alleged that 90% of the known chemicals 
metabolism take place by one of these five isoforms: CYP1A2, CYP2C9, CYP2C19, CYP2D6 and 
CYP3A4 (Woolf, 1999; Guengerich, 2001; Coleman, 2010; Foye et al., 2012).  
The CYP3A subfamily enzymes are of significant importance as they are one of the most abundant 
CYP450 enzymes in the human body and being responsible for the metabolism of wide range of 
chemicals in terms of types and molecular weight (i.e. they can metabolize large number of different 
types of molecules and chemicals either with high or low molecular weight). More than 50% of the 
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hepatic content of the CYP450 enzymes alone belongs to the CYP3A subfamily, mostly one of the 
two isoforms: CYP3A4 and CYP3A5, where they represent around 30% of the total CYP450 
contents of the liver. In addition, those two specific isoforms, CYP3A4 and CYP3A5, represent a 
significant amount of the total content of CYP450 in the lung (Woolf, 1999; Coleman, 2010; Foye 
et al., 2012). 
Flavin Monoxygenases (FMOs) are another important oxidation system, mainly responsible for the 
metabolism of endogenous chemicals that are widely available in the human body. They have 
comparatively similar nomenclature system like CYP450, relying on the similarity of the amino acids 
sequence within one family or subfamily. FMO-3 is the most abundant enzyme of the FMOs in 
human liver, while FMO-1 is the most abundant in the liver of experimental animals. This significant 
difference in type and abundance is very important when transferring research results regarding 
FMOs from animals to humans. It is believed that FMO-3 is expressed a little less than two-thirds 
the rate of expression of CYP3A4; the most abundant CYP450 enzyme in human liver (Woolf, 1999; 
Coleman, 2010; Foye et al., 2012).  
Monoamine Oxidase (MAOs) is another significant enzymatic system, which is not only responsible 
for the metabolism of exogenous chemical, but also for the metabolism of endogenous chemicals. 
There are only two forms of the MAOs, A and B, both having similar functions and present almost 
in every part of the human body (Woolf, 1999; Coleman, 2010; Foye et al., 2012). 
1.4.1.2.  Phase II metabolism 
Phase II reactions are mainly conjugation reactions that add an endogenous substance to the parent 
or processed drug. This conjugation reaction needs the compound to have a functional group (i.e. 
hydroxyl group) to act as the conjugation site. This functional group maybe already present, which 
make the conjugation process occurs directly or may be produced by one or more of the metabolic 
process (i.e. phase I reactions). Phase II reactions include sulphation, glucuronidation and 
methylation.   
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As it was discussed earlier, the main aims of metabolism are to alter the effect of chemicals by either 
activation, deactivation or modification. Make the chemical itself, or produce metabolites that will 
be more water-soluble to ease its excretion in body wastes. 
The first aim is usually achieved by phase I enzymatic reactions while phase II is responsible mainly 
for achieving the second aim. The CYP450 and other enzymatic systems typically change the polarity 
of every chemical more toward hydrophilicity, but not enough for the processed chemical to be 
excreted in polar body wastes, e.g.: bile, urine and sweat. This problem, most of the time, is solved 
by phase II reaction (Coleman, 2010; Foye et al., 2012).  
Glucuronidation is the major Phase II reactions, which is catalysed by UDP-glucuronosyltransferases 
(UGTs), an enzyme with more than one known isoforms in human. The glucuronidation reaction 
involves the relocation of glucuronic acid to a chemical functional group leading to increasing in the 
polarity of the chemical, which in result increases the chemical solubility in water facilitating its 
excretion. The liver, as it is in Phase I reactions, is a major site in humans for glucuronidation.  
Glucuronidation takes place in other sites of the body, and for some drugs, some sites are preferred 
for glucuronidation. Sulphonation is another important Phase II reaction catalysed by 
sulphotransferases (Woolf, 1999; Coleman, 2010; Foye et al., 2012). 
1.4.1.3.  Phase III metabolism 
In general, the aim of biotransformation is to detoxify the effects of the exogenous chemical, and to 
change its chemical structure into a more water soluble one to facilitate its excretion, mainly through 
urine. This is achieved by Phase I and Phase II reactions. However, those reactions take place in the 
intracellular space, i.e. inside the cell, and the produced chemicals, i.e. the metabolites and their 
conjugates, needs to be transferred into the extracellular space, i.e. outside the cell, against a 
concentration gradient to enter the blood stream and ultimately be filtered by the kidneys.  
The structure of the cell membrane, which is composed mainly of phospholipids, is relatively 
impermeable for large and water-soluble molecules. The products of Phase I and Phase II metabolism 
are relatively water soluble and large molecules that will then be entrapped inside the cell unless they 
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are actively transferred from the intracellular space into the extracellular space. Phase III metabolism 
refers mainly to the transport process of the metabolic products from the intracellular space into the 
extracellular space. This process needs a specific transport system in addition to energy. Phase III is 
important because the hydrophilic products of phase II metabolism inside the cells, may either 
undergo hydrolysis to give the original xenobiotic, inhibit the conjugating enzymes or even they can 
be themselves cell-toxic (Coleman, 2010). 
 
1.5.  in vitro models for the study of drugs of abuse 
Historically, animal models have been used for decades aimed at studying the effect of chemicals as 
a predictive in vivo system, but sometimes they produce unreliable prediction of human metabolism 
and toxicity (Olson et al., 2000; Turpeinen et al., 2009). Russel and Burch suggested- for the first 
time the concept of the 3R’s, standing for Replacement, Reduction and Refinement, suggesting 
replacing the living animals by non-conscious alternatives, reducing the number of used animals to 
the minimum to obtaining same or comparable results and refining methods that would causes 
minimal pain and distress for the used animal models (Flecknell, 2002). 
In order to bring the 3R's concept into application, the development of in vitro systems to study the 
effect of drugs has been considered as an alternative for the animal models, drawing the attention of 
researchers and scientists. However, it is thought that full replacement of the animal models is not 
yet possible. The search for alternatives is very important because, most of the time, local regulations 
have restrictions for using animals, in addition to the expense of using animal models. Furthermore, 
there is always a query about the assumption that the chosen animal model will adequately predict 
those effects in humans. Frequent interspecies difference in pharmacokinetic studies may explain 
low prediction rates of drug-induced toxicity in humans when data are collected from animal studies 
(Olson et al., 2000; Flecknell, 2002; Guguen-Guillouzo and Guillouzo, 2010; Adler et al., 2011; 
Anthérieu et al., 2012). 
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There are diverse available in vitro models, such as whole organs, tissue slice, cells and subcellular 
fractions. Utilizing cells or subcellular fractions makes the study system easier, also permitting the 
assessment of a specific reaction-related mechanism (Chiu, 1993; Olson et al., 2000). 
There is little information on methods mainly using computer-based approaches, where the basic 
theory behind such methods is to link the toxic and/or clinical effect to molecular parameters 
associated with the chemical structure. This is a predictive tool that may be transferred later into 
testing method, depending on the type of the information to be obtained (Davila et al., 1998; 
Flecknell, 2002; Turpeinen et al., 2005; Adler et al., 2011). 
The clinical effects of drugs are mainly dependent on its absorption/ distribution/ metabolism/ 
excretion parameters, and so the metabolic steps that it goes through would affect its behaviour 
(Turpeinen et al., 2005). Liver preparations are the most commonly used metabolic and toxicological 
in vitro models, e.g.  Hepatocytes, cytosol, S9 fractions, HepaRG cell lines and microsomes (Asha 
and Vidyavathi, 2010). 
In vitro approaches have been considered as one of the preferred methods for studying the 
metabolism of NPS as clinical studies using humans or animals, to a lesser extent, have ethical 
implications. Additionally, in vitro drug metabolism methods are generally easier and more rapid to 
apply than in vivo approaches. In vitro drug metabolism studies using microsomes are more widely 
used in the pharmaceutical industry than to study the metabolic profile of new emerging drugs of 
abuse. 
The reason behind choosing freshly prepared pig liver for the preparation of microsomes and S9 
fraction for in vitro metabolic models of NPSs of interest was its similarity in size and physiology 
with that of humans. In addition, a similar distribution of different families of CYP450 enzymes 
between pigs and humans can be found. Collectively, these factors can be helpful in increasing the 
degree of reliability of the proposed metabolic procedure (Puccinelli et al., 2011; Achour et al., 2011). 
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The liver S9 fraction covers both cytosolic and microsomal fractions. Exogenous cofactors such as a 
NADPH-regenerating system is also needed to supply the energy for the CYP enzymes. S9 fractions 
comprise both phase I and phase II activities, however, they are poor in enzymes if compared to 
microsomes (Sepuri Asha, 2010). 
1.5.1.  Microsomes 
In 1936, Potter & Elvehjem improved procedures of preparing tissue homogenates. Liver 
homogenates were then prepared and were considered as successful in vitro metabolic systems as 
they contain both phase I and phase II enzymes. Consequently, differential centrifugation methods 
were developed enabling the preparation of subcellular fractions such as microsomes (Potter and 
Elvehjem, 1936; Ekins et al., 2000). Microsomes are vesicle-like artefacts that are made from 
portions of endoplasmic reticulum (ER) after disintegrating eukaryotic cells; they can be 
concentrated and separated from other cellular debris by differential centrifugation (Houston, 1994; 
Nakamura et al., 2007). 
Liver microsomes are clinically successful in vitro models for the assessment of drug metabolism 
and one of the most commonly used approaches. In addition, using microsomes is a relatively cheap, 
simple and easy method and the prepared microsomes can be stored in frozen form for years. On the 
other hand, they have many drawbacks, being unsuitable for quantitative in vivo human assessments 
of metabolism and not containing all of the enzymes and cytosolic cofactors. Thus, exogenous 
cofactors consisting of a NADPH-regenerating system (phase I oxidation) or uridine-5′-diphospho-
α-D-glucuronic acid (UDPGA; phase II glucuronidation) are needed to activate microsomes. 
Microsomal in vitro models have significant variations depending on the liver donor and the 
incubation settings such as pH, ionic strength, organic solvents (Brandon et al., 2003; Asha and 
Vidyavathi, 2010). 
1.5.2.  Primary Human Hepatocytes 
Primary human hepatocytes are one of the recently used in vitro metabolizing systems, and still the 
standard model to mimic in vivo pharmacokinetics of drugs and their toxicity in human liver. In fact, 
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it is well established in the scientific community that primary human hepatocytes are the best source 
for primary studies of drugs metabolism which make them a very important in vitro model for drug 
pharmacokinetics study, mainly for metabolic and toxicity studies (Guillouzo et al., 2007). 
Primary human hepatocytes, in current times, are isolated from surgically dissected liver fragments 
because of tumour or other liver diseases which results in deficiency of some liver specific functions, 
especially P450 enzymatic activity. In general, primary hepatocytes have limited activity and wide 
variation in P450 levels. Additionally, primary human hepatocytes usually lose their metabolizing 
function quickly, especially when they are in the suspension form as they lose their naturally 
occurring polarity. 
Use of primary human hepatocytes is affected by many limitations, such as the insufficiency of 
appropriate human liver samples and the variability observed when the cells are prepared from 
different human donors. In vivo hepatocytes are polarized two-sided cells, they have a sinusoidal side 
(blood) and canalicular side (bile) and they become nonpolar when are isolated from liver and re-
suspended. All these are very important factors that complicate the use of this type of cells on a 
routine basis (Guillouzo et al., 2007; Gomez-Lechon et al., 2008; Guguen-Guillouzo and Guillouzo, 
2010; Andersson et al., 2012). 
1.5.3.  HepaRG cells line 
HepaRG cell lines are relatively new human cell lines which can differentiate to both hepatocyte-
like and canaliculi-like cells.  They are originally taken from a liver tumour of a human donor with 
chronic hepatitis C (Parent et al., 2004; Andersson et al., 2012; Anthérieu et al., 2012). HepaRG cell 
lines were reported to be the most comparable to primary human hepatocytes and human liver tissue 
among other liver cell lines (Hart et al., 2010) 
HepaRG has many improvements over primary human hepatocytes in in vitro metabolic and 
toxicological studies. When compared to primary human hepatocytes, HepaRG cells lines have 
unlimited life span and are easier to handle, in addition to the stability of enzymatic phenotyping 
while primary human hepatocytes have variable enzymatic phenotyping. However, HepaRG cells 
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lines have some limitations mainly as they are of a particular genotype which affects the type of 
produced drug-metabolizing enzymes. HepaRG cells lines mainly produce intermediately active 
CYP2D6 and CYP2C9, while other genotypes such as CYP1A2, CYP2A6 and even CYP2D6 (one 
on the main produced CYP) are considerably less expressed in HepaRG cells than in primary human 
hepatocytes. This in turn leads to reduction in their metabolic capacity (Andersson et al., 2012). 
In general, different strategies have been proposed to generate metabolically competent immortalized 
hepatocytes: transformation of human hepatocytes with plasmids encoding immortalizing genes, 
hepatocyte-like cells derived from stem cells, cell lines generated from transgenic animals and 
hepatocyte/hepatoma hybrid cells. Moreover, heterologous recombinant models expressing P450 
enzymes in different host cells have been developed and successfully used in drug metabolism 
testing. 
1.6.  Cell death and cytotoxicity 
Cell death is usually described as a process rather than an event, though there is no clear definition 
of cell death in literature. For that, cells are described as ‘dying’ in a reversible course until passing 
the point of irreversibility or ‘point-of-no-return’. However, even this ‘point-of-no-return’ in the 
literature is not clearly defined, as the leading events to this are not clearly defined.  Since 2005 and 
subsequently on 2009, the Nomenclature Committee on Cell Death (NCCD) is suggestively updating 
the criteria and recommendation to unify the definition of cell death within the scientific community. 
They classified cell death depending on four major criteria: morphological, enzymological, 
functional and immunological criteria (Kroemer et al., 2008; Galluzzi et al., 2011). 
Cytotoxicity describes the effects that chemicals have on cells, which usually ends in cell death, 
though some toxic effects are reversible causing disruption of the function of the cell.  Cytotoxicity 
studies are a very important part of any study on drug effects on cells and very commonly used as 
screening tools. It has much application, not only in the toxicology field, but also in other important 
fields, especially in the drug discovery and the drug industry. A common approach is the use of 
exclusion tests that involve the evaluation of the integrity of the cell membrane as a measure of cell 
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viability and cytotoxic effect. Another common approach is the use of colorimetric reaction that 
involves monitoring the chemical capacity of the cell to reduce specific agents. These types of tests 
have the advantage of being easy to implement and time-effective, where variable compounds at 
variable concentrations can be tested competently at the same time. 
Exclusion tests depend mainly on the integrity of the cell membrane and its ability to keep 
impermeable to dyes, where damaged cell membrane will allow the dye to pass through and stain 
intracellular structure. Intact cell membranes will protect the intracellular environment and exclude 
the dye, keeping the cell unstained. The procedure simply consists of mixing the dye with cell 
suspension and then examining whether cells take it up (dead cells with damaged cell membrane) or 
exclude the dye (viable cells with intact cell membrane). (Longo-Sorbello et al., 2005). 
Trypan blue, naphthalene black, propidium iodide and eosin are some examples of the vital dyes 
used in exclusion tests. Trypan blue is one of the most commonly used vital dyes in exclusion tests, 
a simple and non-expensive alternative. Trypan blue will stain dead cells cytoplasm dark blue while 
keeping viable cells clear with surrounding refractive ring (Longo-Sorbello et al., 2005). 
Colorimetric assays are useful techniques to estimate viable non-damaged cells using microplate 
reading spectrophotometer. The cleavage reaction of MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazoliumbromide) salts to form the blue coloured non-soluble product (formazan), is one 
of the most commonly used procedures. This reaction take place only in viable cells by one of the 
mitochondrial enzymes, and the amount of produced formazan is directly proportional to the number 
of viable cells, which make it a very useful tool to study quantitatively the viable percentage of cell 
population (Vignati et al., 2005; Longo-Sorbello et al., 2005). 
1.7.  Sample preparation 
Separating the analytes of interest from interfering materials, especially when biological samples are 
used, is one of the major challenges met while developing analytical methods. In the case of the 
analysis of drugs and their metabolites in biological fluids, where they are commonly existing in low 
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concentrations with the presence of large number of biological materials, sample preparation is most 
essential (Ahuja and Diehl, 2006; Snow, 2007). 
The need for many steps of sample preparation makes it one of the most time consuming steps of 
analytical method development. Automated systems have been applied for sample preparation 
especially in laboratories overloaded with repetitive analyses. However, these systems are not 
popular as they are unreliable, inflexible and they need to be continuously maintained (Biddlecombe 
and Smith, 2004; Sastre and Szymanowski, 2005; Ahuja and Diehl, 2006).  The primary aims of 
sample preparation are: producing representative sample of the original; isolation of analytes of 
interest from other unwanted interferences; pre-concentration of the analytes of interest; introducing 
the analytes onto the analytical instrumentation in a suitable solvent/carrier; and exclusion of 
biomaterials that may lead to analytical system decay, either physically or chemically. 
1.7.1.  Sampling 
Sampling involves sample assortment, carrying, storage and later, selection of the sample before 
introducing in a suitable form into the analytical system.  The choice of sampling techniques depends 
merely on the nature of the matrix, and the chosen type and method of sampling will affect the quality 
of the results, which in turn would affect data interpretation. 
Sampling should assure minimal loss, degradation, instability, contamination or any other external 
interference with the sample. Sample collection and latter sample selection should be representative 
of the original sample, which raises the issue of homogeneity of the original collected and selected 
sample. Other negative effects on the quality of sampling by other factors (i.e. transport and storage) 
may be minimized by using preservative techniques. Commonly used techniques for preservation of 
the sample are proper choice of sampling container, addition of chemical stabilizers and freezing the 
sample. (Biddlecombe and Smith, 2004; Ahuja and Diehl, 2006). 
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1.7.2.  General approach for sample preparation of different types of samples 
After proper sample collection, transportation and sample selection comes the step of sample 
preparation. Sample preparation methods are usually aiming to clean the sample from interferences, 
and to separate the sample into its subcomponents and extract the analytes of interest. 
Biological samples, the primary matrices dealt with in forensic analysis, are very complex matrices 
as they contain many components that may affect the quality of separation and analytical signal. 
Whatever the type and nature of the biological sample, a proper preparation is an inevitable 
prerequisite for introducing the sample onto the analytical instrumentation or performing other 
analytical steps (Biddlecombe and Smith, 2004; Ahuja and Diehl, 2006). 
Biological samples need usually different sample preparation techniques when compared to other 
types of samples. This is very important to preserve the integrity and activity of the biological sample. 
Either urine samples may need pre-treatment by only adjusting the pH before extraction, using strong 
acids or strong bases to ensure basic analytes or acid analytes, respectively, are freely solvated in the 
sample. Serum and plasma samples most of the time need to be pre-treated in the same way as urine 
before extraction, mainly to free the protein-bound analytes. Liquid samples are easier to prepare 
when compared to solid or volatile samples, as liquid samples may not be in need of extraction or 
dissolution before introduction onto the analytical system. However, liquid samples usually contain 
many more interfering components and, relatively, low concentration of the analytes of interest. Solid 
samples may need more complex preparation procedures, depending on whether the whole sample 
or only part of it is of interest. 
The two-phase system is the most common approach in sample extraction, where in this system the 
analytes of interest are distributed into one phase while the interfering components are distributed 
into the other. In liquid-liquid extraction, the distribution is into two immiscible liquid phases, while 
in liquid-solid extraction the distribution is into one liquid and another solid phase (Biddlecombe and 
Smith, 2004; Ahuja and Diehl, 2006). 
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1.7.3.  Sample pre-treatment of different types of samples 
1.7.3.1.  Solid samples 
Solid samples preparation may need only dissolving the whole sample in a suitable solvent, which is 
more applicable to homogeneous samples such as drug tablet formulation. Prior to that, physical 
techniques (e.g. grinding) maybe enough to turn solid a sample into smaller sized particles, easing 
dissolution of the sample and increasing the efficiency of further extraction steps. Sonicating the 
sample after will increase the efficiency of the whole process, as the ultrasonic action and the heat 
produced will ease the dissolution of the ground particles that will enhance sample recovery. Solid 
samples with water content, like soil, may need to be evaluated for water content before analysis to 
interpret final results properly, as water content will definitely affect the results. Drying of the sample 
and weighing it before and after will usually be enough to evaluate the relative amount of water and 
adjust results accordingly. 
Generally, most solid samples are pre-treated by a solid-liquid extraction technique. The basic steps 
of this technique include physical removal of remaining insoluble interference (e.g. centrifugation) 
after homogenizing the sample with a buffer or an organic solvent. When an aqueous solvent is used 
to dissolve the solid sample, the resultant solution may be further extracted into an organic solvent 
by solution-solvent extraction, which is similar to liquid-liquid extraction (Wells, 2003; 
Biddlecombe and Smith, 2004; Ahuja and Diehl, 2006). 
1.7.3.2.  Volatile samples 
Volatile samples are pre-treated by a different technique; usually in preparation for gas 
chromatography, the one tool commonly used for the analysis of volatile samples. The use of one or 
more techniques depends on the laboratory setup, researcher experience, analytical needs and 
physicochemical properties of the sample. 
In headspace sampling, the sample is placed in glass vial having enough space above the sample. 
The glass vial is then heated and the above space will be occupied by the gaseous phase of the volatile 
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analyte of interest. The volatile analytes are then allowed to reach equilibrium with the whole sample, 
and the gaseous phase is then sampled and analysed. 
In solid phase trapping, the gaseous sample is passed in a tube through a solid support, the captured 
vapour analytes are then extracted into a suitable solvent, and the solvent – with the extracted analytes 
- is analysed. Compared to solid phase trapping, in liquid phase trapping, the gaseous sample is 
passed through a liquid and the liquid, with the captured analytes; is analysed. In comparison, in 
liquid trapping, the gaseous sample is passed into an extraction solvent with affinity to the analytes 
of interest that is later analysed either directly or after being processed with one or more preparation 
steps. 
The ‘Purge and Trap’ technique is relatively similar to headspace sampling. The sample is similarly 
heated and the vapour is allowed to collect in the space above the sample. However, in this type of 
technique, the vapour analytes are washed continuously, and the collected vapours are either directly 
analysed or go into further preparation steps. 
In grab sampling, the gaseous sample is simply collected in a container and then rinsed with a solvent 
that is injected onto the analytical system, either directly or after pre-treatment. The sample can be 
collected simply using a bag or in a more advanced way using instrumental apparatus (Peach and 
Carr, 1986; Ahuja and Diehl, 2006) 
1.7.3.3.  Liquid samples 
Liquid samples are the most common type of samples to be faced, and sometimes need only dilution 
before being introduced onto the analytical system. Liquid samples are commonly the product of one 
or more sample preparation steps of other types of samples as discussed earlier, but can be genuinely 
liquid. 
In filtration, the simplest technique to pre-treat liquid samples, the liquid is passed through filter 
paper. This procedure could be enough to remove most of the solid interferences. In comparison, in 
microdialysis technique, the analytes are allowed to move from one liquid to another through a 
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membrane placed in between these two liquids. This is very useful technique to remove large sized 
protein from a sample prior to liquid chromatography. Centrifugation is another commonly useful 
technique to pre-treat liquid samples, and will remove efficiently most of the suspended solid 
interferences from the sample. Liquid-liquid extraction and solid phase extraction are of the most 
common techniques used for liquid sample preparation (Ahuja and Diehl, 2006). 
1.7.4.  General approaches for sample extraction 
1.7.4.1.  Liquid-liquid extraction 
Liquid-liquid extraction (LLE) is a technique based on the separation of analytes from a liquid sample 
matrix into another liquid. The two liquids are immiscible and typically, one of them is of aqueous 
nature while the other is an organic solvent. Typically, as most of the drugs are lipophilic or of 
organic nature, the analytes distribute between two immiscible liquids with preferable distribution 
into the organic phase, leaving behind the interferences in the aqueous liquid (Wells, 2003; Sastre 
and Szymanowski, 2005; Ahuja and Diehl, 2006). 
Because of its advantages, LLE is still of the handiest techniques for sample preparation. LLE is a 
simple, relatively inexpensive and with high separation capacity. However, it is disadvantageous 
because of the high volumes of solvents needed, not being applicable to all types of analytes, 
emulsion formation and the difficulty to automate the process (Wells, 2003; Sastre and 
Szymanowski, 2005). 
The ratio of partitioning of the analytes between the two immiscible liquids depends on many factors 
related mainly to the properties of the analytes and the liquids. The analytes will preferably partition 
onto the organic solvent when they are in their unionized form, and when they show solubility in the 
organic solvent. The selection of the extraction solvent would affect the ratio of partitioning and 
improve the efficiency of extraction process. (Wells, 2003; Ahuja and Diehl, 2006). 
An ideal extraction solvent is the one that is insoluble in water, of low viscosity, of low boiling point, 
of high affinity for analytes and has the lowest hazards. The low viscosity will allow the solvent to 
mix easily with the biological sample – the very common type of samples in forensic settings, while 
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the low boiling point will make it easier to evaporate the solvent – a very common step after 
extraction.  Changing pH values of the matrix liquid and ratio of organic solvent to aqueous liquid 
ratio, in addition to the type of solvent, are other important factors adjusting the extraction process. 
Changing pH values affect the ionization state of the analytes, controlling how these analytes 
partition between the immiscible liquids (Ahuja and Diehl, 2006). According to the distribution law 
that was derived by Nernst in 1898, unionized analytes will distribute between two immiscible liquids 
at a constant rate. In typical settings, though in practical settings the assumption of the presence of 
ideal solvent is invalid, Equation 1 applies at equilibrium 
𝑲𝑫=
[𝑿]𝒐𝒓𝒈
[𝑿]𝒂𝒒𝒖
𝒎𝒗𝟐 
Equation 1 
Where KD: Distribution constant, [X]org: concentration of analyte X in organic liquid and [X]aqu: 
concentration of analyte X in aqueous liquid 
 
 
Applying (Equation 1), a high KD value indicates high ratio of partitioning in favour of the organic 
phase, which reflects an efficient extraction process. Many parameters can be adjusted to increase 
the KD value. For example, Adjusting the pH value to make the analyte uncharged, selection of a 
solvent where the analytes preferably partition into and using high volume of the extraction solvent, 
all would increase the KD value and hence the amount of the extracted analytes (Ahuja and Diehl, 
2006; Dey, 2014). 
From a practical point of view, adjusting the pH would allow the separation of different types of 
analytes into neutral, basic and acid analytes. The best results of extraction are achieved when 
adjusting the pH values two units below the expected pKa value in the case of acidic analytes, while 
adjusting it two units above the expected pKa values in the case of basic analytes (Wells, 2003; 
Biddlecombe and Smith, 2004). Increasing the surface area of contact between the immiscible liquids 
is another important factor that would speed the equilibrium process. A large surface area of contact 
between the two liquids would ensure rapid equilibrium, and this can be achieved by thoroughly 
mixing the two liquids, either mechanically, manually or using vortex. Emulsion formation, one of 
the major disadvantages of LLE, would cause inefficient extraction of the analytes, as they will be 
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trapped within the emulsion. Gentle mixing of the liquids and using large volumes of the extraction 
solvent may help to reduce the formation of emulsion (Biddlecombe and Smith, 2004). LLE provides 
efficient sample clean-up and concentration, and evaporating the resultant organic fraction 
containing the extracted analytes followed by reconstitution with compatible solvent will produce a 
sample ready for analysis. 
1.7.4.2.  Solid phase extraction 
Solid-phase extraction (SPE), as a method of sample preparation, is a classical method, but still one 
of the techniques commonly used for separation of drugs and metabolites from complex biological 
matrices in preparation for chromatographic analysis (Wells, 2003; Ahuja and Diehl, 2006; Snow, 
2007). The history of SPE dates back to the1950s, and commercial availability to the 1970s. Since 
then, SPE has become one of the most popular sample preparation methods (Snow, 2007). The basic 
principle of SPE is to adsorb the analytes onto a surface and then wash the surface with elution 
solvent, either keeping the interferences behind in the original solution after adsorption of the 
selected analytes, or adsorbed onto the surface after washing with elution solvent. Due to the 
described principle of extraction, SPE is more commonly termed sorbent extraction. A classical SPE 
extraction system consists of sorbent particles packed into a cartridge, the sorbent consists of porous 
particles of chemically modified silica backbone and the packing is held in place using frits. The 
silica backbone is modified by binding different types of organic moieties. The different type of 
moieties that can be bound to the silica backbone will afford a countless number of application of 
SPE system. (Wells, 2003; Ahuja and Diehl, 2006; Snow, 2007). 
A typical process of SPE mainly consists of four steps: conditioning, sample addition, washing and 
elution. In step 1, the sorbent is conditioned with one or more solvents, depending on the expected 
chemical properties of target analytes, where one of these condition solvents is the elution solvent. 
Conditioning is aiming to prepare the sorbent for the extraction process. This will guarantee the 
functional moieties, the ones attached to the silica backbone, are appropriately solvated, assuring the 
best exposure of the analytes to these functional moieties and hence the maximum extraction 
recovery. In step 2, the sample is applied onto the sorbent, drawn through the sorbent usually by 
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vacuum suction or pushed through with pressure applied by a plunger. The chosen type of sorbent 
should have high affinity for the analytes of interest. The amount of extracted analytes depends on 
the partition coefficient between the sample and the sorbent, similarly to the previously discussed 
liquid-liquid extraction (LLE). The sorbent in step 2 will retain the analytes and maybe some 
interfering materials adsorbed onto the surface matrix. In step 3, the sorbent is washed with one or 
more solvents that have the ability to release the adsorbed interferences yet retain the analytes. In the 
final step, step 4, the sorbent, with the analytes adsorbed onto its surface matrix, is eluted with a 
solvent that has the ability to release the adsorbed analytes only (Figure 6). 
 
Figure 6: schematic representation of typical SPE protocol 
 
 
The resultant extract is made ready for analysis in the same way as described for LLE during the 
extraction process. The pH adjustment of sample solution, washing solution and elution solvent plays 
a major role to increase the efficiency of extraction. (Wells, 2003; Ahuja and Diehl, 2006; Snow, 
2007). 
Compared to other sample preparation techniques, SPE appears to be superior and more 
advantageous. For example, compared to LLE, SPE uses significantly lower volumes of solvents, 
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has lower risk of exposure to hazards, has no risk of emulsion formation, has lower risk of 
contamination, is relatively inexpensive and generally has wider range of extraction applications 
(Ahuja and Diehl, 2006; Snow, 2007). 
The type of the functional moiety bounded to the silica backbone is very wide and varied, and the 
choice of one type depends on the nature of analytes to be extracted. Hydrocarbons, anion or cation 
exchange functional groups can be bound to the silica backbone, depending on the type of 
application. The most common type of sorbent used in SPE is the one with a bound hydrocarbon 
functional moiety, most commonly C18. This is similar to the most common type of sorbent used in 
chromatography columns. The hydrocarbon moiety provides a nonpolar and hydrophobic surface, 
the one preferable to adsorb the common type of analytes needing analysis in toxicology – drugs of 
abuse and their metabolites (Ahuja and Diehl, 2006; Snow, 2007). 
1.8.  Basic principles of Chromatography 
In 1993, The International Union of Pure and Applied chemistry (IUPAC) presented a definition for 
all terms, symbols used in chromatography, and defined: ‘Chromatography is a physical method of 
separation in which the components to be separated are distributed between two phases, one of which 
is stationary (stationary phase) while the other (the mobile phase) moves in a definite direction’ 
(IUPAC, 1993). 
The history of modern chromatography dates back to the start of the 20th century when the Russian 
scientist Twsett separated chloroplast pigments using CaCO3 as a stationary solid phase and 
petroleum ether as a mobile phase, though the basic principles of separation were presented earlier 
(Grob and Barry, 2004; Little, 2008). Thereafter, there was tremendous developmental milestones in 
the field of chromatography, reaching the status of being a major technique in many science fields 
(Table 1) 
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Table 1: Major developmental milestones in the field of Chromatography 
Scientist Major Development 
1
9
0
0
s 
Twsett, M. Separated chloroplast pigment 
1
9
4
0
s Tiselius, A. 
Adsorption analyses. 
Liquid chromatography. 
Pointed out different modes of chromatography. 
Consden, R., et al. Paper chromatography 
Claesson, S. Liquid–solid chromatography 
1
9
5
0
s 
Cremer, E. Gas–solid chromatography. 
Phillips, C. S. G. Liquid–liquid chromatography (Frontal mode) 
James, A. T., and 
Martin, A. J. P 
Gas–liquid chromatography 
1
9
6
0
s 
Giddings, J. C. Reviewed theories of chromatography 
 
As pointed out by Tiselius in 1941 with current application up to date, there are three modes of 
chromatography analysis: Frontal analysis mode, Displacement mode and Elution mode. 
In frontal analysis mode chromatography, the sample mixture acts as its own carrier (i.e. mobile 
phase) when injected into the column that contains the stationary phase. The sample mixture 
components separate depending on the capability of each component to bind - and so be retained - 
by the stationary phase, based on their affinity. A variety of this technique is the zonal elution 
analysis, where the sample is injected in small volume rather than continuous flow (Grob and Barry, 
2004; Calleri et al., 2012). The least binding component is the one eluted firstly in its pure form, and 
with the continuous flow elute the second least binding is eluted and so on. The term ‘frontal analysis’ 
relates to the initial use of this method for the assessment of the alteration in concentration of the 
front exit of the column. This method is disadvantageous for the need of large quantity of sample 
mixture, and for that it is used mainly as preparative chromatographic technique. 
In displacement mode chromatography, a mobile phase, either liquid or gas, is used to carry the 
sample mixture. The mobile phase must have more binding capacity to the stationary phase than any 
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component of the sample mixture. This method has application in LC, or as a preparative step in 
analysing traces in GC (Grob and Barry, 2004). 
In elution mode chromatography, the components in the sample mixture, carried by a mobile phase, 
move over the column at different rates according to their binding capacity on the solid stationary 
phase (Grob and Barry, 2004). In modern practice, nearly all methods of chromatography are 
performed in elution mode, to the extent all other modes are negligible other than as preparative steps 
(Little, 2008).  Ideally, in this mode of chromatography, the components of the sample mixture would 
elute from the stationary phase in separated peaks on a baseline, achieving the best resolution. The 
travel speed of each component through the stationary phase depends mainly on the interaction 
between each component and the stationary phase. This interaction can be maximized to obtain the 
best resolution by adjusting the operation parameters (low column loading, gradient elution ... etc.). 
Elution mode has drawbacks of being time consuming and operationally complex (Grob and Barry, 
2004; Little, 2008). 
1.8.1.  Liquid Chromatography 
The HPLC technique is based on a solid (stationary) phase and a liquid (mobile) phase. This contrasts 
with Gas Chromatography (GC), where the technique is based on a gaseous (mobile) phase. HPLC 
is superior for the analysis of organic compounds, which are mostly non-volatile or unstable. HPLC 
is the core instrumentation used for analysis of drugs of abuse, where reversed phase chromatography 
(RPC) is the main utilized HPLC mode. It is a combination of a non-polar stationary phase (the 
column), and a polar mixture of water and an organic solvent-mobile phase (Mc Fadden et al., 2006; 
Snyder et al., 2009; Bayne and Carlin, 2010). 
Liquid chromatography instrumentation consists of four major components: sample introduction, 
mobile phase, stationary phase and detector component. 
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Figure 7: schematic representation of major components of liquid chromatography system 
 
 
1.8.1.1.  Mobile Phase 
The mobile phase major component is the pump that should deliver stable flow rate depending on 
the type of mounted interface and diameter of the separation column. This stability in flow is more 
crucial when the LC is coupled into MS instrumentation. The type of the mobile phase is extremely 
important because, as has been discussed earlier, it is the interaction between the analytes, mobile 
phase and stationary phase that determines how these analytes separate. 
Reversed phase chromatography mode is the most commonly used in most liquid chromatography 
applications. In this mode of chromatography, a relatively high polar mobile phase, in comparison to 
the polarity of the stationary phase is used for separation. Mobile phases are usually prepared as a 
mixture of solvents. Buffers are added to the mixture to control the pH and hence degree of ionization 
and provide reproducible peaks. The type and degree of buffering depends on the type of application 
and mounted interface. 
The composition of mobile phase, i.e. type and ratio of solvent mixture, is another important factor 
when separating different types of analytes. For example, a mobile phase of specific composition 
that is efficient for the separation of polar analytes will not separate non-polar analytes with the same 
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efficiency, and vice versa. In the presence of different analytes of different polarities the change of 
the mobile composition as the analysis progress will separate different analytes with different polarity 
more efficiently. A separation using a mobile phase with the constant compositions is called 
‘isocratic elution’ in contrast to ‘gradient elution’ where the composition of the mobile phase is 
changing with time (Ardrey, 2003; Snyder et al., 2009; Bayne and Carlin, 2010). 
1.8.1.2.  Sample introduction system (Injector) 
The sample introduction and the injector component is usually a valve injector. The function of the 
injector is to introduce the sample in its liquid form onto the flowing mobile phase stream (Figure 
8). The mechanism of introduction is quiet simple, but very important. When the rotating valve is in 
position A, a loop with specific volume is loaded by the sample solution while the mobile phase is 
continuously flowing onto the column. When the rotating valve switches to position B, mobile phase 
flow will be diverted through the loop in the opposite direction of the sample load, flushing the loop 
contents onto the column, (Ardrey, 2003). 
 
Figure 8: schematic diagram of sample introduction system and its mechanism of function 
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1.8.1.3.  Stationary phase 
The type of stationary phase, as discussed earlier, is another important factor that determines the 
efficiency of separation. It has been mentioned that reversed phase chromatography is the most 
commonly used mode in chromatography. For that, a low polar stationary phase, in comparison to 
the polarity of the mobile phase is the most common type of stationary phases used in 
chromatography. The most commonly used columns are those with a chemically modified silica 
backbone, mainly with C18 alkyl groups. As the column length increases, separation efficiency will 
also be increased. However, the working pressure and analysis time will also be increased. As the 
internal diameter of the column is squared, the amount of the sample that can be analysed increases. 
As the average packing particle diameter is squared the separation efficiency and working pressure 
decreases (Ardrey, 2003; Bayne and Carlin, 2010; McCalley, 2010). 
1.8.1.4.  Detectors 
A number of detectors are in routine use, depending on the type and application of analysis, and the 
properties of the analytes, solutes and solvents used for analysis. UV-Vis detector is one of the most 
widely used type of detectors with liquid chromatography. Analytes with known wavelength of 
maximum absorption can be monitored selectively through this type of detector. However, with the 
availability of diode array detectors (DAD), it is more accurate to record the spectral scan of the 
absorbance at different wavelengths, which could be used more selectively for the identification of 
the analyte. HPLC instrumentation is commonly coupled to MS instrumentation as a detector, which 
is very advantageous for analysis of different compounds, both qualitatively and quantitatively 
(Ardrey, 2003). 
1.8.2.  Gas chromatography 
Gas chromatography (GC) is widely applied in analytical chemistry and one of the main tools in 
forensic laboratories for separating and analysing compounds that are able to evaporate without being 
decomposed. Mobile phase in GC is typically a non-reactive carrier gas, such as helium or nitrogen, 
while the stationary phase is a solid or liquid. The major components of a GC instrument are: source 
of carrier gas, port of injection, column, detector and a recording device or PC. The sample mixture 
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components shall interact with both the stationary phase and the carrier gas. The separation of the 
sample mixture components depends on their interactions with the stationary phase and their vapour 
pressure. Temperature during the separation procedure in GC must be controlled slightly higher than 
the expected boiling point of sample mixture components. The choice of detectors in GC depends on 
the physicochemical properties of the tested components. Common detectors are thermal 
conductivity, flame ionization and mass spectrometry detectors. Compared to the time consuming 
LC, the time of analysis is generally shorter in GC. Analysis time can be reduced by using shorter 
and narrower columns, higher temperatures and faster flow rate. However, the use of high 
temperatures may worsen the resolution (USP; Hinshaw, et al. 2013, Grob, 2004). 
1.9.  Basic principles of Mass Spectrometry (MS) 
Mass spectrometry is one of the fundamental analytical tools in chemistry, biochemistry, pharmacy, 
and medicine. It is also one of the essential tools in toxicological laboratories. Mass spectrometry 
was introduced as a routine technique in the 1950s, providing the molecular formula for compounds 
and a closer insight into structure and fragmentation patterns. 
The basic principle of mass spectrometry is based the motion of charged ions in an electric or 
magnetic field, which is achieved by creating gas phase ions from molecules and then separating 
these ions according to their mass-to-charge ratio (m/z) and finally measuring the abundance of each 
ionized fragments by the detector. Mass spectrometry can be used for both qualitative and 
quantitative studies. It can provide data about the mass and structure of the atoms or molecules, which 
can characterize and identify the material of interest. 
The mass spectrometer separates gas phase ionized fragments and atoms based on the difference in 
(m/z), where (m) is the unified mass unit which equals one Dalton (Da), and (z) is the charge on the 
ion, either positive or negative. As the ionized fragments travel and are separated in the spectrometer, 
a spectrum is produced graphically. This spectrum represents a plot of m/z values against the relative 
abundance. The produced spectrum shows fragmentation patterns of the analyte which, in 
combination with m/z values, are used to determine the molecular weight and structure of the analyte. 
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A mass spectrometer is typically composed of five main components: sample input system, 
ionization source, the mass analyser, detector and computer-based data processing system (Figure 
9). 
 
 
Figure 9: Major components of Mass Spectrometer. 
 
1.9.1.  Sample input system 
There are different methods for the input of the sample onto the mass spectrometry system; each with 
its application with advantages and disadvantages.  The selection of the sample input system depends 
upon the nature of the sample, sample matrix, and sample physicochemical properties. As to be 
discussed later, ionization techniques are typically designed for gas phase molecules, which needs 
the sample to be introduced onto the mass spectrometry system in gas phase. The most basic sample 
input method is directly injecting the sample in vaporous gas phase onto the ionization source of the 
MS system. This method is called direct infusion.  Where the analyte itself, or dissolved in a solvent 
can be directly injected onto the ionization source component of MS system. This method is 
applicable for liquids with low boiling point and high risk of contamination. 
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Currently, chromatography instruments are the most commonly used sample front end, either: gas 
chromatography (GC) or liquid chromatography (LC). This allows the separation of a mixture sample 
before being introduced onto the ionization source of mass spectrometry system. 
1.9.2.  Ionization source 
The mass spectrometer detects molecules by using charged molecules (ions), which mandate the 
molecules to be charged or ionized in advance before introduction onto the mass spectrometer. In 
addition, as the process takes place in a vacuum, those ions must be introduced in the gaseous phase. 
The process of ionization and production of the gaseous phase is easily done for volatile samples, 
but it becomes more challenging for thermally labile molecules. The choice of the ionization method 
depends mainly on the nature of the sample, but also on the type of information required. There are 
two classical methods for ionization: electron ionization (EI) and chemical ionization (CI), with 
different applications. 
The principle of EI is to pass a beam of electrons through a gas phase sample producing, most of the 
time, single charged molecular ions, but also negatively charged molecular ions can be produced.  In 
addition to ionizing the target molecule, EI would fragment the molecule into smaller fragments 
producing single charged smaller fragment ions. This method is referred in the literature as hard 
ionization source due to the high energy used, and much fragmentation is produced a consequence. 
This much fragmentation is very useful for structural elucidation of unknown spectra. EI is the most 
common ionization method used for MS, and it is best applicable to volatile substances. 
The principle of CI is to introduce a large excess of reagent gas relative to the sample, into the 
ionization region allowing the electrons to bombard the mixture. As reagent gas is present in excess, 
it is more likely to be ionized than the sample itself, which allow the sample to be ionized by collision 
with gas molecules. This method is usually referred in the literature as soft ionization source, and it 
causes less fragmentation but more molecular ions. 
Fast Atom Bombardment (FAB) and Secondary Ion Mass Spectrometry (SIMS) are another two 
ionization methods. In both techniques, high impact energy, without the need of heat, is used. This 
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makes both these techniques more suitable for the study of thermally labile compounds. Atmospheric 
Pressure Ionization (API) sources ionize the sample at atmospheric pressure before being introduced 
onto the mass spectrometer, and they are applicable to ionize thermally labile samples. 
Electrospray Ionization (ESI) is the most common ionization method for non-volatile thermal-labile 
molecules and high molecular weight compounds, and it can be easily coupled to liquid 
chromatography.  ESI has many advantages: sensitivity, robustness and simplicity, in addition to the 
ability to couple continuous flow methods – like liquid chromatography - with MS (Van Bramer, 
1997; Pramanik et al., 2002; Glish and Vachet, 2003; Ardrey, 2003; Gross, 2004; Herbert and 
Johnstone, 2010) 
1.9.3.  Mass analyser 
As has been discussed earlier, the mass spectrum is mainly a plot of the number of ions for each m/z 
ratio produced by an analyte after been ionized. Generally, single ionized species are produced, so 
the spectrometer detects the mass (m value). The ions are streamed then into the mass analyser 
through series of electro-magnetic fields, and the stream of ions will be affected and deflected from 
their original trajectory path. The extent of deflection is affected by the ion’s mass and type and the 
strength and geometry of the electro-magnetic fields. 
When the ion passes through the electromagnetic fields, many forces will affect the direction and 
magnitude of deflection. The ions entering the electro-magnetic field are having a kinetic energy 
when accelerated out of the ion source, and for the practically single charged ions, equation 2 applies 
(Equation 2). Centrifugal force will act on the moving ion deflecting its path, depending on mass and 
velocity of the charged ions when entering the field. In case of magnetic field, the radius of deflection 
depends also on the magnetic field strength (Equation 3), and in case of electrostatic field, the radius 
of deflection depends on the electric potential (Equation 4) 
𝑽=
1
2
𝑚𝑣2 Equation 2 
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𝐵 =
𝑚𝑣
𝑟
 Equation 3 
𝐸 =
𝑚𝑣2
𝑟
 Equation 4 
 
Where:    V: acceleration potential applied to ion in the magnetic field. 
B: magnetic field strength. 
E: electric potential applied to ion in the magnetic field 
m: mass of ion. 
v: velocity of ion entering the field. 
r: radius of ion deflection in the field. 
 
For magnetic fields, rearranging the variables of (Equation 2) and (Equation 3) for velocity (v) and 
combining them for radius of deflection (r) then (Equation 5) applies 
𝒓=
√𝟐𝒎𝑽
𝑩
 Equation 5 
 
 
For electrostatic fields, rearranging the variables of (Equation 2) and (Equation 4) for velocity (v) 
and combining them for radius of deflection (r) then (Equation 6) applies 
𝒓=
√𝟐𝑽
𝑬
 Equation 6 
 
Considering Equation 5 for magnetic field, the radius of deflection (r)  is directly proportional to the  
mass of the ion (m) and acceleration potential of the filed, while inversely proportional to magnetic 
field strength (B), and in case both acceleration potential (V) and  magnetic field strength are kept 
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constant, then radius of deflection (r) will increase with increasing ion mass (m), separating ions on 
different position according to their masses (Figure 10). 
 
Figure 10 : Magnetic sector mass analyzer. 
 
However, the modern instrumentation mandates to keep the radius of deflection to be constant to 
guide ions into a single position for collection and analysis. This constant radius is achieved by 
varying the acceleration potential (V) and magnetic field (B) strength. Rearranging the variables of 
(Equation 5) for ion mass (m) while deflection radius (r) is constant then (Equation 7) 
𝒎 =
𝑩𝟐
𝟐𝑽
 Equation 7 
It can be concluded from (Equation 7) that a single mass ion can be selectively monitored adjusting 
the acceleration potential (V) or magnetic field strength (B) or both variables. 
Considering (Equation 6) for electrostatic field, the radius of deflection is dependent on acceleration 
potential (V) and electrostatic field strength (E) – i.e. acceleration potential of ion on entering the 
field and electrical potential applied on the ion in the field. Thus, ions having same kinetic energy 
will be selected and guided to the collection point, though may have different ion mass (Herbert and 
Johnstone, 2010) 
  Introduction 
44 
 
Electromagnetic and electrostatic fields are both used in modern instrumentation analyses, in 
combination, sequential or crossed geometry. The aim is to focus adjust the ion stream to arrive the 
collection and analysis point in focus, according to their mass, kinetic energy or both. The stream of 
ions collector produces the mass spectrum, which is a measure of the different m/z values and their 
respective abundance. 
Many mass analysers are available in use currently each with its advantage and disadvantages. The 
power of the mass analyser is measured by resolution (R), which is calculated mathematically as: 
R=m/Δm 
Where R is the resolution, m is the m/z to be measured, Δm is the difference between m/z value, and the ion 
from which is to be separated. 
The linear quadrupole ion trap mass analyser, 3D quadrupole ion-trap mass analyser, time-of-flight 
mass analyser, double focusing and trisector mass analysers are all different examples of currently 
used mass analyser. 
The linear quadrupole ion trap mass analyser (quadrupole mass analyser or transmission quadrupole 
as termed in different literature) consists of four rods arranged geometrically parallel to each other, 
and each two opposite rods are connected to an electric current and voltage (Figure 11). On a 
quadrupole mass analyser, one opposed pair is connected to positive potential while the other 
opposed pair is connected to negative potential. The potential is of two components: fixed potential 
(U) and radiofrequency (RF). RF is of amplitude (V) and angular frequency (ω) represented by the 
function Vcos(ωt) and as cos(ωt) cycle with time (t), voltage (V) change in a manner resulting in net 
electric field of zero at any time and along the planes and axis of the quadrupole analyser. The motion 
of ions within the quadrupole field is quite complex when compared to the ones in electromagnetic 
and electrostatic type of fields.  Adjusting the voltage will change the field strengths, will make a 
specific m/z value ion to oscillate in the central axis and on the two transverse plans, and to follow a 
stable path until reaching the detector, while others m/z values ions will be deflected to periphery 
toward the rods. Because the net electric field is zero, ions matching the selected m/z will trap in the 
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analyser and will not pass to the detector unless given an initial momentum. This momentum is 
provided through potential between the analyser and ion source. 
 
Figure 11: Linear quadrupole mass analyzer 
 
 
The 3D quadrupole Ion-Trap Mass Analyser (ion trap or quadrupole ion trap as termed in different 
literature), as the name implies, is related to the linear quadrupole mass analyser. Both types of 
detectors were invented and developed by Paul and Steinwedel in the 1960 and this work was 
recognised by the award of Nobel prize in physics in 1989. Both types of detectors, linear and 3D 
quadrupole mass analyser are working in a relatively similar way, but the path through the 3D 
quadrupole mass analyser is more complex than that in linear quadrupole mass analyser. Both types, 
linear and 3D quadruple mass analyser are low-resolution devices and this maybe a disadvantage 
when studying the elemental composition (Stafford, 2002). 
Time of Flight Mass Analyser (ToF) is the simplest mass analyser device (Figure 12). Working 
theory behind ToF instrument is applying the same energy on the ions while passing through, which 
will make each ion travel at a velocity inversely proportional to the mass, producing a spectrum 
related to the time each ion needed to reach the detector. This theory is basically different for other 
mass analysers, where there is no selection of specific mass in advance before entering the mass 
analyser, only one ion at a time enter the mass analyser. The first generation of ToF mass analyser 
were low resolution devices, but modification of the next generation improved tremendously the 
resolution of ToF. As the basic theory behind the work of ToF depends on the travelling speed and 
time needed for ions to reach the detector, increasing the length of the ToF tube would emphasise 
small difference on traveling speed of ions and hence the time needed to reach the detector. However, 
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this increase in the length of the tube is practically inappropriate as it would increase the size of the 
instrumentation The use of ion mirrors within the ToF tube increased the travelling distance without 
the need to increase the length of the tube which dramatically increased the resolution of ToF mass 
analyser thousands folds. In addition to the simplicity and fast scanning capability, ToF are 
increasingly used when high resolution analysis is needed. (Van Bramer, 1997; March, 2000; 
Pramanik et al., 2002; Glish and Vachet, 2003; Ardrey, 2003; Gross, 2004; Herbert and Johnstone, 
2010). 
 
 
Figure 12: simple schematic representation of Time of Flight Mass Analyzer. 
 
1.9.4.  Ion detectors 
In all types of mass spectrometry instrumentation, mass analysers would separate ions according to 
their m/z values to reach the detector area for the mass value and ion abundance to be detected and 
recorded. A mass spectrometry, as mentioned earlier, is a measure of the different m/z values and 
their respective abundance. 
The ions, after being analysed, may reach selectively to the detector in a sequential pattern according 
to m/z value – i.e. one selected mass at a time. This mode of detection, sequential detection of one 
mass at a time, is referred to as ‘point ion detector’. Other types of mass analysers’ separate ions 
according m/z value but without focusing one m/z value, and ion stream reach the detector separated 
but dispersed. This mode of detection is referred to as ‘array detectors’. In practice, mass 
spectrometry instrumentation may use one type or both of ion detectors. 
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1.9.4.1.  Point ion detectors 
Point ion detectors are the most in use for the common type of mass analysers. Three main types of 
point detectors are used: Faraday Cup, Electron Multiplier and Scintillator.  Those three types of 
detectors utilize the phenomena of ‘secondary electron emission’, which refers to the emission of 
secondary electrons when ions or more widely charged particles strike a metal surface (Figure 13). 
 
Figure 13: Schematic representation of different types of point ion detectors. 
A: Faraday cup, B; electron multiplier and C: scintillator 
In Faraday Cup ion detector, ions strike a metallic cup shaped collector and the secondary emitted 
electrons will be collected within the cup. The flow of electrons converts into an electrical current 
that is recorded respectively. In Electron Multiplier, the secondary emitted electrons when ions strike 
one plate (dynode) are accelerated to another plate and then to another third or more dynodes in 
serial. This will provide logarithmic multiplication of the ions, and the currently available electron 
multipliers have ten or more dynodes in serial providing millions times amplification power of the 
primary electron count. Again, the flow of electrons converts into an electrical current that is recorded 
respectively. In scintillator, or Daly detector, after the primary ion stream strike one dynode, the 
secondary electrons are accelerated to another dynode.   In Daly detector, the second dynode is a 
scintillator that emits photons when stroke by electrons. In these types of detectors, the emitted 
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photons are converted into an electrical current that is recorded respectively (Herbert and Johnstone, 
2010). 
1.9.4.2.  Array detectors 
Mass analysers separate ions according to their m/z values, and either they focus the separated ions 
into one point or deliver them to the detector side, separated but dispersed in space. A typical example 
of the latter is magnetic sector mass analyser. The dispersed ions can be recorded simultaneously 
through a detector type consisting of number of ion collection elements arranged in a line (Figure 
14). 
 
Figure 14: multichannel array detector 
 
 
Single-unit electron collector is one-collection element represents an electron multiplier, utilizing the 
phenomena of ‘secondary electron emission’. Compared to the ‘one-point detector’ type described 
earlier m single unit electron collector multiplier re much smaller in size, and the ‘secondary 
electrons’ emit when ions strike serially the side of the collection element, instead of serial dynodes, 
accelerated by potential (Figure 15). 
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Figure 15: single unit electron collector 
 
 
Due to the difficulty of fitting large number of ‘collection elements’ into an array, the range of ions 
can be scanned is narrow. For example, a compact array of 50 ‘collection elements’ allow only a 
range of 50 m/z scan with integer values. However, assuming the need to increase the resolution to 
0.5 instead of integer values, this allows only a range of 25 m/z scan. Hence, ‘array detectors’ allow 
wide range m/z scan with low resolution, or narrow range m/z scan with high resolution (Herbert and 
Johnstone, 2010). 
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Chapter 2  Literature Review 
2.1.  Current role of HPLC-DAD for the analysis of mephedrone and other selected 
NPS 
At the start of this thesis in 2009- 2010, mephedrone was starting to appear and traded as legal high. 
Mephedrone was selected due to its high significance and succeeding reports about its toxic and 
morbid effects. At that point, no data were available about its analytical and toxicological profile 
apart from subjective data presented by mephedrone users in community discussion forums. 
Though mephedrone was banned in most European countries in 2010, some fatal cases were reported 
after, and mephedrone has been traded in the illicit drug market. In addition, no reference standards 
were available which challenges researchers when developing analytical techniques for the detection 
of mephedrone, potential metabolites and toxic effects. This lack of data prompted the study of 
mephedrone, with other structurally related cathinones, with adulterants and other drugs of abuse. 
HPLC-DAD was the instrument of choice for preliminary studies about mephedrone because of its 
availability in most forensic laboratories and relatively low cost. 
What follow is a literature survey about the role of HPLC-DAD in the analysis of mephedrone and 
methcathinone, which was the selected synthetic cathinone for simultaneous analysis with 
mephedrone. Some articles were published after 2010 regarding qualitative and quantitative HPLC 
analysis of mephedrone and methcathinone. 
In 2011, both Santali et al. and Maskell et al. developed and validated a quantitative HPLC-DAD 
method for mephedrone. Both studies validation parameters were satisfactory. However, the Maskell 
et al. method was more sensitive and takes less time. Santali et al. tested their own synthesized 
mephedrone salts, where the method was applied for the analysis of mephedrone alone or 
simultaneously with other adulterants commonly used in the illegal drug market, such as caffeine, 
paracetamol, lidocaine, ketamine, sucrose and lactose. In contrast Maskell et al. analysed 
mephedrone and other cathinones in post-mortem blood samples, where in many of these cases, 
mephedrone was attributed to be the main cause of death. Data collected by Maskell et al. showed 
concentrations of mephedrone in the range of (0.13 - 2.24 µg/ml) in blood samples. Santali used 
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nicotinamide as an internal standard, and Maskell used cinchonine. (Santali et al., 2011; Maskell et 
al., 2011). 
In 2014, Golasik et al. qualitatively analysed urine samples taken from methcathinone long-term 
users by HPLC-DAD. The main aim of their work was to determine manganese in urine of long-term 
methcathinone users, however, methcathinone detection was carried via HPLC-DAD. Urine samples 
were extracted with ethyl acetate, evaporated and reconstituted with mobile phase before HPLC-
DAD analysis (Golasik et al., 2014) 
Adamowicz et.al. Analysed seized powders of mephedrone using HPLC-DAD and applied this 
method to analyse vitreous humour samples. Gradient elution of mobile phase consisting of ACN: 
water containing 100 µL 85% orthophosphoric acid per 1 L was used. Mephedrone-d3 was used as 
internal standard. Method was linear, with R2= 0.999.  LOD and LOQ were 0.08 and 1 ng/ml, 
respectively (Adamowicz et al., 2013) 
A summary of the most significant literature review data about the current role of HPLC in the 
analysis of mephedrone and related methcathinone is presented in Table 2. 
2.2.  Current role of chromatography-mass spectrometry in the analysis of selected 
NPSs and their metabolites in biological fluids 
Chromatography techniques coupled to mass spectrometry have become an essential part of modern 
forensic laboratories as screening as well identification tools. Utilizing the highly specific and 
accurate mass spectrometry instruments has significantly increased the analytical efficiency of the 
forensic laboratories. However, the problem in the analysis of NPSs and their metabolites using 
Chromatography-Mass spectrometry is mainly due to their wide range that fluctuates from newly 
synthesized molecules to herbal psychoactive substances. Additionally, pure standards of these 
compounds and their metabolites are not always available, and there is not enough data available 
about their chromatographic features up until late after their appearance (Favretto et al., 2013). 
Electron-impact MS (EI-MS) is the typical method used for the identification of illegal drugs, using 
the NIST Mass Spectral Library or other data bases. However, most designer drugs are not contained 
  Literature Review 
52 
 
within these libraries. GC-MS is the most commonly used analytical technique in forensic 
laboratories for analysis of designer drugs as most of these designer drugs have volatile properties. 
GC most of the time needs a relatively short period of time for analysis. The usual column is non-
polar DB-5MS [(5%-phenyl)-methylpolysiloxane] or an analogue, as it has high separation 
efficiency. 
2.2.1.  Currently available analytical studies of the selected NPS using LC-MS 
Systematic toxicological analysis of serum collected in an emergency department from patients with 
history of acute mephedrone toxicity was performed by Wood et.al. They combined GC-MS and LC-
MS/MS to confirm qualitatively the presence of mephedrone. For LC-MS, MS in Multiple Reaction 
Monitoring (MRM) analysis were utilized to confirm the fragments of mephedrone of m/z: 178, 160 
145 and 119 (Wood et al., 2010). 
Sorenson studied the simultaneous quantitative analysis of mephedrone and some other cathinone 
derivatives in human whole blood samples of both live and post-mortem cases, developed a liquid 
chromatography–tandem mass spectrometry method via pneumatically aided electrospray ionization. 
Methanol was used, as a pre-treatment step for protein precipitation, supernatant was ultra-filtered 
and mixed with deionised water before injection onto the LC-MS system. Method was validated, 
with LOD of 0.5-3 ng/ml, recovery percent of 87-106% and SD values better than 7% at 20 ng/ml. 
For the stability of cathinones, extracts were acidified with formic acid (Sorensen, 2011). 
Jankovics et al. developed a LC–MS/MS method for screening of mephedrone, methcathinone and 
other five-methcathinone analogues. Samples source were unknown bulk powders that were claimed 
to be harmless substances, which turned to contain at least methcathinone or one of the studied 
methcathinone derivatives. Separation was carried on reverse phase chromatography with gradient 
mode elution. DAD was used to record UV spectra (210-240 nm), and MS in MRM mode was 
utilized to identify fragmentation characteristics. The fragmentation characteristics were discussed 
thoroughly in this work in comparison with previously published work. Limit of detection was 2 
ng/mL, and total run time was less than 8 min. Typical fragmentation characteristics of the studied 
compounds were discussed (Jankovics et al., 2011). 
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Shah et al. developed and validated a quantitative analysis study of mephedrone and its metabolites 
4-methylephedrine and 4-methylnorephedrine by LC-MS/MS, and applied it to human hair samples. 
Method was proven to be linear in the range 5–100 pg/mg for mephedrone and 10–150 pg/mg for 
the two metabolites. They used LLE for sample preparation using hexane for mephedrone and 
mixture of chloroform, ethanol and diethyl ether (3:1:1 ratio) for the metabolites. Precision, accuracy, 
limit of detection, limit of quantitation and extraction recovery were determined and all were within 
limits specified by FDA guidelines. LOD was 2.5 pg/mg and LOQ was 5 pg/mg. For the metabolites 
LOD and LOQ were 5 pg/mg and 10 pg/mg, respectively (Shah et al., 2012). 
Pedersen et al., in 2012, performed analysis of blood and urine samples of forensic cases using 
UPLC-MS/MS and UPLC-QToF/ MS, they could detect mephedrone and its metabolites in blood, 
the mephedrone concentration in blood samples was 1-51 µg/kg, and up to 9 µg/kg for its metabolite 
hydroxyl tolyl mephedrone, in one of the cases the concentration of mephedrone was as high as 700 
µg/kg, and 190 µg/kg for hydroxyl tolyl mephedrone (Pedersen et al., 2013). 
Swortwood et al. analysed a number of cathinones, including mephedrone, and other designer drugs 
in serum samples by a quantitative LC -MS/MS analytical method. Samples were prepared by SPE, 
LOD for all analytes was found to be about 10 pg/mL, while LOQ values ranged from 1 to 10 ng/mL 
(Swortwood et al., 2013). 
In 2013, Marinetti and Antonides developed an LC-MS method for analysis of synthetic cathinones, 
including mephedrone, in blood and urine samples collected from real cases. Samples were prepared 
by LLE (Marinetti and Antonides, 2013) 
For the study and analysis of synthetic cathinone and two piprazines, including mephedrone and 4-
fluoromethamphetamine, de Castro et al. applied and validated an LC-MS/MS for analysis in oral 
fluid. Samples were SPE extracted and chromatographic separation was achieved using 0.1% formic 
acid in acetonitrile mobile phase. The method showed to be linear over the specified range of 0.2/0.5-
200 ng/ml with LOD and LOQ of 0.025-0.1 ng/ml and 0.2-0.5 ng/ml respectively with recovery 
percent of 87.9-134.3 (de Castro et al., 2014). 
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Elian et al.  analysed a number of amphetamines and cathinones, including mephedrone, in human 
hair samples by LC-MS/MS. Sample preparation was performed by SPE, mobile phase contained 
acetonitrile and formic acid, gradient chromatography mode was performed using C18 column. Run 
time was less than 5 minutes (Elian et al., 2014). 
In 2014, Reid et al. analysed amphetamine-like drugs including mephedrone, synthetic cannabinoids 
and their urine metabolites in sewage using a quantitative UHPLC-MS/MS, where samples collected 
from sewage of three Norwegian cities. LOD was 1 ng/L for mephedrone and other amphetamine-
like drugs, while LOQ was 3 ng/L (Reid et al., 2014) 
In 2013, Paoli et al. purchased methoxetamine and other two psychoactive drugs through the internet 
under the label “research chemicals,” and analysed them using GC-MS. They also developed and 
validated a quantitative HPLC-MS/MS method and HPLC-UV method for determination of these 
materials in urine, blood, and vitreous humour. The developed HPLC–UV method was found to be 
satisfactorily valid in the range between 0.16 and 5.0 mg/L (De Paoli et al., 2013). 
Amaratunga performed quantitative analysis of cathinones in oral fluid. They applied UHPLC-
MS/MS method, with gradient mode, and SPE for sample preparation. The method was validated 
and found to be accurate, precise, linear and sensitive, with acceptable recovery. The method was 
successfully applied on human oral fluid samples (Amaratunga et al., 2013). 
In 2013, Meyer et al. applied GC-MS and LC-MS methods to analyse methoxetamine and its phases 
I and II metabolites in rat and human urine samples. Moreover, human CYP 450 enzymes were found 
to be responsible for the initial steps of methoxetamine metabolism in vitro. The last step was the 
analysis of human urine samples collected from patients. They could detect eight metabolites 
suggesting O-demethylation, N-deethylation or hydroxylation phase I metabolic pathways. Phase II 
metabolism, namely sulfation or glucuronidation, or combinations of more than one pathway were 
also suggested (Meyer et al., 2013). 
In 2013, Saffar et al. developed and validated a LC–MS/MS method for screening of novel 
psychoactive drugs, including mephedrone and methoxetamine, in urine. Samples were diluted, 
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pethidine-d5 was used as an internal standard. Gradient elution mode was applied and run time was 
4.0 min. Method was validated and found to be linear in the range of 0.1–10 µg/mL, with suitable 
precision where CV< 15% (Al-Saffar et al., 2013). 
Elliot et al., in 2013, screened and confirmed presence of mephedrone and other cathinones in bath 
salts using direct sample analysis ToF/MS. They suggested the presence of this technique in forensic 
laboratories and replacing the commonly used lengthy GC/MS and LC/MS/MS methods techniques 
can be helpful as it does not need sample preparation and takes much less time for training and 
analysis and improves laboratory efficiency (Elliott et al., 2013). 
Recently, Chen Applied a LC–MS method to quantitatively analyse methcathinone and other 3 
designer drugs and some of their metabolites through in vitro study.  He performed a metabolism 
study for each drug separately using microsomes S9 fraction prepared from rat liver. The selected 
drugs and five of their major metabolites were successfully detected. The method was validated, it 
was linear in the range from 0.01 to 5.0 g/mL, limits of detection were less than 0.03 g/mL where 
RSD values were below 5.9%, and recoveries were more than 77.4% (Chen, 2015) 
Very recently in 2015, Pasin et.al developed and validated a quantitative LC-MS analytical method 
of novel designer drugs, including mephedrone and methcathinone, in post mortem blood samples. 
LLE with acetonitrile was used for sample preparation, mephedrone-d3 was the used internal 
standard, and run time was 15 minutes. Method was found to be linear in the range of 0.05–2 mg/L. 
LOD for analytes ranged from 0.007 to 0.07 mg/L, while LOQ values were in the range of 0.05–0.1 
mg/L. Extraction recoveries were from 71 to 100% (Pasin et al., 2015). 
Summary of the most significant literature review data about the currently available analytical studies 
of selected and related NPS using LC-MS are presented in Table 3. 
2.2.2.  Currently available analytical studies of NPS using GC-MS 
Torrance and Cooper performed quantitative analysis of mephedrone. They used a certified standard 
of mephedrone from and the method was an accredited method for amphetamines taken from in 
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blood using GC–MS-EI and using derivatization with PFP. Selected ions monitored were m/z 204, 
160 and 91 using the internal standard MDA-d5., and LOQ was determined to be 0.1 mg/L (Torrance 
and Cooper, 2010). 
In 2010, Meyer et al. applied a GC-MS method to rat and human urine samples and detected 
metabolites of mephedrone and other Beta-keto amphetamines. They suggested the metabolic 
mechanisms of reduction of the ketone group to the corresponding alcohol, N-demethylation to give 
a primary amine, and the oxidation of the tolyl functionality to alcohol or carboxylic acid (Meyer et 
al., 2010). 
Brandt et al. performed a relatively similar work, where they purchased a number of legal high 
products from different internet websites and performed qualitative analysis using GC-MS/ion trap 
and NMR spectroscopy. They dissolved samples in methanol, and applied methods that were used 
before for psychoactive drugs with related structure. The results were compared with reference 
standards, and they concluded that more than two thirds of the NRG-1 and NRG-2 products that were 
marketed legal as highs or as a replacement for banned mephedrone were truly containing banned 
cathinones (Brandt et al., 2010). 
In 2011, Baron et al. performed analysis of seven legal high samples purchased from online traders, 
to validate the identity and purity of the labelled materials which claimed to contain either bath salts, 
research chemicals or plant food.  They analysed samples using FTIR.  Subsequently, GC-MS 
analysis was performed, after being extracted with methanol, run time was about 10 minutes. NIST 
spectra library and reference standards were utilized for comparison. The analytical study proves that 
only one sample contained what it was claimed on the label, while others contained different 
materials (Baron et al., 2011). 
In 2011, Power et al. studied the chemical analysis of substituted cathinones using GC-MS, where 
the isomers 2-, 3- and 4-methylmethcathinone were analysed. They synthesized 2- and 3-
methylmethcathinone. They found that the isomers can be separated by GC-MS without need to 
derivatization. They also analysed a seized sample by GC-MS, it contained mephedrone and 
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benzocaine with minimal amounts of 2- and 3-methylmethcathinone. Additionally, they performed 
NMR analysis, the results confirmed those obtained by GC-MS (Power et al., 2011). 
In 2011, McDermott et al. studied mephedrone, ethcathinone and their isomers. The research team 
performed GC-MS analysis of drug samples assumed to contain mephedrone and ethcathinone, and 
they observed other compounds in the chromatogram. The initial proposal that these other 
compounds were isomers of mephedrone and ethcathinone was confirmed by the comparison and 
analysis of in-house synthesized isomers of these two designer drugs. They proposed these isomers 
are contaminants due to impure starting materials or rearrangement of the propiophenone originating 
products to the phenylacetone ones. In addition, they suggested that the presence of isomeric 
compounds might lead to common origin of the samples (McDermott et al., 2011). 
In 2012, Martin et al.  applied GC-MS using hair samples to prove mephedrone chronic toxicity. 
They extracted samples using ethyl acetate (after alkalinisation with 1 N NaOH). Applied 
derivatization using a mixture of heptafluorobutyric anhydride/ethyl acetate (100:50, v/v), Detection 
was achieved in single ion monitoring mode. The detected mephedrone concentrations ranging from 
0.2 to 313.2 ng/mg. Method was linear, precise and accurate with LOQ of 0.2 ng/mg. The LOD was 
0.08 ng/mg. The intra-day variations (CV) at two concentrations was less than 4%, while inter-day 
variation was less than 15% (Martin et al., 2012). 
As a replacement for immunoassays screening methods, Lua et al. studied GC-MS analysis of 
mephedrone, ketamine and other amphetamine-type stimulants. They suggested that due to the 
limitations of availability of new immunoassays to keep with the rapidly emerging NPS market, GC-
MS analyses are potentially one of the alternatives for the analysis of NPS for which no immunoassay 
kits are available (Lua et al., 2012). 
Elie, et.al developed a rapid screening method for the analysis of 23 analytes, including 
methoxetamine. They analysed 35 products bought through internet, head shops, and successfully 
identified the active ingredients. The separation was achieved within 4 minutes using low bleed and 
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highly inert chromatography column, and their method showed to be efficient even with the 
unavailability of reference standards (Elie et al., 2013). 
For the evaluation of whether designer drugs, especially designer amphetamines and cathinones, 
would interfere with currently existing and used amine confirmation methods, Holler et al. studied 
the effect of a number of synthetic amphetamines, including 4-fluoromethamphetamine, through 
immunoassays screening and utilizing MS and using three different derivatization methods. The 
initial proposal was that due to structural similarity, these designer amphetamines would potentially 
interfere with existing immunoassays and GC-MS confirmatory methods. They concluded the need 
of validation and revalidation of existing detection methods for amines to keep up with challenging 
rapidly appearing NPS (Holler et al., 2014). 
Leffler et al., in 2014, analysed a number of cathinone analogues including mephedrone, in street 
samples, using GC–MS, HPLC and MS/MS. Methanol was used as extraction solvent, and GC–MS 
was applied for initial analysis, while direct infusion MS/MS was performed for identification of 
unknown molecules, and finally HPLC fractionation was used for accurate masses and information 
in order to predict structural formula of molecules. Standards were then purchased from Cayman 
chemical company and used as a proof of identity of the analytes using GC–MS. The claimed active 
materials of the designer drugs samples were found to constitute only 11% to 85% of the labelled 
amount (Leffler et al., 2014). 
In 2014, Daeid et al. synthesized mephedrone and another 15 legal high cathinone derivatives and 
then developed a qualitative GC–MS method to analyse them. Samples were prepared by dissolving 
analytes in methanol, and direct injecting them into GC–MS system, without the need for 
derivatization. Cathinone mixtures with commonly added adulterants, which are lidocaine, 
benzocaine, and procaine, were successfully identified and separated (Daeid et al., 2014). 
Very recently, Meng et al. performed analysis of selected drugs of abuse including methcathinone in 
blood and urine via GC-MS. The aim of the study was a comparison of different types of 
microextraction methods. Method was linear for the selected analytes in 0.0030–10 g/ml 
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concentration range. LOD was calculated in both methods to be 0.5 and 5 ng/ml and 0.5 to 4 ng/ml, 
respectively (Meng et al., 2015). 
Summary of the most significant literature review data about the currently available analytical studies 
of selected and related NPS using GC-MS are presented in Table 4. 
2.3.  Currently available data for in vitro studies of selected NPS 
Limited data are available regarding in vitro studies of the selected NPS and related drugs, and most 
of the available data was about identification of the metabolites of NPS followed by analytical 
techniques, mostly MS. A few other studies were concerned about the effects of NPS at the cellular 
level and to mimic potentially harmful effects in vivo. 
Meyer et al performed in vivo metabolic studies of mephedrone, and applied GC-MS which enabled 
them to detect mephedrone metabolites in human and rat urine. They concluded that mephedrone 
may be metabolized through phase 1 enzymatic systems through demethylation, reduction or 
oxidization. Demethylation involves the removal of the N-methyl functional group producing nor-
mephedrone which will go further into reduction of the ketone moiety producing the corresponding 
alcohol, nor-dihydro mephedrone Also, hydroxytolyl-mephedrone, 4-carboxy-dihydro mephedrone 
and nor-hydroxytolyl mephedrone were detected at their study as products of an overlapping 
metabolic pathway of oxidation, reduction and N-demethylation. It was concluded through their 
study also that phase II metabolic pathways are involved in the metabolism of mephedrone through 
sulphontaion or glucuronidation of the hydroxytolyl- mephedrone and its demethylated form (Meyer 
et al., 2010). 
Pedersen et al. , in 2013, performed in vitro studies using CYP enzymes and human liver microsomes, 
followed by analysis of blood and urine samples of forensic cases using UPLC-MS/MS and UPLC-
QToF/ MS , they found that mephedrone is mainly metabolized by CYP450 2D6 enzyme in phase I 
metabolism giving two major metabolites which are nor-mephedrone and hydroxyltolyl mephedrone, 
these two metabolites were identified in addition to other three metabolites, namely carboxy  
mephedrone,  dihydro mephedrone and 4-carboxy-dihydro-mephedrone,  the mephedrone 
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concentration in blood samples was 1-51 µg/kg, and up to 9 µg/kg for its metabolite hydroxyl tolyl 
mephedrone, In one of the cases the concentration of mephedrone was as high as 700 µg/kg, and 190 
µg/kg for hydroxyl tolyl mephedrone (Pedersen et al., 2013). 
Meyer et al. recently utilised GC-MS for in vivo studies and detection of MXE metabolites in human 
and rat urine. They concluded that MXE may be metabolised through phase I and phase II enzymatic 
systems. Phase I enzymatic reactions involve N-demethylation, O-demethylation and hydroxylation 
or a combination of these metabolic steps. It was concluded through their study also that phase II 
metabolic pathways are involved in the metabolism of MXE through sulphontaion or glucuronidation 
of most of these metabolites (Meyer et al., 2013). 
Menzies et al. performed in vitro studies utilizing LC-MS for the analysis of MXE metabolites after 
incubation with human liver microsomes. Phase I and phase II metabolites were detected in their 
study, where phase I metabolites were the product of N-demethylation, O-demethylation, reduction, 
hydroxylation and dehydrogenation. 
Regarding the in vitro metabolic studies of methcathinone, although it appeared in the market for 
drugs of abuse many years ago, only recently has there been published data about its metabolism. 
Recently, Chen published data about in vitro studies of metabolism of designer drugs including 
methcathinone. Cathinone was reported as a metabolite for methcathinone through N-demethylation 
(Chen, 2015). 
A search for literature about in vitro studies on 4-fluromethamphetamine yielded no hits, and no 
published data could be found about the metabolic and toxic profile of 4-fluoromethamphetamine. 
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Table 2: Summary of significant analytical methods for analysis of mephedrone using HPLC-DAD 
Reference Analytes Biological 
matrix 
Sample 
preparation 
Chromatography conditions validation parameters 
Santali et al., 2011 Mephedrone 
and adulterants 
NA1 in methanol Mobile phase: Gradient mode: phase A: methanol:10 mM 
ammonium formate (pH 3.5) (40:60); phase B: methanol 
 
Stationary Phase: ACE 3C18 
 
Total Run Time: <10 minutes 
Range of Linearity: 0.5–10 µg 
/mL 
Linearity: R2> 0.999 
Precision: 0.36 –0.90% 
LOD: 0.1 µg/ mL 
LOQ: 0.3 µg/ mL 
Maskell et al., 
2011 
Mephedrone 
and other 
cathinones 
Post-
mortem 
blood 
LLE with 1-
hlorobutane 
Mobile phase:10% acetonitrile (with 25mM TEAP buffer) 
 
Stationary Phase: C18 
 
Total Run Time: <6 minutes 
Range of Linearity: 0.078-10 
µg/ml 
Linearity: R2 > 0.999 
Precision: within 3%. 
LOD: 0.039 µg/mL 
LOQ: 0.078 µg/mL 
Adamowicz, 2013 mephedrone NA In methanol Mobile phase: Gradiant.Acetonitrile: water containing 100 µL 
85% orthophosphoric acid per 1 L  
 
Stationary Phase: LiChroCART 125-4 LiChrospher RP-select B 
 
Total Run Time: 14 min 
Range of Linearity: 1-100ng/ml 
Linearity: R2 0.996 
Precision: 10.4-14.2 
LOD: 0.08 ng/ml 
LOQ: 1 ng/ml 
Golasik et al., 
2014 
Methcathinone Urine of 
chronic 
abusers 
LLE with 
ethyl acetate 
Mobile phase: Gradient mode: phase A: 500 mL of deionized 
water with 100 μL of concentrated phosphoric acid; phase B: 
acetonitrile  
 
Stationary Phase: LiChroCART 125-4 LiChrospher RP-select B 
 
Total Run Time: 30 minutes 
Range of Linearity: NDA2 
Linearity: NDA 
Precision: Not tested 
LOD: NDA 
LOQ: NDA 
1: NA: Not applicable    2: NDA: No data available 
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Table 3: Summary of significant analytical methods for analysis of selected NPS using LC-MS 
Reference Analytes Matrix Sample preparation Stationary phase Chromatography Mass spectrometry validation parameters 
Sorensen et 
al., 2011 
Mephedrone, 
methcathinone and other 
cathinones 
NA protein precipitation, 
ultrafiltration 
Internal standard: 
Mephedrone-D3 
methcathinone-D3 
Agilent Zorbax 
EclipseXDBC-18 
(75 mm x 4.6 mm) 
Mobile phase: Gradient: Phase A: water 
Phase B: MeOH (both acidified with 0.1% 
formic acid) 
Stationary phase: Prodigy Phenyl-3 
Total run time: <20 minutes 
pneumatically aided 
electrospray 
ionisation, SRM 
Range of linearity; 10–250 µg/L 
Linearity: R2>0.997 
Precision: SD <7% At 20 g/L 
LOD: 0.5-3 µg/mL 
LOQ: NDA 
Jankovics et 
al, 2011 
Mephedrone, 
methcathinone & its 
analogues 
NA Dissolved in methanol 
Internal standard: 
NDA1 
Agilent, DB-1 (30 
m×0.25 mm×0.25 
μm) 
Mobile phase: Gradient: Eluent A: 95% 
water, 5% ACN, 0.1% formic acid. Eluent 
B: 95% ACN, 5% water, 0.1% formic acid. 
Stationary phase: Agilent Zorbax 
EclipseXDBC-18 (75 mm x 4.6 mm) 
Total run time: <8 minutes 
MRM mode Range of linearity; NDA 
Linearity: NDA 
Precision: NDA 
LOD: Average: about 2 ng/mL for 
all analytes 
LOQ: NDA 
Pedersen et 
al., 2011 
Mephedrone and its 
metabolites 
Blood and 
urine 
SPE 
Internal standard: 
Amphetamine-D5 and 
orphenadrine 
Agilent SB-C18 
column 
Mobile phase: 0.1% formic acid (solvent A) 
and 100%acetonitrile (B), gradient 
Stationary phase: UPLC BEH C18 
Total run time: 
QToF, MRM, ESI Range of linearity; 1 - 400 mg/kg 
for mephedrone 
Linearity: NDA 
Precision: CV < 10% 
LOD: NDA 
LOQ: NDA 
Shah et al., 
2012 
Mephedrone and 
metabolites 
Human hair LLE with hexane 
Internal standard: 
Mephedrone-d3 
Phenomenex, C18 
(50 x 2 mm x4 µm) 
Mobile phase: Acetonitrile: water, different 
conc., gradient mode 
Stationary phase: Agilent SB-C18 column 
Total run time: ~ 10 minutes 
selective reaction 
monitoring (SRM) 
mode 
Range of linearity; 5–100 pg/mg 
for mephedrone 
Linearity: R2 >0.999 
Precision: RSD %: 0.4-0.8 for 
mephedrone 
LOD: 2.5pg/ml for mephedrone 
LOQ: 5 pg/ml for mephedrone 
Paoli et al., 
2013 
methoxetamine and other 
two psychoactive drugs 
Blood, 
urine and 
vitreous 
humour 
LLE with 1-
chlorobutane 
Internal standard: 
NDA 
C18 Mobile phase: Gradient: soln. A: ammonium 
formate, formic acid Soln. B: acetonitrile, 
ammoniumFormate, formic acid 
Stationary phase: Phenomenex, C18 (50 x 2 
mm x4 µm)  
Total run time: 20 minutes 
MRM Range of linearity; 0.16-5.0 mg/L 
Linearity: NDA 
Precision: RSD%= 1.62% 
LOD: 0.03 mg/L in blood, 0.04 
mg/L in urine 
LOQ: 0.16 mg/L in all matrixes 
Amaratunga 
et al., 2013 
Mephedrone, 
methcathinone and other 
cathinones 
Human oral 
fluid 
SPE 
Internal standard: 
NDA 
TF TG-1MS 
capillary column 
Mobile phase: Mobile phase A: 0.1% formic 
acid in water: acetonitrile (95: 5, v/v), 
mobile phase B: 0.1% formic acid in 
acetonitrile 
Stationary phase: C18 
Total run time: 
ESI+, multiple 
reaction 
monitoring(MRM) 
mode 
Range of linearity; 1.0 –500.0 
ng/mL 
Linearity: R2 >0.990 
Precision: NDA 
LOD: NDA 
LOQ: 1.0 ng/mL 
Meyer et al., 
2013 
methoxetamine and its 
phases I and II 
metabolites 
rat and 
human 
urine 
SPE 
Internal standard: 
ketamine 
1MS capillary 
column 
 
Mobile phase: helium 
Stationary phase: TF TG-1MS capillary 
column 
Total run time: About 20 minutes 
Electronic ionization 
(EI) and positive-ion 
chemical ionization 
(PICI) 
Range of linearity; NDA 
Linearity: NDA 
Precision: NDA 
LOD: NDA, LOQ: NDA 
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Continued 
Reference Analytes Matrix Sample preparation Stationary phase Chromatography Mass spectrometry validation parameters 
Saffar et al., 
2013 
Mephedrone, 
methoxetamine and other 
NPS 
urine dilution 
Internal standard: 
pethidine-d5 
C18 column Mobile phase: CHECK 
Stationary phase: Ethylene Bridged Hybrid 
(BEH) C18 
Total run time: 4 minutes 
LC-MS/MS Range of linearity; 0.1–10 µg/mL 
Linearity: NDA 
Precision: LOD and LOQ:  NDA 
De Castro et 
al., 2014 
mephedrone and 4-
fluoromethamphetamine 
Oral fluid SPE 
Internal standard: 
NDA 
C18 Mobile phase: formic acid 0.1% and 
acetonitrile 
Stationary phase: T3 column 
Total run time: NDA 
CHECK Range of linearity; 0.2/0.5-200 
ng/ml 
Linearity: R2 >0.990 
Precision: %CV = 0.0–12.7% 
LOD: 0.025-0.1 ng/ml 
LOQ: 0.2-0.5 ng/ml 
Elian et al., 
2014 
Mephedrone, other 
amphetamines and 
cathinones 
human hair SPE 
Internal standard: 
mephedrone-d3 
Acquity UPLC BEH 
C8 column 
Mobile phase: acetonitrile and formic acid 
Stationary phase: C18 
Total run time: 5 minutes 
Tandem mass 
spectroscopy 
Range of linearity; 0.1-10 ng/mg 
Linearity: R2 > 0.995 
Precision: As percent recovery: 
106 ± 7, for 2ng/mg 
LOD: 0.05 ng/mg 
LOQ: 10 ng/mg 
Reid et al., 
2014 
Mephedrone and other 
amphetamine-like drugs 
and their urine 
metabolites 
Sewage 
samples 
SPE 
Internal standard: 
mephedrone-d3 
Waters, C18 column 
(2.1x150 mm,1.8 
mm) 
Mobile phase: Gradient: Solvent A: NH4AC 
10 mM and 0.1 % acetic acid in water. 
Solvent B: NH4AC10 mM & 0.1 % acetic 
acid in MeOH 
Stationary phase: Acquity UPLC BEH C8 
column  
Total run time: NDA 
MRM Range of linearity; 1.6 to 50 ng/L 
Linearity: R2 > 0.99 
Precision: RSD% of recover 5-40 
% 
LOD: 1 ng/L 
LOQ: 3 ng/L 
Pasin et.al, 
2015 
mephedrone and 
methcathinone and other 
drugs 
Spiked 
blood 
samples 
LLE with acetonitrile 
Internal standard: 
mephedrone-d3 
C18 Mobile phase: Gradient: A: (5 mM 
Ammonium Formate), B [Acetonitrile, 0.1% 
(v/v) Formic Acid]:  
Stationary phase: Waters, C18 column 
(2.1x150 mm,1.8 mm) 
Total run time: 15 minutes 
positive electrospray 
ionization mode 
Range of linearity; 0.05–2 mg/L 
Linearity: R2> 0.98 
Precision: % CV <15 
LOD: 0.007 to 0.07 mg/L 
LOQ: 0.05–0.1 mg/L 
Chen, 2015 Methcathinone, other 
designer drugs and them 
in vitro metabolites 
in vitro 
drug 
metabolites 
Extraction by 
acetonitrile 
Internal standard: 
NDA 
C18 Mobile phase: phase A (water, 10 mM 
ammonium acetate, 0.1% acetic acid) and B 
(methanol) 
Stationary phase: C18 
Total run time: ~10 minutes 
Ion trap Range of linearity; 0.08- 5.0 
(µg/mL) 
Linearity: R2=0.9991 
Precision: For inter and intra-days< 
5.9% 
LOD: 0.03 µg/mL 
LOQ: 0.08 µg/mL 
1: NDA: No data available 
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Table 4: Summary of significant analytical methods for analysis of selected NPS using GC-MS 
Reference Analytes Analytical method Matrix Sample preparation Chromatography Mass spectrometry validation parameters 
Wood et.al., 
2010 
Mephedrone GC-MS and LC-MS/MS 
quantitative 
Serum from 
patients 
 
Internal standard: 
MDMA D5 
Mobile phase: Methanol, 
deionized water, 
Stationary phase: HP5MS 
column 
Total run time: 12 minutes 
MRM mode Range of linearity; 
0.01 to 1 mg/L 
Linearity: NDA 
Precision: NDA 
LOD: NDA 
LOQ: NDA 
Meyer et al., 
2010 
Mephedrone, other 
Beta-keto 
amphetamines and 
their metabolites 
GC-MS rat and human 
urine 
NDA 
Internal standard: NDA 
Mobile phase: NDA 
Stationary phase: NDA 
Total run time: 
NDA2 Range of linearity;  
Linearity: NDA 
Precision: NDA 
LOD: NDA 
LOQ: NDA 
Torrance and 
Cooper, 2010 
mephedrone GC–MS-EI, quantitative NA1 Post mortem blood, 
urine and hair 
Internal standard: 
MDA-d5 
Mobile phase: According to 
ISO/IEC 17025 accredited 
method 
Stationary phase: According to 
ISO/IEC 17025 accredited 
method 
Total run time: Not mentioned 
ToF Range of linearity; Not 
tested 
Linearity: Not tested 
Precision: Not tested 
LOD: 0.1 mg/L 
LOQ: 0.1 mg/ 
Meyer et al., 
2010 
Mephedrone, other 
Beta-keto 
amphetamines and 
their metabolites 
GC-MS rat and human 
urine 
SPE 
Internal standard: NDA 
Mobile phase: Helium 
Stationary phase: HP-1 capillary 
(12 m×0.2 mm ID) 
Total run time: About 16 
minutes 
EI mode Range of linearity; Not 
tested 
Linearity: Not tested 
Precision: Not tested 
LOD: Not tested 
LOQ: Not tested 
Baron et al., 
2011 
Unknown legal highs GC-MS NA Extraction with 
methanol 
Internal standard: NDA 
Mobile phase: Helium 
Stationary phase: Agilent, DB-1 
MS column (30 m×0.25 
mm×0.25 μm) 
Total run time: 10.25 minutes 
total ion count (TIC) 
mode 
Range of linearity; 
NDA 
Linearity: NDA 
Precision: NDA 
LOD: NDA 
LOQ: NDA 
Power et.al, 
2011 
Mephedrone and other 
ring substituted 
isomers 
GC-MS NA Dissolved in methanol 
Internal standard: NDA 
Mobile phase: helium 
Stationary phase: HP-ULTRA 1 
capillary column 
Total run time: 20 minutes 
NDA Range of linearity; 
NDA 
Linearity: NDA 
Precision: NDA 
LOD: NDA 
LOQ: NDA 
McDermott et 
al., 2011 
Mephedrone, 
methcathinone and 
their isomers 
GC-MS NA Dissolved in methanol 
Internal standard: NDA 
Mobile phase: helium 
Stationary phase: HP-ULTRA 1 
capillary column 
Total run time: 20 minutes 
NDA Range of linearity; 
NDA 
Linearity: NDA 
Precision: NDA 
LOD: NDA 
LOQ: NDA 
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Continued 
Reference Analytes Analytical method Matrix Sample preparation Chromatography Mass spectrometry validation parameters 
Martin et al, 
2012 
mephedrone GC-MS hair Extraction with ethyl 
acetate 
Internal standard: NDA 
Mobile phase: NDA 
Stationary phase: NDA 
Total run time: NDA 
NDA Range of linearity; 
NDA 
Linearity: NDA 
Precision: NDA 
LOD: 0.08 ng/ml 
LOQ: 0.2 ng/ml 
Martin et al, 
2012 
mephedrone GC-MS hair Extraction with ethyl 
acetate 
Internal standard: NDA 
Mobile phase: NDA 
Stationary phase: NDA 
Total run time: NDA 
NDA Range of linearity; 
NDA 
Linearity: NDA 
Precision: NDA 
LOD: 0.08 ng/ml 
LOQ: 0.2 ng/ml 
Lua et al, 2012 Mephedrone, ketamine 
and other 
amphetamine-like 
stimulants 
GC-MS NA NDA 
Internal standard: NDA 
Mobile phase: NDA 
Stationary phase: NDA 
Total run time: NDA 
NDA Range of linearity; 
NDA 
Linearity: NDA 
Precision: NDA 
LOD: NDA 
LOQ: NDA 
Holler et al., 
2014 
4-
fluoromethamhetamine 
and other 
amphetamines 
GC-MS, qualitative urine SPE 
Internal standard: NDA 
Mobile phase: helium 
Stationary phase: DB-5MS 
Total run time: NDA 
NDA Range of linearity; 
NDA 
Linearity: NDA 
Precision: NDA 
LOD: NDA 
LOQ: NDA 
Daeid et al., 
2014 
Mephedrone and other 
legal highs and 
adulterants 
GC-MS, qualitative NA Dissolved in methanol 
Internal standard: 
eicosane 
Mobile phase: helium 
Stationary phase: capillary 
column HP5 MS 
Total run time: 10 minutes 
mass selective 
detector (MSD) 
Range of linearity; 
NDA 
Linearity: NDA 
Precision: NDA 
LOD: NDA 
LOQ: NDA 
Meng et al., 
2015 
methcathinone GC-MS blood and 
urine 
microextraction 
methods 
Internal standard: NDA 
Mobile phase: NDA 
Stationary phase: NDA 
Total run time: NDA 
NDA Range of linearity; 
0.0030–10 g/ml 
Linearity: NDA 
Precision: NDA 
LOD: 0.5 to 5 ng/ml  
LOQ: 0.5 to 4 ng/m 
1: NA: Not applicable    2: NDA: No data available 
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Chapter 3  Materials and Methods 
3.1.  Analysis of mephedrone and other selected drugs of abuse utilizing HPLC after 
extraction from biological samples 
The HPLC technique is based on a solid (stationary) phase and a liquid (mobile) phase, which 
contrasts with Gas Chromatography (GC), where the technique is based on a gaseous (mobile) phase. 
HPLC is superior for the analysis of non-volatile or unstable organic compounds (Engelhardt, 2004; 
USP-NF, 2007b). HPLC is the core instrumentation used for analysing non-volatile drugs of abuse 
(Mc Fadden et al., 2006), where reversed phase chromatography (RPC) is the main HPLC mode 
used. It is a combination of a non-polar stationary phase (the column), and a polar mixture of water 
and an organic solvent-mobile phase (Snyder et al., 2009). HPLC is one of the most common 
available analytical instruments in forensic and analytical laboratories. Reversed phase 
chromatography is the most common form of liquid chromatography and it is advantageous for its 
compatibility with aqueous samples and flexibility in modifying the mobile phase, with either 
organic modifiers or buffer solutions (Snyder et al., 2009; McCalley, 2010). 
In method development utilizing chromatography, the selection of suitable stationary phases is of 
prime importance, since it contributes differential interactions with components of a mixture 
resulting in their separation (Snyder et al., 2009). The type of stationary phase suitable for the 
analysis is dependent on the physicochemical characteristics of the analytes of interest. The column 
length affects separation efficiency, working pressure and analysis time. Other column variables - 
e.g., column diameter, packing material - are equally important and affect analytical method 
parameters differently - separation efficiency, working pressures, sample amount … etc. (Bayne and 
Carlin, 2010; McCalley, 2010). 
The composition of the mobile phase is also a core element that affects the separation. For reversed 
phase, the most common mode used in HPLC analytical methods, the mobile phase is usually a 
mixture of aqueous solution with one or more organic modifier. When choosing the organic modifier, 
parameters such as purity, detector compatibility, solubility of the sample, low viscosity and 
chemical inertness should be taken into consideration, in addition to the possible hazards using some 
types of solvents. The separation in HPLC is a combination of differential interactions of the analytes 
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with both stationary phase and mobile phase. Buffering the mobile phase is very important, as this 
assures reproducible retention peaks. 
The use of a suitable internal standard for chromatographic assays is highly recommended.  The 
internal standard must have physicochemical properties as similar to the drugs of interest as possible, 
and it must be added to the sample at the earliest possible stage in the method, before pH modification 
and extraction of the sample (SOFT/AAFS, 2006). The diode array detector (DAD) is one of the 
most commonly available detector types in forensic laboratories, and it is able to provide more 
spectral information than the fixed UV/Vis detector. 
3.1.1.  Materials 
Mephedrone was purchased legally from web-based companies before it was declared illegal 
(plantfeedchemicals.com). The percentage purity of mephedrone was confirmed by Fourier 
transform infrared spectroscopy (FTIR). Mass spectrometry (MS) was used to verify the structure. 
Methcathinone was synthesized and identified in the analytical laboratory according to a previously 
published method (DeRuiter et al., 1994). Caffeine, monobasic potassium phosphate was from Sigma 
(UK), potassium chloride, (Fisher, UK). Methanol of analytical grade, acetonitrile (HPLC grade), 
boric acid (100.04%), n-butanol (99.96%), dichloromethane (99.88%), sodium acetate trihydrate (99-
100.5%), potassium chloride (100.5 %), glacial acetic acid (99.88%), sodium hydroxide (98.9%) 
were all from Fisher Scientific. 2-acetamidophenol (≥97.0%) and nicotinamide (98.5%) were from 
Fluka (UK). Whole blood sample and blank horse blood was form oxoid limited (UK). Blank foetal 
bovine serum from Gibco® (UK). 
3.1.2.  Equipment 
Electronic balance from Sartorius (Germany), Ultrasonic bath was from Kerry (UK) and centrifuge 
model was Allegra X-22 from Beckman Coulter™ (UK). Sample concentrator model was DRI-
BLOCK®, DB.3A from TECHNE (UK), vacuum manifold from Agilent (USA), shaking water bath 
was from Grant Instruments (UK), Mikro 20 Hettich Zentrefugen Microcentrifuge (USA), Beckman 
Coulter Ultracentrifuge (USA). 
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HPLC components were from Merck Hitachi LaChrom (USA) and consisted of an interface D-7000, 
pump L-7100, an auto sampler L-7200 and a Diode Array Detector L-7455. Data acquisition and 
analysis were performed using EzChrome software. Phenomenex® (C18, 150 ×4.6 mm, 5μm) 
separation column was from Phenomenex (USA) 
3.1.3.  Methods 
3.1.3.1.  Developing HPLC method (I) for the analysis of mephedrone 
For primary qualitative and quantitative analysis of mephedrone utilizing HPLC-DAD, a master 
stock solution was prepared in deionised water at 10 times the maximum concentration used (10x20 
µg/ml). Maximum standard concentration was prepared by topping up 100 µL with 900 µL deionized 
water to achieve the final concentrations of mephedrone 20 µg/ml and other standards concentration 
(range 2-20 µg/ml) were prepared by dilution of maximum standard concentration with water to 
achieve the desired concentration. Standards were then injected onto HPLC to determine the 
retention time and validate the linearity of the method. Mobile phase consisted of H2O: ACN: Acetic 
Acid (85:10:2.5) under isocratic elution conditions of 1 ml/minute. The column used for analysis was 
Phenomenex® (C18, 150 ×4.6 mm, 5μm); temperature was ambient; DAD recording spectral data 
wavelength were between 200 and 400 nm; injection volume was 20 µL and total run time was 30 
minutes. 
To experiment on the effect of different solution on the retention time, peak shape and maximum 
absorbance of the mephedrone, mobile phase was used to prepare standards. New standards 
maximum concentration was prepared by topping up 100 µL with 900 µL mobile phase solution to 
achieve the final concentrations of mephedrone 20 µg/ml and other concentration standards (range 
2-20 µg/ml) were prepared by dilution of maximum concentration standard with mobile phase to 
achieve the desired concentrations. New standards were injected onto HPLC to experiment the effect 
of changing the solution. HPLC condition were the same but total run time was adjusted from 30 to 
10 minutes as it was expected that mephedrone will elute in less than 10 minutes. 
Two internal standards were used, which are acetamidophenol and nicotinamide, to optimize the 
analysis. The choice of these two internal standards was due to their structural similarity to 
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mephedrone and the expectation that they will behave similarly later when developing extraction 
methods. Acetamidophenol was prepared as stock solution of 80mg/L and 100 µL added to each 
sample. Nicotinamide was prepared as stock solution of 20 mg/L and 100 µL added to each sample 
HPLC condition were the same but different flow rates were experimented obtain the best resolution 
between the analytes. Accordingly, total run time was adjusted to keep with adjustments of flow rate 
(Table 5). 
Table 5: Summary of the key trials performed to optimize the developed HPLC-DAD method (I) for the 
analysis of mephedrone 
Chromatography conditions FR1 I.S2 
Mobile phase: H2O: ACN: Acetic Acid (85:10:2.5). 
Column: Phenomenex® (C18, 150 ×4.6 mm, 5μm). 
Isocratic elution, ambient temperature 
DAD spectral scan range: 200-400 nm 
1 Acetamidophenol 
0.2 Acetamidophenol 
0.5 Acetamidophenol 
1 Nicotinamide 
1: mobile phase flow rate (ml/min)  2: internal standard 
 
 
Spectral scan was performed for the analytes to identify the maximum absorbance. For qualitative 
analysis, wavelength of maximum absorbance and retention time was used as qualifiers for 
identification. For quantitative analysis peaks the wavelength of maximum absorbance of 
mephedrone of 262 nm was used to integrate the peaks. A summary the optimised HPLC method 
parameters for the analysis of mephedrone are presented in Table 6. 
Table 6: Optimized HPLC method (I) parameters for the analysis of mephedrone 
Stationary phase Chemically modified C18, 150 mm, 4.6 mm, 5 μm 
Mobile phase H2O: ACN: Acetic Acid (85:10:2.5) 
Temperature Ambient 
Elution Isocratic 
Flow rate 1 ml /min 
Total run time 10 minutes 
Internal standard Nicotinamide (100µl of 20mg/L into 1 ml sample) 
 
3.1.3.2.  Experimentation of LLE of mephedrone from whole blood samples followed 
by analysis applying the optimized HPLC-DAD method (I) 
Liquid-liquid extraction (LLE) of mephedrone was experimented followed by analysis of the extracts 
using the previously optimized HPLC method (I) – see Table 6 above. Different pH buffer solutions 
and different extraction solvents were used to evaluate the optimum extraction parameters. 
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Standard Buffer solutions were prepared following USP general recommendations (USP-NF, 2007a). 
Mixture solutions of boric acid and potassium chloride (H3BO3 /KCl) were prepared by dissolving 
618.4 mg of H3BO3 (MW=61.83) and 745.5 mg of KCl (MW-74.55) in water and then diluting with 
water to 50 mL to produce a 0.2 M mixture solution. Sodium hydroxide (NaOH) solutions were 
prepared by dissolving 400 mg of NaOH (MW=39.997) in water and then diluting with water to 50 
mL.to produce 0.2 M solution. Monobasic potassium phosphate (KH2PO4) solutions were prepared 
by dissolving 1.361 mg of KH2PO4 (MW=136.09) in water and then diluted with water to 50 ml to 
produce 0.2 M solution.   To prepare pH=10 buffer solution, to 50 ml of H3BO3 /KCl (0.2 M) mixture 
solution added 43.7 ml of NaOH solution (0.2 M) and topped up to 200 ml with deionized water. To 
prepare pH=7 buffer solution, to 50 ml of KH2PO4 solution (0.2 M) added 29.1ml of NaOH solution 
(0.2 M) and topped up to 200 ml with deionized water. 
Master stock solutions of the drug mephedrone were prepared in deionised water at 10 times (10x) 
the concentration needed, i.e. (10, 20, 30, 40 and 50 µg/ml). Whole blood samples were spiked with 
the drug mephedrone, by adding 100µL of 10x mephedrone stock solutions to 900 µL mL blood 
achieving final concentrations of 1, 2, 3, 4, or 5 µg/mL. 100 µL of the internal standard nicotinamide 
reference solution (20 µg/mL) was added. Whole blood samples were buffered by adding 1 ml of 
one type of buffer solution to determine the best pH value, and extraction was performed by adding 
5 ml of one type of extraction solvents. Samples were then agitated via vortex mixer for 1 minute 
and finally centrifuged at 3500 rpm for 10 minutes. The organic layer was removed into a clean glass 
vial via a pipette and evaporated to dryness using a sample concentrator under streaming N2 at 40 ºC. 
The residue was reconstituted with 1 mL of the mobile phase, sonicated, filtered through 0.45 µm 
filters and then injected onto the HPLC system under the optimized condition (Table 7). 
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Table 7: Summary of the key experimentation performed for LLE of mephedrone from blood samples 
Extraction solvent Modifying buffer pH 
Ethyl acetate 3 
Ethyl acetate 7 
Ethyl acetate 10 
Hexane 10 
 
3.1.3.3.  Validation of the optimized method of LLE of mephedrone from blood 
samples followed by analysis utilizing HPLC-DAD 
Master stock solutions were prepared at 10 times (10x) of the desired concentrations, i.e. 
(20,40,60,80 and 100 µg/ml). Whole blood samples were spiked with the drug mephedrone, by 
adding 100µL of 10x mephedrone stock solutions to 900 µL mL blood achieving final concentration 
in the range of (2-10 µg/ml), then added 100 µL of the internal standard nicotinamide reference 
solution (20 µg/mL). 
The optimized LLE method for mephedrone was the following: Samples were buffered by adding 1 
ml of Borate buffer pH 10 buffer and extraction was performed by adding 5 ml of ethyl acetate. 
Samples were then agitated via vortex mixer for 1 minute and finally centrifuged at 3500 rpm for 10 
minutes. The organic layer was transferred into a clean glass vial via a pipette and then evaporated 
to dryness using a sample concentrator and streaming N2 at 40 ºC. The residue was reconstituted with 
1 mL of the mobile phase, sonicated, filtered through 0.45 µm filters and then injected onto the HPLC 
system. 
Linearity of the HPLC method was assessed by preparing new standards in mobile phase in the range 
of (2-10µg/ml), injection onto the HPLC-DAD under optimized conditions and plotting the peak area 
ratios against corresponding concentrations. 
Linearity of the analytical method was assessed by preparing pre-spiked whole blood samples with 
known concentrations of the drug mephedrone and the internal standard nicotinamide. Five standards 
were prepared within the working range (2-10 μg/mL), each standard was injected onto HPLC system 
in triplicate, and each peak area of the analyte mephedrone and the internal standard nicotinamide 
was integrated and the peak area ratio (PAR) calculated and plotted against corresponding 
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concentrations. Repeatability of the analytical method was assessed by preparing standards (n=5) of 
the drug mephedrone at 100% of the maximum range (i.e. 10 µg/mL), extracted the same day 
following the optimized LLE protocol and injected onto the HPLC-DAD under the specified 
conditions. 
Intermediate precision was assessed by preparing standards of the drug mephedrone at 100% of the 
maximum range (i.e. 10 µg/mL) extracted over different days (n=3) following the optimized LLE 
protocol and injected onto the HPLC-DAD under the specified conditions. 
Accuracy was assessed by calculating percent recovery by computing the ratio of peak area of each 
concentration against the peak area of the corresponding standard concentration. 
Limit of detection and limit of quantification were calculated mathematically following these 
equations 


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Equation 8 
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Equation 9 
Where: Cs=concentration of the sample, hs: height of measured peak and hn: height of background 
noise (Bayne and Carlin, 2010). 
 
3.1.3.4.  Applying and validation of the optimized LLE followed by HPLC-DAD for 
simultaneous analysis of mephedrone, d-amphetamine, codeine, caffeine and 
ketamine from blood sample 
The optimized LLE protocol from blood sample was used here with the following minor 
modification: whole blood samples were spiked with the specified drug, by adding 200 µL of 10x 
drug stock solutions to 1800 µL blood to achieve the desired final concentration (Table 8), then added 
100 µL of the internal standard nicotinamide reference solution (20 µg/mL). 
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Table 8: Final concentrations for simultaneous analysis of the selected drugs. 
 Mephedrone1 Codeine1 Caffeine1 d-amphetamine1 ketamine1 
1 0.2 20 0.2 10 10 
2 0.5 30 0.5 15 15 
3 1 40 1 20 20 
4 2 50 2 25 25 
5 5 60 5 50 50 
1: µg/mL 
 
Samples were buffered by adding 1 ml of borate buffer pH=10 and extraction was performed by 
adding 5 ml of ethyl acetate. Samples were then agitated via vortex mixer for 1 minute and finally 
centrifuged at 3500 rpm for 10 minutes. The organic layer was transferred into a clean glass vial via 
a pipette and then evaporated to dryness using sample concentrator and N2 at 40 ºC. The residue was 
reconstituted with 750 µL of the mobile phase, sonicated, filtered through 0.45 µm filters and then 
injected onto the HPLC system. 
Precision of the analytical method was assessed through intermediate precision by computing RSD% 
for different samples prepared and extracted over different days. 
Accuracy was assessed by calculating percent recovery by computing the ratio of peak area of each 
concentration against the peak area of the corresponding standard concentration. 
3.1.3.5.  Optimized HPLC method for the simultaneous analysis of mephedrone and 
methcathinone 
The previously developed HPLC method was applied with some optimization. Standard Buffer 
solutions were prepared following USP general recommendation (USP-NF, 2007a). Acetic acid 
solution was prepared by adding 11.6 ml glacial acetic to water to make 100 ml of 2N acetic acid 
solution.   To prepare pH=4.1 acetate buffer solution, 1.5 g of sodium acetate (NaC2H3O2.3H2O) was 
placed in 1000-ml volumetric flask, added 19.5 of 2N acetic solution ad diluted with deionised water 
to make 1000 ml acetate buffer pH 4.1 solution.  The new optimized HPLC method (II) conditions 
were: mobile phase consisted of acetate buffer of pH=4.1: ACN (85:15) under isocratic elution 
conditions at flow rate of 1 ml/min. The column used for analysis was Phenomenex® (C18, 150 ×4.6 
mm, 5μm); temperature was ambient; DAD recording spectral data wavelength were between 200 
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and 400 nm; injection volume was 20 µL and total run time was 10 minutes. Aniline was used as 
internal standard. 
3.1.3.6.  Optimized LLE method of mephedrone and methcathinone mixture followed 
by analysis utilizing HPLC method (II) 
Standard Buffer solutions were prepared following USP general recommendation (USP-NF, 2007a). 
Mixture solutions of boric acid and potassium chloride (H3BO3 /KCl) were prepared by dissolving 
618.4 mg of H3BO3 (MW=61.83) and 745.5 mg of KCl (MW-74.55) in water and then diluted with 
water to 50 mL to produce 0.2 M mixture solution. To prepare pH 9.2 buffer solution, to 50 ml of 
H3BO3 /KCl (0.2 M) mixture solution added 26.4 ml of NaOH solution (0.2 M) and topped up to 200 
ml with deionized water. Master stock solution of drug and mephedrone were prepared at 10 
times(10x) the concentrations used in water (i.e. 0.4, 1, 2, 4, 20, 50 and 100 µg/ml). To prepare 
working sample, 100 µL of the 10x concentration added to 900 µL of whole blood or serum. 
In a separation funnel, 1 mL of pre-spiked blood (or serum) samples with known concentrations of 
mephedrone and methcathinone was taken; 50 µL of the internal standard aniline (0.25% in ACN: 
H2O, 80:20, v/v) were added to the sample, and pH was modified by adding 1 mL of Borate buffer 
solution pH=9.2. The sample was extracted by 5 mL of the extraction solvent (Dichloromethane: n-
Butanol, 8:2. v/v) sample solution for 15 minutes. The organic layer was transferred to a clean glass 
tube, re-extracted with 1 mL of 0.01M H2SO4, shaken, and then centrifuged for 10 minutes at 3500 
rpm. The aqueous layer was filtered and injected onto HPLC system. All samples preparations were 
repeated over different days, and HPLC injections were carried out in triplicates. 
3.1.3.7.  Validation of the LLE method of mephedrone and methcathinone mixture 
followed by analysis utilizing HPLC method (II 
Linearity: Linearity of the HPLC-DAD method (II) was assessed by injecting different concentration 
of standard solutions onto the HPLC system. Standard solution with concentrations covering the 
working range (0.1, 0.2, 0.4, 2, 4 and 10 µg/mL) of both analytes were prepared. Each prepared 
standard solution was filtered through 0.45 µm membrane filters before it was automatically injected. 
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A plot of peak area ratios against corresponding concentrations was produced, and least square 
regression analysis was performed 
Precision: Precision of the analytical method included repeatability (intra-day variation) and an 
intermediate precision (inter-day variation). Repeatability was assessed by computing the RSD% 
values for different samples prepared and extracted in the same day(n=5), containing 5 µg/mL of 
each of the analytes. Intermediate precision was assessed by computing the RSD% for different 
samples prepared and extracted in different days, containing 5 µg/mL of each of the analytes. 
Accuracy: Accuracy of the analytical method was assessed by calculating recovery percentages of 
the tested drugs at different days against drug controls. Drug controls were prepared at different 
concentration to allow the calculation of recovery percentages (ICH, 2005). 
Specificity: Specificity of the HPLC method test was performed by assessment of sufficient 
resolution in addition to estimation of peak purity for the analytes. Peak purity was calculated by 
taking absorbance values for the peaks at 240 and 280 nm wavelengths and computing the ratio at 
every point across the peak. Constant ratios indicate pure peaks (i.e. no interference), and so 
specificity to the corresponding analytes (Papadoyannis and Gika, 2005; Snyder et al., 2009). 
Limit of detection and Limit of quantification were calculated mathematically following previously 
mentioned equations. Equation 8 (p.72) was used to calculate LOD and Equation 9 (p.72) was used 
to assess LOQ for both analytes (Bayne and Carlin, 2010). 
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3.2.  In vitro metabolism studies of selected NPS using pig liver microsomes followed 
by analysis utilizing LC-MS 
3.2.1.  Materials 
Mephedrone and methoxetamine were purchased legally from web-based companies before any of 
them were declared illegal. Methcathinone was synthesized and identified in the analytical laboratory 
according to a previously published method (DeRuiter et al., 1994). MDAI was from LGC (UK). 
Ethylenediaminetetraacetic acid (EDTA), glycerol and sodium pyrophosphate was all from Sigma 
(UK), potassium chloride (100.5 %), was from Fisher Scientific. Tris Buffer saline from Biorad (UK) 
Pig liver was obtained freshly from a local abattoir, kept ice cold and transferred directly to the 
laboratory for processing. For the NADPH regeneration system: nicotinamide adenine dinucleotide 
phosphate (NADP), glucose-6-phosphate dehydrogenase enzyme (G6PD) and glucose-6-phosphate 
(G6P) were purchased from Sigma (UK). Deionized water was used in all preparations, filtered and 
degassed prior to use when needed. 
3.2.2.  Equipment 
An Electronic balance from Sartorius (Germany), Ultrasonic bath was from Kerry (UK) and 
centrifuge model was Allegra X-22 from Beckman Coulter™ (UK). Sample concentrator model was 
DRI-BLOCK®, DB.3A from TECHNE (UK), shaking water bath was from Grant Instruments (UK), 
Teflon mortar & pestle (UK), Mikro 20 Hettich Zentrefugen Microcentrifuge (USA), Beckman 
Coulter Ultracentrifuge (USA), GPE-scientific. LC-MS were an Agilent (USA).  LC-MS series 6310 
ion trap system equipped with electrospray ionization (ESI). Data acquisition was performed using 
DataAnalysis for 6300 Series Ion Trap LC/MS version 4.0 © software. 
3.2.3.  Methods 
3.2.3.1.  Preparation of buffers and solutions 
Master drug stock solution of the drugs mephedrone, methcathinone and methoxetamine were 
prepared in deionized water at 10 times of the desired concentration (i.e. 1000 µg/ml). 
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The homogenizing buffer (0.1 M Tris Buffer, 10 mM   EDTA and 150 mM KCl) was prepared by 
adding 2.922 g of EDTA and 11.1827 g of KCl to 100 mL of 1M Tris buffer saline stock solution, 
and then top up to 1L with deionized water. The microsomes preservation buffer (0.05 M Tris Buffer 
10 mM EDTA and 20% (v/v) glycerol) was prepared by adding 0.292 g of EDTA to 5 mL of 1M 
Tris. Buffer stock solution, added 20 mL glycerol, and then made up to 100 mL with deionized water. 
The pyrophosphate buffer (0.1 M Na-pyrophosphate and 10 mM EDTA) was prepared by dissolving 
2.659 g of Na-pyrophosphate and 0.292 g of EDTA in 100 mL deionized water. The final pH values 
were adjusted to pH 7.4 with sodium hydroxide or hydrochloric acid. 
The NADPH regenerating system (30 mM G6P, 5 U/mL G6PD, 10 mM NADP and 30 mM MgCl2) 
was prepared freshly every day before incubation. 
3.2.3.2.  Isolation of liver microsomes and S9 fraction 
Liver microsomes were isolated following previously published protocols with minor modifications 
(Hill, 2003; Pigatto et al., 2011; Hofer et al., 2012). Liver was donated and obtained freshly from a 
local abattoir collected less than 5 minutes after slaughtering in the very early morning and directly 
kept ice cooled in icebox until delivery to the laboratory. Pig liver was washed with homogenizing 
buffer and sliced into 4 g portions. The sliced portions were further cut into small pieces using a 
surgical blade, broken apart with 3 volumes of ice-cold homogenizing buffer using a handheld bio-
homogenizer and homogenized using a Teflon mortar and pestle. The homogenate was centrifuged 
for 15 min at 12,500 x g at 4°C, and the supernatant was divided into two portions, one of which was 
stored as S9 fraction, and the remaining fraction was further ultra-centrifuged for 45 min at 76,800 
x g at 4°C. The pellet was re-suspended with 2 volumes of ice cold pyrophosphate buffer, further 
homogenized and ultra-centrifuged for 70 min at 76,800 x g at 4°C. The supernatant was discarded 
and the pellet was suspended with 3 volumes of microsomes preservation buffer and further 
homogenized and stored at -80°C until needed. All steps were performed over an ice bath. 
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3.2.3.3.  Using isolated liver microsomes and S9 for metabolism studies 
For each type of in vitro model (i.e. microsomes and S9 fraction), five 1.5-mL microcentrifuge tubes 
for each test compound were prepared. The five 1.5-mL microcentrifuge tubes include duplicate 
tubes for both 0- and 3 hours’ time, and one tube for the negative control. Each tube contained 375 
µL 0.1 M phosphate buffers, pH 7.4, pre-warmed to 37°C, 50 µL NADPH regeneration system and 
50 µL of 10x concentration of test compound stock solution (final concentration of the drug 100 
µg/mL). The mixture was then incubated in a water bath for 5 min at 37°C. For the negative control, 
50 µL NADPH regeneration systems were replaced by 50 µL 0.1 M phosphate buffer. Prepared 
microsomes or S9 fractions were thawed and diluted to 10 mg/L and 25 µL added to each tube. 
Samples were mixed and incubated at 37°C in a shaking water bath. The process was terminated by 
adding 250 µL ice cold methanol at 0 time for two of the positive test tubes and at 3 hours for the 
other two positive tubes and the negative tube sample. Samples tubes were centrifuged for 10 minutes 
at 13,000 x g. The supernatant was then filtered through 0.45 µm filters and 5 µL injected directly 
onto the LC/MS system. 
3.2.3.4.  LC-MS detection and conditions 
Chromatographic separations were carried out on Agilent Eclipse plus C18, 3.5 µm, 4.6x150 mm at 
room temperature. The mobile phase consisted of methanol/water/formic acid (50/50/0.1, v: v: v), 
isocratic flow rate of 0.300 ml/min for 10 minutes. The analytes were detected in positive ionization 
mode (MS+). The MS instrument was tuned and calibrated according to the following conditions: 
Capillary voltage: 3500 V, Capillary intensity: 1 nA, Maximum acquisition time: 200 ms, Nebulizer 
pressure: 30 psi, Dry gas flow: 11 L/min, Dry gas temperature: 325 C. 
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3.3.  In vitro studies of selected NPS using hepatocytes and analysis utilizing GC-MS 
3.3.1.  Materials 
Mephedrone, methoxetamine, and 4-fluoromethamphetamine were purchased legally from web-
based companies before any of them were declared illegal. Methcathinone was synthesized and 
identified in the analytical laboratory according to previously published method (DeRuiter et al., 
1994). Trypan blue and phosphate buffer (pH=7) solution were from Sigma (UK). 
For derivatization, BSTFA (N, O-bis (trimethylsilyl) trifluoroacetamide) was from Supelco (UK). 
For the study of selected NPS using pooled human suspension hepatocytes: Primary Human 
Hepatocytes, Cryopreserved Hepatocytes Recovery Medium (catalogue number: CM7000) and 
Primary Human Hepatocytes Maintenance Supplement Pack (catalogue number: CM4000) 
containing dexamethasone and COCKTAIL-B solution were all from Gibco (UK). 
For the study of selected NPS using HepaRG: HepaRG cryopreserved cell line (catalogue number: 
HPRGC10), William's E Medium-no phenol red (catalogue number: A12176-01), HepaRG Thaw, 
Plate & General Purpose Medium Supplement (catalogue number: HPRG770), HepaRG Tox 
Medium Supplement (catalogue number: HPRG730), HepaRG Maintenance/Metabolism Medium 
Supplement (catalogue number: HPRG720) and GlutaMAX™-I Supplement (catalogue number: 
A12860-01) were all from Gibco (UK). 
3.3.2.  Equipment 
Electronic balance from Sartorius (Germany), Ultrasonic bath was from Kerry (UK) and centrifuge 
model was Allegra X-22 from Beckman Coulter™ (UK). Sample concentrator model was DRI-
BLOCK®, DB.3A from TECHNE (UK), shaking water bath was from Grant Instruments. 
GC and MS components were from Perkin Elmer (USA). GC model Clarus 600 equipped with an 
auto sampler and MS model Clarus 600 operated with Perkin Elmer TurboMass (2008) software. 
Standards and samples were run on an Agilent Technologies DB-1 MS column (30 m × 0.25 mm × 
0.25 µm). 
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3.3.3.  Methods 
3.3.3.1.  Preparation of buffers and solutions 
HepaRG Thaw, Plate, & General Purpose Medium was prepared freshly and aseptically as needed 
by adding 1 ml of GlutaMAX and 14 ml of HepaRG Thaw, Plate, & General Purpose Medium 
Supplement to 100 ml of William’s Medium E. 
HepaRG Tox Medium was prepared freshly and aseptically as needed by adding 1 ml of GlutaMAX 
and 14 ml of HepaRG™ Tox Medium Supplement to 100 ml of William’s Medium E. 
HepaRG Maintenance/Metabolism Medium was prepared freshly and aseptically as needed by 
adding 1 ml of GlutaMAX and 16 ml of HepaRG Maintenance/Metabolism Medium Supplement to 
100 ml of William’s Medium E 
Master stock solutions of mephedrone, methcathinone, methoxetamine and fluoromethamphetamine 
were prepared in HepaRG™ Thaw, Plate, & General Purpose Working Medium and were at least 10 
times more concentrated than the highest concentration tested (i.e. 1.6x102 mM). All stock solutions 
were preserved at -20C° for later use. 
3.3.3.2.  Preparation of cryopreserved pooled hepatocytes 
Pooled Human Hepatocytes stocks were stored and maintained under liquid nitrogen (-196°C) until 
needed. The cryopreserved pooled hepatocytes vial was thawed and re-suspended into 10 ml media 
to final concentration of 1x106 cells/ml (10x106 total cells count). Cell viability was estimated to be 
greater than 85% using trypan blue exclusion test. Trypan blue test solution test was prepared at 0.4% 
in phosphate buffered solution and 0.1 ml added to 1 ml cell solution and examined under microscope 
3.3.3.3.  Using Cryopreserved Pooled Human hepatocytes for metabolism study: 
The following final concentration of the drugs mephedrone, methcathinone, methoxetamine and 
4-fluoromethamphetamine were used for metabolism studies using Pooled Human Hepatocytes (10, 
20, 40, 60, 80 and 100 µM). For each one concentration, the metabolic profile was studied at the 
following specified times (0, 30, 60, 90 and 120 minutes). The metabolic reaction was initiated by 
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adding 60 µL of the prepared cell suspension and 15 µL of the 10x stock drug onto 1.5 ml Eppendorf 
tube and topped up with media into 150 µL (final drug concentration= 1x, final cell count > 50x103 
viable cells). At the specified time, the reaction was terminated by adding 50µL 10% DMSO. 
3.3.3.4.  Preparation and culture of cryopreserved HepaRG™ cells 
HepaRG™ Cell stocks were stored and maintained under liquid nitrogen (-196°C) until needed. 
HepaRG™ vial was semi-thawed in a water bath at 37° C and the cell suspension was aseptically 
transferred into pre-warmed 9 ml of HepaRG™ Thaw, Plate, & General Purpose Working Medium. 
After centrifuging cells at room temperature at 357 g for 2 minutes, the supernatant was aspirated 
and the pellet re-suspended in 5 ml of the HepaRG™ Thaw, Plate, & General Purpose Working 
Medium. The viability of the HepaRG™ was estimated to be greater than 85% using trypan blue 
exclusion test (see section 3.3.3.2. ). 
3.3.3.5.  Using HepaRG for metabolism studies 
The following final concentration of the drugs mephedrone, methcathinone, methoxetamine and 
4-fluoromethamphetamine were used for metabolism studies using HepaRG™ (10, 20, 40, 60, 80 
and 100 µM). For each one concentration, the metabolic profile was studied at the following specified 
times (0, 90 minute and 24 hrs). Previously prepared HepaRG cells were seeded onto central wells 
of collagen coated 96-well plates at a density of 50X103 cells/well in HepaRG™ Thaw, Plate, & 
General Purpose Working Medium (50 µL cell solution topped up to 200 µL media). After 6 hours’ 
media was renewed with 20 µL10x master solution of each drug concentration and topped up to 200 
µL HepaRG™ Tox Medium Supplement. Two wells were spared as blank which were topped up to 
200 µL HepaRG™ Tox Medium Supplement media and for zero times sample, 20 µL of each drug 
concentration was topped up to 200 µL HepaRG™ Tox Medium Supplement media. 
3.3.3.6.  Preparation of samples produced from using Pooled Human Hepatocytes for 
metabolism studies for GC-MS analysis 
The final 200 µL resultant aqueous mixture was extracted using with 400µL ethyl acetate, and then 
centrifuged at 3500 rpm for 10 minutes. Organic layer was moved into a clean glass vial via a pipette 
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and then evaporated to dryness using sample concentrator under streaming N2, reconstituted with 
50µL acetonitrile and then injected onto the GC-MS system under the specified conditions. 
After initial runs for the prepared samples utilizing GC-MS, samples were derivatized with BSTFA. 
BSTFA was added in excess – 100 µL - to the sample and the mixture warmed in water bath at 50 
C◦ for 10 minutes to enhance the derivatization reaction. The derivatized sample was then injected 
into the GC-MS system under the specified conditions. 
3.3.3.7.  GC-MS detection and conditions 
Oven temperature was an initial 4-min plateau at 150C˚ increasing at 25C˚/min to a final temperature 
of 350C˚. Programmable injector port temperature was held at 250C˚ for 4 min and then increased 
to 300C˚ at 50C˚/min. The final temperature was held for 7 min to correlate with the total run time 
of 12 minutes. The carrier gas was helium at 1 ml/min and the injection volume was 1 µl.  The 
transfer line temperature was held at 280 C◦. Positive ionization was achieved using an Electron 
Impact (EI+) source at 200C◦ with electron energy of 70 eV and the multiplier was set to 300 V. The 
peaks were observed in total ion count (TIC) mode for 9 minutes after 3 min solvent delay giving a 
total run time of 12 minutes. The scan range was 45–320 m/z with scan time of 0.5 second and an 
inter-scan delay of 0.01 seconds. 
3.3.3.8.  Using HepaRG™ for MTT reduction studies – cytotoxicity 
Previously prepared HepaRGTM cells were seeded onto central wells of collagen coated 96-well 
plates at a density of 100X103 cells/well in HepaRG™ Thaw, Plate, & General Purpose Working 
Medium (50 µL cell solution topped up to 200 µL media). Two wells were spared as blank control, 
and the peripheral wells were filled with sterile water to prevent media evaporation. The 96-well 
plate was incubated at 37C° in a humidified atmosphere with 5%/95% CO2/ambient atmosphere and 
100% relative humidity for cell adhesion. After 6 h the medium was renewed, and on day 1 and day 
4 the medium was replaced with HepaRG™ Tox medium and keep incubated under same conditions, 
while observing cell morphology on time of replacing media, the MTT reduction assay experiments 
were carried on day 7 with freshly prepared test drugs. On day 7 after cell seeding, the HepaRG™ 
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Tox medium was renewed and the cells were incubated for 48 h with the different concentrations of 
the drugs mephedrone, methcathinone, methoxetamine and fluoromethamphetamine at 37C°, in a 
humidified atmosphere with 5%/95% CO2/ambient atmosphere and 100% relative humidity. Those 
drugs concentrations were freshly prepared by from master stock concentration in HepaRG™ Tox 
medium. Each individual plate included two replicates blank controls (just media) and two replicates 
of negative control (full cell and media with no test agents). After the 48 h incubation period, the 
incubation medium was aspirated, and the attached cells were washed one time, followed by the 
addition of fresh HepaRG™ Tox medium containing 0.5 mg/L MTT. The cells were re-incubated at 
37C° in a humidified atmosphere with 5%/95% CO2/ambient atmosphere and 100% relative 
humidity for 3 h. After aspirating the medium, formed insoluble crystals were dissolved in 100% 
dimethyl sulfoxide (DMSO). A multi-well plate reader was used to run the spectrophotometric 
analysis at 570 nm wavelength. 
For each drug, a broad range (4.0x10-2 – 1.6x101 mM) was tested, and each was done in three 
independent experiments. The mean absorbance of the triplicate experiments for each drug 
concentration on each occasion was expressed as a percentage of the mean absorbance of the control 
wells.
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Chapter 4  Results and discussion 
4.1.  Analysis of mephedrone and other selected drugs of abuse utilizing HPLC after 
extraction from biological samples 
Mephedrone is a synthetic cathinone derivative that started to appear online and become available in 
the market in 2007, Until April 2010, when there was a governmental decision in UK of classifying 
mephedrone as class B, so its use, supply or possession was banned (Torrance and Cooper, 2010). 
There was no available valid quantitative HPLC-DAD analytical method for its analysis in biological 
fluids, at the date research started in 2009, and also there was little data available about its clinical 
or toxicological profile. Therefore, the aim of our research was to develop and validate a quantitative 
analytical method for easy and rapid analysis of mephedrone, alone or in combination with other 
drugs of abuse such as methcathinone, utilizing HPLC-DAD after extraction from biological fluids. 
HPLC-DAD is one of the more common analytical instrumentation in most forensic and analytical 
laboratories, and reversed phase chromatography is the most common form used generally in liquid 
chromatography. 
For this part of the work the stationary phase chosen for analysis is, C18, 5 µm, 4.6 x 150 mm columns. 
This type of column contains a chemically modified silica backbone of relatively of low polarity in 
comparison to the polarity of the most type of solvents used in liquid chromatography. The analysis 
of analytes of interest was performed by the use of an isocratic mobile phase consisting of a mixture 
of water and acetonitrile adjusted to acidic pH values Acetonitrile, compared to methanol, is more 
efficient at low pH values, and has a lower viscosity. Considering the reported pKa value of the 
analytes of interest of 8.4-9.5 for mephedrone and methyl cathinones in general (Gibbons and Zloh, 
2010), the mobile phase was adjusted to low pH values, as that would improve the shape of the peaks 
when analysing basic drugs. Buffering the mobile phase is very important, as this would assure 
reproducible retention peaks. These stationary and mobile phases are compatible with reversed phase 
chromatography and were expected to behave well for the analysis of the selected drugs that are 
mainly basic in nature (Neue et al., 2001; USP-NF, 2007b; Snyder et al., 2009; Gibbons and Zloh, 
2010; McCalley, 2010). 
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Acetamidophenol, nicotinamide, or aniline were used as internal standard in this part of the current 
work since they are expected to have nearly similar physicochemical properties; being basic in nature 
due to the presence of amine functional groups and non-polar due to the prevalence of C-C and C-H 
bonds (Figure 16). Similar studies utilizing HPLC for the analysis of the related amphetamines used 
one of them as internal standard (Hutchaleelaha et al., 1994; McAvoy et al., 1999). 
 
Figure 16: Chemical structure of internal standards used in HPLC-DAD analysis 
 
 
As diode array detector (DAD) is one of the commonly available detector types in forensic 
laboratories with its ability to provide more spectral information than the fixed UV detector, it was 
used in this part of the work. Scanning was performed to determine the wavelength of maximum 
absorbance for the analytes, and detections were carried out at each drug’s maximum absorbance 
wavelength to improve method sensitivity. 
4.1.1.  Developing HPLC method(I) for the analysis of mephedrone 
For qualitative and quantitative analysis, chromatograms produced after injection of mephedrone 
standards were identified and observed. Blank samples showed base line chromatograms, while 
different concentration of mephedrone standard chromatograms showed the appearance of one peak 
with retention time of ~ 6.75 minutes where the peak height was proportional to the standard 
concentration, which in conclusion was indicative that these peaks correspond to the drug 
mephedrone. The peaks showed tailing which indicates a type of interaction between the mobile 
phase and stationary phase, which may need further optimization for the type and constituents of the 
mobile phase. Buffering the mobile phase will control the ionization of the analyte and minimize the 
tailing of peaks and insure reproducible retention times (Ardrey, 2003). 
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Diode array detectors (DAD) are very important tool for the identification of compounds, where the 
detector records the absorbance over a range of up to 750 nm covering the UV range (190-380 nm) 
and allowing acquisition of a spectral data profile including the wavelength of maximum absorbance. 
However, some drugs of the same class may show similar UV spectra, which need other qualifiers 
for the identification of the analyte. For mephedrone, spectral scanning of the identified peak was 
carried out via DAD at 220-400 nm, and the wavelength of maximum absorbance, in combination 
with retention time of mephedrone was used as qualifiers for the identification of mephedrone. The 
spectral scanning has many useful applications. Peak purity, for example, can be determined form 
the study of the absorbance of one analyte at different wavelength. In this part of the work, maximum 
absorbance of mephedrone was determined to be 262 nm, which will be used later for qualitative and 
quantitative analysis (Figure 17). 
 
Figure 17: Spectral scanning of mephedrone via DAD (220 nm – 400nm) 
 
The observed maximum absorbance of the mephedrone is comparable to the reported maximum 
absorbance for mephedrone hydrochloride and mephedrone hydro bromide of 263.5 for standards 
either prepared in deionised water or 0.1 M aqueous hydrochloric acid, and of 259.5 for standards 
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either prepared in absolute ethanol or 0.1 M aqueous sodium hydroxide (Santali et al., 2011). 
Retention time and the wavelength of maximum absorbance were used as qualifiers for the 
identification and quantification of the drug mephedrone. The integration of peak areas was carried 
out at the specified wavelength to increase sensitivity of the method. Increasing the standard 
concentration was reflected on peak areas, and the developed HPLC method showed to be linear over 
the specified range with R2= 0.989 (Figure 18) 
 
Figure 18: calibration curve of mephedrone (2-20 µg/ml) in water. 
 
Mephedrone was prepared in mobile phase aiming to study the effect of different solutions on the 
retention time, peak shape and maximum absorbance of the drug. Using different solution other than 
the mobile phase may interfere with the equilibrium and interaction between mobile and stationary 
phase. However, there is no specific recommendation in the literature about specific type of solution 
to prepare samples, though it is preferable if applicable to use the mobile phase (Keunchkarian et al., 
2006; Snyder et al., 2009).  There was no significant difference between retention time, peak shape, 
UV spectrum, wavelength of maximum absorbance or the integrated areas of corresponding 
concentration, prepared in either water or mobile phase. However, there was minor improvement in 
the linearity of the HPLC method with R2=0.999. Peak areas were integrated at the wavelength of 
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maximum absorbance which was determined previously to be 262 nm. The drug mephedrone identity 
was confirmed by previously determined retention time of 6.75 minutes (Figure 19) and the 
wavelength of maximum absorbance at 262 nm ( Figure 20). 
 
Figure 19: representative HPLC chromatogram at 10 µg/ml of mephedrone in mobile phase by DAD (200-
400nm) 
 
Figure 20: representative UV spectrum and wavelength of maximum absorbance at 10 µg/ml of 
mephedrone in mobile phase via DAD (220-400nm) 
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Ruta et.al investigated the effect of sample diluents on peak shape, specifically for hydrophilic liquid 
chromatography, concluding that pure acetonitrile is the best solvent for obtaining the best peak 
shape. However, in case of any issues of using pure acetonitrile, solubility for example, isopropyl 
alcohol only or as a mixture with acetonitrile is a valid alternative (Ruta et al., 2010). 
As discussed by Keunchkarian et.al, sample and standard prepared in different solvents other than 
mobile phase is one of the possible reasons for atypical peak-shapes, affecting mainly the early 
eluting analytes. They concluded that hydrodynamic instability and interference of the sample 
solvent plug with the equilibria between the mobile and stationary phase could produce distortion 
affecting the peak shape and concentration profile when running analysis using reversed phase 
chromatography. In their recommendation, they suggest many solutions to minimize the effect of 
sample solvent/mobile phase viscosity mismatch (Keunchkarian et al., 2006). 
In HPLC, the eluting power of a solvent is measured by its ability to move compound over the 
adsorbent surface. In general, eluting power is related to polarity, where more polar compounds have 
stronger eluting power. The effect of sample solvent on the analysis is more evident when introducing 
the sample in a solvent stronger than the mobile phase. In fact, introduction of the sample in weaker 
solvent is possible without any effect on the peaks (Snyder et al., 2009). This may explain that 
changing using water as sample solvent was having no effect on peak shape or integrated peak areas. 
Compared to later findings by Santali et.al, where mephedrone showed difference in the maximum 
absorbance in different types of solutions, in the current work, there was no difference in maximum 
absorbance in samples prepared either in water or in mobile phase, which is mixture of water and 
acetonitrile. However, the determined maximum absorbance by Santali et al. was confirmative to the 
one observed in the current study. In their study, Santali e.al determined the maximum absorbance 
of mephedrone to be 259.5 and 263.5 compared to 262 nm in our work (Santali et al., 2011). 
The analytical method was optimised by adjusting either the type of the internal standard or flow 
rate. The aim of the optimization was to achieve sufficient resolution between the peaks of the 
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internal standard and that of mephedrone with the shortest run time. Other HPLC conditions were 
kept the same. Separation of mephedrone and the internal standard in less than 10 minutes with good 
resolution between the peaks was satisfactorily achieved for the current part of the work. 
Adjusting the flow rate will have an inversely proportional effect on the total run time, as decreasing 
the flow rate will increase the total run time. In general, the increase in the total run time will allow 
analytes that elute in a narrow window to separate at wider intervals improving the resolution. Long 
run time is disadvantageous and time consuming. By increasing the flow rate, total run time will 
shorten. However, this will negatively affect the resolution between the peaks. In case of presence of 
different analytes with different polarities, using gradient elution may overcome this issue as 
dynamic change of the composition of the mobile phase will separate analytes of different polarities 
within shorter time compared to using isocratic elution 
In the first set of experiments, acetamidophenol was selected as an internal standard. Using isocratic 
elution at a flow rate of 1 ml/min achieved the goal of less than 10 minutes’ analysis time, but there 
was insufficient resolution between the peaks, as the peaks appeared overlapped. The identity of the 
first appearing peak was confirmed to be mephedrone as increasing the concentration of the 
mephedrone standard was reflected by increase in peak height. In addition, the maximum absorbance 
determined by tracing of the UV spectral scanning of the peak and wavelength of maximum 
absorbance. UV spectrum and wavelength of maximum absorbance of mephedrone were similar to 
those previously observed. Using acetamidophenol as internal standard at a flow rate of 1 ml/min, 
there was insufficient resolution between the peaks. Flow rate was adjusted in two separate 
experiments to 0.2 ml/min. and 0.5 ml/min while keeping the mobile phase mixture the same. Both 
trials did not achieve the goal of a less than 10-minute analysis time. However, the resolution between 
the peaks improved in both cases at flow rates of 0.5 and 0.2 ml/min, with the best resolution in the 
latter. The identity of the first appearing peak was confirmed to be mephedrone as increasing the 
concentration of mephedrone standard was reflected in an increase in peak height. The maximum 
absorbance determined using spectral features was also studied and used in the confirmation (Figure 
21). 
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Figure 21…. Continued 
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Figure 21: Representative HPLC profile of the separation of mephedrone standard in presence of the 
internal standard acetamidophenol adjusting flow. Optimizing HPLC method (I) for the analysis of 
mephedrone. 
At flow rate of A = 1ml/min, B =0.5 ml/minute and C =0.2ml/min 
 
In the second set of experiments, nicotinamide was selected as an internal standard instead of 
acetamidophenol. Keeping the mobile phase mixture, the same of H2O: ACN: Acetic acid (85:10:2.5) 
at flow rate of 1 ml/min achieved the goal of a less than 10-minute analysis time and satisfactory 
resolution between the peak. Depending on the results of the optimization steps, the aim of best 
resolution and shortest analysis time was achieved by using nicotinamide as an internal standard and 
adjusting the flow rate to 1 ml/min. (Figure 22). 
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Figure 22: representative HPLC profile of the separation of mephedrone standard in presence of the 
internal standard nicotinamide adjusting flow. Optimizing HPLC method (I) for the analysis of 
mephedrone 
 
In this part of the work, the interest was of one analyte, mephedrone, and the issue of low resolution 
with the aim of short run time was resolved by the selection of an internal standard that elutes very 
early compared with the analyte of interest, mephedrone. Summary of the results are presented in 
Table 9. 
Table 9: Summary of the results obtained optimizing the developed HPLC-DAD method (I) for the analysis of 
mephedrone 
Chromatography conditions FR1 I.S2 rt13 rt24 comments 
Mobile phase: H2O: ACN: Acetic Acid 
(85:10:2.5), Column: Phenomenex® 
(C18, 150 ×4.6 mm, 5μm), Isocratic 
elution, ambient temperature and DAD 
spectral scan range: 200-400 nm 
1 Acetamidophenol 6.6 7.1 
- Total run time < 10min 
- insufficient resolution 
0.5 Acetamidophenol 12.6 14.6 
- Total run time > 10 min 
- insufficient resolution 
0.2 Acetamidophenol 32.0 36.1 
- Total run time > 10 min 
- Better resolution 
1 Nicotinamide 6.7 1.5 
- Total run time < 10 min 
- Satisfactory resolution 
1: mobile phase flow rate (ml/min)  2: internal standard  3: retention time of mephedrone 
(minutes)    4: retention time of internal standard (minutes) 
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4.1.2.  Experimentation of LLE of mephedrone from whole blood samples followed by 
analysis applying the optimized HPLC-DAD method (I) 
The previously optimized HPLC method I (section 4.1.1. , p. 85) was applied after LLE of 
mephedrone from whole blood samples. The experimentation steps involved either modifying pH of 
the sample or type of the extraction solvent. The efficacy of the LLE method was observed by 
calculation of the percent of recovery. 
For LLE, adjusting pH, the extraction liquid to matrix ratio, in addition to the type of solvent are the 
major factors affecting the efficiency of the extraction process The type and pH of buffer solution 
will control the ionization of the analytes and partitioning between the solvents. Increasing the ratio 
of the extracting solvent to matrix, in favour of the extracting solvent will increase the chance of 
transferring fraction of the analytes from their matrix. The type of solvent and its physicochemical 
properties including polarity, miscibility and boiling points are important factors controlling the 
efficacy of LLE process. 
The efficiency of the LLE process was assessed primarily by calculating recovery percentages 
(extraction fraction). Recovery percentages were calculated as the ratio of peak area after extraction 
against the peak area of the corresponding standard concentration Performing LLE of mephedrone 
from unbuffered blood samples, it was possible to extract less than 10% of the known concentration 
of the spiked mephedrone. When modifying sample pH before extraction with a buffer solution of 
pH 3, less than 4% of mephedrone was extracted. Modifying the sample with a neutral buffer solution 
(pH 7), it was possible to extract relatively similar fraction mephedrone of less than 10%. Higher 
recovery percent at the range of 10-35% were obtained by modifying sample pH before extraction 
with buffer solution of pH 10. 
By modification of extraction solvent contents and using buffer solution of pH 10, higher recovery 
percent were obtained using ethyl acetate as an extraction solvent– 10-35% compared to less than 
10% when using hexane as extraction solvent (Table 10) 
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Table 10: Summary of the results of obtained optimizing LLE of mephedrone from blood 
Extraction solvent Modifying buffer pH Comments 
Ethyl acetate Unbuffered Extraction fraction <10 % 
Ethyl acetate 3 Extraction fraction <4% 
Ethyl acetate 7 Extraction fraction <10 % 
Ethyl acetate 10 Extraction fraction 10 - 35% 
Hexane 10 Extraction fraction <10% 
 
The effect of pH and the maximum recovery percent obtained with the modification of pH=10 could 
be explained by the expected pKa values of 8.4-9.5 for mephedrone and methyl cathinones in general 
(Gibbons and Zloh, 2010). In low pH values, basic drugs are in their ionized state and will preferably 
stay into the aqueous phase, which negatively affects the recovery percentage. At high pH values, 
typically above the drugs pKa values, basic drugs are in their unionized state and will preferably 
partition into the organic phase and consequently higher recovery percentages would be obtained.  
Basic drugs are best extracted into organic solvent in pH values 1-2 pH units more than their pKa 
values. Concluded from the above discussion, LLE of buffered samples with buffer solution of pH 
10 were the optimum method parameters. 
4.1.3.  Validation of the optimized method of LLE of mephedrone from blood samples 
followed by analysis utilizing HPLC-DAD 
Linearity of the HPLC analytical method before extraction was assessed by preparing five points of 
mephedrone standards (range 2-10 µg/mL) with added internal standard nicotinamide (100 µL of 20 
mg/dl) into 1 ml drug standards. Each standard injected onto HPLC in triplicate and each peak area 
of the analyte mephedrone and the internal standard nicotinamide was integrated and the peak area 
ratio (PAR) calculated and plotted against corresponding concentrations. The analytical method 
before extraction was shown to be linear wit R2=0.9951. 
Linearity of the HPLC analytical method before extraction was assessed by preparing five points of 
pre-spiked whole blood samples with known concentrations of the drug mephedrone (range 2-10 
µg/mL) with added internal standard nicotinamide (100 µL of 20 mg/dl) into 1 ml blood.  Each 
standard was injected onto the HPLC system in triplicate, and each peak area of the analyte 
mephedrone and the internal standard nicotinamide was integrated and the peak area ratio (PAR) 
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calculated and plotted against corresponding concentrations. The analytical method (after extraction) 
yielded a plot with R2 value > 0.99 (Figure 23). Relative standard deviation (RSD %) at each point 
was less than 2%. The specified range was comparable to the reported fatal plasma concentration of 
the drug mephedrone in the range of 2 μg/ml, (Torrance and Cooper, 2010; Green et al., 2014). 
For the assessment of repeatability (intraday precision), six standards of the drug mephedrone at 
100% of the maximum range (i.e. 10 µg/mL) were prepared, extracted the same day following the 
optimized LLE protocol and injected onto the HPLC-DAD under the specified condition. LLE 
extraction process showed repeatability within the same day with RSD% = 4.36%. For the 
assessment of intermediate precision (interday precision) method was assessed over different days at 
drug concentration 10 µg/mL. LLE extraction process showed intermediate precision over different 
days with RSD% = 4.77%. Accuracy, which is reported as percent recovery (ICH, 2005), was low 
and variable. Percent recovery values were calculated as ratio of peak areas after extraction against 
the corresponding peak area before extraction for each drug concentration and for the internal 
standard. Recovery fraction for mephedrone ranged between 28 – 37% and 16-23% for the internal 
standard. 
Limit of detection and limit of quantification were calculated mathematically applying the previously 
mentioned equation in section 3.1.3.3. Peak areas were applied instead of peak heights. The minimum 
tested sample concentration with acceptable RSD% was 2 µg/mL. Average background noise was 
calculated 480. The calculated LOD and LOQ were 0.025 and 0.083 µg/mL, respectively. 
Emulsion formation was the major problem faced, affecting both repeatability and recovery percent. 
Summary of the results of the validation parameters are presented in Table 11. 
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Figure 23: Calibration curve of method of analysis of mephedrone utilizing HPLC-DAD after LLE from 
whole blood samples 
 
 
Table 11: summary of the results for the validation of the optimized method of LLE of mephedrone from 
blood samples followed by analysis utilizing HPLC-DAD 
Linearity (R2) Precision (RSD%) Accuracy (recovery 
percent) 
Limits 
(µg/mL) 
Before 
LLE 
0.9951 
Repeatability 
(intraday precision) 
4.36% mephedrone 28-37% LOD 0.025 
After LLE 0.9953 
Intermediate 
precision (interday 
precision) 
4.77% nicotinamide 16-23% LOQ 0.082 
 
4.1.4.  Applying and validation of the optimized LLE followed by HPLC-DAD for 
simultaneous analysis of mephedrone, amphetamine, caffeine, ketamine, and codeine 
from blood sample 
Following the LLE protocol in section 3.1.3.4. , as noticed earlier, the results showed impairment for 
the extraction process for all drugs including the internal standard at all concentrations reflected by 
variable and low recovery values. Emulsion formation was the major problem faced, affecting both 
repeatability and recovery percent. Calibration curves were produced by injecting standard 
concentrations of the analytes mixture onto the HPLC in the presence of internal standard. For 
quantitative analysis, peaks were integrated at the wavelength of maximum absorbance of 
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mephedrone and peak area ratios plotted against the corresponding concentration. The produced 
calibration curves showed linearity for all analytes with R2> 0.99 for all analytes. 
Linearity of the method (after extraction) was assessed by plotting peak area ratios against 
corresponding concentration. The analytical method was shown to be linear over the specified range 
for each analyte with R2 > 0.99 for all analytes. For the assessment of precision, peak area ratios 
variations were calculated for each concentration. 
Repeatability (intraday precision) was assessed by computing RSD of triplicates analysed the same 
day and intermediate precision (interday precision) was assessed by computing RSD values for 
samples analysed over different days. For repeatability, RSD% values ranged between 0.17% and 
3.47%, and for intermediate precision RSD% values ranged between 1.17% and 4.78%. The recovery 
values were variable and ranged between 9% and 90%. Lowest recovery values were obtained for 
mephedrone which ranged between 9-30% (average 23%) and recovery values of other analytes were 
relatively comparable and ranged between 20-90 % (average 55-67%). 
Emulsion formation was the major problem faced also and affected both repeatability and recovery 
percent, as demonstrated by variable and low recovery values. Summary of the results of the 
validation parameters are presented in Table 12. 
Table 12: summary the validation results for applying the optimized LLE followed by HPLC-DAD for 
simultaneous analysis of mephedrone, amphetamine, caffeine, ketamine, and codeine from blood sample 
 mephedrone amphetamine caffeine ketamine codeine 
Range (µg/ml) 0.2 – 5 0.2-5 20-60 10-50 10-50 
calibration (R2) >0.99 >0.99 >0.99 >0.99 >0.99 
Linearity – after LLE 
(R2) 
>0.99 >0.99 >0.99 >0.99 >0.99 
repeatability 0.28-2.88% 0.17-2.69% 0.22-2.11% 0.47-3.47% 0.20-2.33% 
Intermediate precision 2.10-4.07% 1.51-478% 20.6-3.15% 1.17-4.32% 2.06-3.67% 
Recovery% 
9-30% (23%) 20-79% (55%) 
23-88% 
(61%) 
25-90% 
(67%) 
25-90%(63%) 
 
When the validation parameters of the analytical method when applied for the analysis of different 
drugs mixture are compared to the validation parameters when applying the same analytical method 
for the analysis of mephedrone are compared, values were relatively comparable. The recovery 
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percentage of the drug mephedrone were relatively similar and were below 37% in both cases. 
However, the recovery percentages of other drugs were relatively higher and were above 55% for all 
drugs other than mephedrone. In both applications of the analytical method, recovery percentage 
were variable and ranged between 9-90%. Precision values resembled by RSD% were relatively 
comparable. 
Though emulsion formation was the major problem faced, it was possible to recover up to 90% of 
ketamine and codeine for example, while the maximum recovered mephedrone was 37%. This is 
suggestive that it is not only the emulsion formation that impaired the recovery of mephedrone. 
Another possible factor that affected the efficacy of the extraction process is the type of the extraction 
solvent (ethyl acetate) and the preference of mephedrone to partition into it. 
4.1.5.  Optimization of the developed HPLC method for the simultaneous analysis of 
mephedrone and methcathinone (method II) 
As discussed earlier, the retention of ionisable basic drugs in the column during HPLC analysis, is 
extremely dependent on the type and ratio of organic modifier and on pH of the mobile phase. 
Buffering the mobile phase is very important to ensure reproducible retention peaks, due to the 
expected basic nature of the drugs mephedrone and methcathinone. In this optimization, the mobile 
phase was pH buffered by acetate buffer of pH 4.1. 
As the nicotinamide retention time was very early (1.5 minutes), and most of the interferences were 
appearing early in the chromatogram, it was preferable to use another internal standard. Aniline was 
selected as new internal standard as it is expected to have nearly similar chemical properties and to 
behave in a similar way to the analytes of interest when extracted, being basic in nature due to the 
presence of amine functional groups and non-polar due to the prevalence of C-C and C-H bonds (see 
Figure 16,p 85). 
Adjusting the pH of mobile phase with acetate buffer, good resolution between the peaks and less 
than 10 minutes run time has been obtained using aniline as internal standard and peak shapes 
improved when using low pH buffered mobile phase. Adjusting pH of the mobile phase in reversed 
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phase chromatography will not only improve the peak shapes, but also the selectivity of the analysis 
(Neue et al., 2001; McCalley, 2010). 
Compared to previous chromatograms using unbuffered mobile phase (e.g. see Figure 19 , p. 88), 
there was an improvement in the peak shapes. Aniline was used as internal standard in this optimized 
HPLC method, and it was eluted between the two analytes of interest. Satisfactory resolution between 
the peaks was obtained. The risk of early appearing peaks observed previously with nicotinamide 
and the possible interference with solvent fronts peaks was overcome improving the qualitative and 
quantitative analysis (Figure 24). 
 
 
Figure 24: representative HPLC profile of the separation of mephedrone, methcathinone and internal 
standard (aniline) optimizing HPLC method (II) 
 
 
Earlier in this thesis, the wavelength of maximum absorbance for mephedrone was determined to be 
262 nm (see Figure 17, p 86). The wavelength of maximum absorbance for methcathinone was 
determined to be 250 nm (Figure 25) as an optimum in this separation. The spectral scan for the 
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peaks of aniline showed two maximal absorbance’s at 278 and 237 nm (Figure 26) and the 
wavelength of 237 was used for quantitative analysis as an optimum in this separation. 
 
Figure 25: Spectral scanning of methcathinone by DAD (200 nm – 400nm) 
 
Figure 26: Spectral scanning of aniline by DAD (200 nm – 400nm) 
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4.1.6.  Optimization of the LLE method of mephedrone and methcathinone mixture 
followed by analysis utilizing HPLC method (II) 
The protocol for LLE simultaneous extraction of mephedrone and methcathinone from whole blood 
or serum matrix, as described in section 03.1.3.6. , has produced significant improvement in the 
percent recovery and avoidance of the emulsion formation problem by choosing the type of solvent 
and avoiding extreme pH values during LLE process.  The efficacy of this newly developed LLE 
protocol was observed qualitatively through chromatograms, which showed the appearance of three 
distinctive separated peaks corresponding to the analytes, mephedrone and methcathinone, and the 
internal standard with minimal interfering peaks. The identity of each analyte peak was confirmed 
by its retention time and the wavelength of maximum absorbance, which were determined 
previously. The chromatograms showed satisfactory resolution between the analytes and the internal 
standard, for samples extracted from whole blood or serum matrix (Figure 27) 
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Figure 27: representative HPLC profile of the separation of 5 µg/ml mephedrone and 5µg/ml 
methcathinone standard in presence of the internal standard aniline after LLE from (A) blood and (B) 
serum samples 
During the extraction procedure, emulsion formation was one of the major problems faced through 
the work, which is expected to negatively affect the recovery, precision and other validation 
parameters. Emulsion formation will cause low recovery due to low partition efficiency and volume 
loss (Hardy and Jones, 1997). There are many suggested procedures to prevent emulsion formation 
or to break any that form. Gentle shaking, avoiding the use of extreme pH values, the use of low 
polarity organic solvent, salting the sample, adding alcohol ...etc., are all possible precautions to take 
in order to minimize the effect of emulsion formation. Experimental modifications were performed 
to minimize the emulsion formation effect and so improve precision and accuracy including changing 
the pH value and type of extracting solvent.  In addition to the mechanical precautions, using a less 
polar extraction solvent, combining the extraction solvent with alcohol and avoiding extreme high 
pH values may minimize emulsion formation. 
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Studying the theoretical rules for the formation, stabilization and breakage of emulsions, suggested 
precautions maybe explained. When two immiscible liquids come in contact, the most 
thermodynamically stable setup is to form two separate layers to minimize the area of contact 
between the two liquids. To form an emulsion, energy is needed to overcome this thermodynamically 
stable status, which can be provided by simple mechanical forces like shaking the two liquids or 
using a stirrer. However, an emulsifying agent can be used. The simplest types of emulsifying agents 
are ions like hydroxyl ions, which may be adsorbed onto the dispersed droplets producing 
electrostatic repulsion forces and hence stabilization of the formed emulsion (McClements and 
Weiss, 2005; Tadros, 2013). The use of extreme pH may increase the chance of formed ions and 
charged dispersed droplets, and in turn stabilize the emulsion formed. Protein and phospholipids are 
other important emulsifying agents, and biological samples contain high levels of these two 
components (McClements and Weiss, 2005). Phospholipids are of the major component of cell 
membranes, but also industrially available in food technology as emulsifying agents. The high 
content of proteins and phospholipids in biological samples will act as emulsifying agents, and as a 
precaution toward minimizing their effect, protein precipitation is often performed as a pre-treatment 
step which will help in minimizing formation and stability of those emulsions. 
Ethyl acetate is relatively polar solvent (polarity index= 4.4), and emulsion formation could be 
minimized by using a less polar solvent like dichloromethane (polarity index = 3.1). 
Dichloromethane is a volatile solvent (boiling point 39.6 C˚) and immiscible with water, making it 
one of the possible working extraction solvents. The alcohol butanol is immiscible with water while 
it is miscible with dichloromethane, and has comparable polarity to ethyl acetate (polarity index= 
4.0). However, the boiling point of butanol is quiet high (117.7 C˚), which may decrease the volatility 
of the organic mixture. Different solvent mixture ratios were tested for the time required to fully 
evaporate under streaming N2. The solvent mixture of dichloromethane: butanol (8:2, v: v) worked 
well and the mixture totally evaporated to dryness under streaming N2 in about 5 minutes. 
Consequently, using the less polar extraction solvent dichloromethane, combined with the alcohol 
butanol, and using buffer pH 9.2 instead of pH10 worked very well and improved the LLE outcome. 
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4.1.7.  Validation of an LLE method for mephedrone and methcathinone mixture 
followed by analysis utilizing HPLC method (II) 
Linearity: Calibration curve of the HPLC method using standard concentrations (before extraction) 
was produced by plotting average peak areas against corresponding concentrations, and the plot 
yields R2> 0.99 for both of the drugs mephedrone and methcathinone emphasizing the linearity of 
the specified HPLC method over the working range of 0.2 -10 µg/ml. 
The linearity of the HPLC method after extraction was assessed by plotting average peak area ratios 
- Drug/I.S.- against corresponding sample concentrations of mephedrone and methcathinone within 
the working range (0.1-10 μg/mL) for both blood and serum samples, yielding R2 > 0.99 in both 
matrices (Figure 28). 
 
continued 
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Figure 28: calibration curves of mephedrone and methcathinone standards over the specified ranges (0.1-
10 µg/mL) applying developed HPLC method (II) after LLE from blood and serum matrix 
mephedrone from blood (A) and serum (B), methcathinone from blood (C) and serum (D) 
 
 
Precision: considering the repeatability (intraday precision), the method was assessed within the 
same day and showed to be repeatable, for both mephedrone and methcathinone, with LLE extraction 
performed on blood or serum samples reflected by RSD% values (n=5). The RSD% values were 
nearly similar ranging between 3.01 - 3.98%. Considering Intermediate precision (inter-day 
precision) the method was assessed over different days and showed to be intermediately precise, for 
both mephedrone and methcathinone, with LLE extraction performed on blood or serum matrices, 
reflected by RSD% values (n=3). The RSD% values were nearly similar ranging 4.16 - 6.73%, and 
no matrix effect was noticed for both drugs. 
Accuracy was assessed by calculating recovery percentages of the tested drugs at different days, drug 
controls were prepared to allow the calculation of recovery percentages. 
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Considering specificity, chromatograms showed good resolution between peaks, and one pure peak 
for each drug and the internal standards was recorded. The purity of the peaks utilizing HPLC-DAD 
was confirmed by computing the ratio of signals at every point across the peak at different 
wavelengths. A constant ratio, which will produce a rectangular form, indicates a pure peak- i.e. no 
interference, and so specificity to the corresponding analyte. Any distortion to the rectangular form 
indicates differential absorbance indicating the presence of impurities (Papadoyannis and Gika, 
2005; Snyder et al., 2009). Theoretically, any two wavelengths in the spectrum can be used to 
compute the ratio of absorbance. However, most of the analytes have maximum absorbance at 258 
nm (Ardrey, 2003), and practically the measured maximum absorbance of mephedrone and 
methcathinone were determined to be 262 and 250 nm respectively. For that, the 240 and 280 nm 
wavelengths, which cover that range of the determined maximum absorbance of the major analytes, 
were used to compute peak purity by calculating the ratio. Mephedrone, methcathinone and the 
internal standard ratiograms produced the typical rectangular form which reflect the purity of the 
produced peaks and hence specificity of the developed HPLC method (Figure 29). 
 
Figure 29: Peak ratios at wavelengths 240/280 nm for the assessment of peak purity 
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Limit of detection and Limit of quantitation were calculated mathematically applying the previously 
mentioned equations in section 3.1.3.3. Peak areas were applied in the above mentioned equation 
instead of peak heights. The minimum tested sample concentration with acceptable RSD was 0.1 
µg/mL for both drugs. Peak areas of the minimum concentration with accepted RSD% value were 
nearly comparable in both matrices ranging between 16289 - 19699 and between 19309 - 23580 for 
mephedrone and methcathinone, respectively. Average background noise was calculated to 350, and 
peak areas were applied instead of the peak heights. LOD ranged between 0.010 and 0.013 µg/mL 
and LOQ ranged between 0.032 and 0.043 µg/mL for both drugs extracted from both matrices. 
Summary of the validation parameters are presented in Table 13. 
Table 13: Summery of the validation parameters for LLE of mephedrone and methcathinone mixture 
followed by analysis utilizing HPLC -DAD 
Drug matrix Linearity Repeatability Intermediate 
precision 
recovery% LOD1 
µg/ml 
LOQ2 
µg/ml 
mephedrone Blood >0.99 3.01% 6.73% 84-109% 0.011 0.036 
Serum >0.99 4.30% 5.03% 80-108% 0.013 0.043 
methcathinone Blood >0.99 3.98% 6.33% 83-110% 0.010 0.032 
Serum >0.99 3.69% 4.16% 81-106% 0.011 0.036 
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4.2.  In vitro metabolism studies of selected NPS using pig liver microsomes followed 
by analysis utilizing LC-MS 
Mephedrone is structurally related to cathinones (MW=177), relatively polar compounds with a 
peripheral tolyl moiety and beta ketoamine backbone. Standards of mephedrone were injected onto 
the LC-MS system and eluted at 6.7 min. The mass spectrum of the detected peak showed abundant 
MH+ ions at m/z= 178 that is an evidence of the drug molecular weight. Another m/z value of 160 
was identified that is produced from neutral loss of water. 
For methcathinone (MW=163), it eluted at 5.8 min. The mass spectrum of the detected peak showed 
a similar pattern to the one observed for mephedrone. Two m/z values were identified: the abundant 
MH+ ions at m/z= 164 which is an evidence of the drug molecular weight and the m/z value of 146, 
the product of neutral loss of water. 
For MXE (MW=247), the drug eluted at 7.6 min. The mass spectrum of the detected peak showed 
three identifiable m/z values of the molecular ion and two fragments of m/z values 175 and 203 
(Figure 30). 
After incubation of the drugs with the metabolic system, new peaks appearing were investigated, and 
proposed structures for the proposed detected metabolites were determined from the fragments 
present in the respective mass spectra and interpreted in correlation to those of the parent drug. 
Negative controls were used to verify the absence of these metabolites in the absence of these drugs. 
No new identifiable peaks were detected when injecting the sample produced from the incubation of 
the selected drugs with S9 fraction. It was possible to identify some newly appearing peaks for the 
drugs mephedrone and methoxetamine when injecting the samples produced from the incubation of 
these drugs with microsomes, while no new identifiable peaks where detected when injecting the 
samples produced from the incubation of methcathinone and MDAI with microsomes. 
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Figure 30: Representative chromatogram and mass spectrum for each of the selected drugs produced 
utilizing LC-MS., with the proposed structure of detected fragments 
(A): mephedrone, (B): methcathinone and (C): methoxetamine 
 
4.2.1.  Mephedrone 
Mephedrone was incubated with in-house prepared pig liver microsomes under the specified 
conditions and after termination of the metabolic process, samples were centrifuged, filtered and 
injected onto the LC-MS system. The possible metabolic pathway that mephedrone will go through 
can be proposed depending on published data about structurally related drugs and other in vivo or in 
vitro studies about the metabolism of mephedrone. Meyer et al. utilised GC-MS for in vivo studies 
and detection of mephedrone metabolites in human and rat urine. They concluded that mephedrone 
may be metabolised through phase 1 enzymatic system through demethylation, reduction or 
oxidization. Demethylation involves the removal of the N-methyl functional group producing nor-
mephedrone (IUPAC: 2-Amino-1-p-tolyl-propan-1-one, MW=163) which will go further into 
reduction of the ketone moiety producing the corresponding alcohol, nor-dihydro mephedrone 
(IUPAC: 2-Amino-1-p-tolyl-propan-1-ol, MW: 165). Also, hydroxytolyl-mephedrone (IUPAC: 1-
(4-Hydroxymethyl-phenyl)-2-methylamino-propan-1-one, MW=193) and nor-hydroxytolyl 
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mephedrone (2-Amino-1-(4-hydroxymethyl-phenyl)-propan-1-one, MW=179) in addition to 4-
carboxy-dihydro mephedrone (IUPAC: 4-(2-Amino-1-hydroxy-propyl)-benzoic acid, MW=195) 
were detected at their study as a product of an overlapping metabolic pathway of oxidation, reduction 
and N-demethylation. It was concluded through their study also that phase II metabolic pathways are 
involved in the metabolism of mephedrone through sulphonation or glucuronidation of the 
hydroxytolyl- mephedrone and its demethylated form (Meyer et al., 2010). 
Accordingly, a possible metabolic pathway can be proposed for mephedrone (Figure 31), which is 
useful for the prediction and detection of metabolites by tracing specific m/z values and extraction 
the chromatograms for specific ion mass. As noticed, three major metabolic reactions are involved 
that may overlap, i.e. the drug may go through more than one metabolic reaction step producing 
different metabolites. Chromatograms were traced and extracted for the selected masses that 
correspond to the molecular ions (MH+) of each of the suggested metabolites, and further the 
detected mass spectra peaks were analyzed for the fragmentation pattern in relation to the one 
observed for the drug mephedrone. The suggested metabolites either contain a β-ketone moiety 
which may produce (MH+ - 18) ion due to neutral loss water or the reduced form of the corresponding 
alcohol which may either produce (MH+ - 18) or (MH+ - 17) due to neutral loss of water or hydroxyl, 
respectively (Table 14). 
 
Figure 31: Suggested phase I metabolic pathway of mephedrone adapted from published data for the 
metabolism of mephedrone and similar drugs. 
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Table 14: Suggested metabolites produced from phase I metabolism of mephedrone after incubation with liver 
microsomes and analysis utilizing LC-MS/IOT and the monitored ion masses 
Number1 Name MW2 Extracted MH+ -H2O3 -OH4 
1 mephedrone 177 178 160 ---- 
2 nor-mephedrone 163 164 146 --- 
3 nor-dihydro-mephedrone 165 166 148 149 
4 dihydro mephedrone 179 180 162 163 
5 4-hydroxytolyl-dihydro-
mephedrone 
195 196 178 179 
6 4-hydroxytolyl-mephedrone 193 194 176 --- 
7 4-hydroxytolyl-nor-mephedrone 179 180 162 --- 
8 4-carboxy-nor-diydro-mephedrone 195 196 178 179 
9 4-carboxy-nor-mephedrone 193 194 176 --- 
10 4-carboxy-mephedrone 207 208 190 --- 
11 4-carboxy-diydro-mephedrone 209 210 192 193 
1: molecule number in reference to Figure 31 2: molecular weight 
3: neutral loss of water     4: loss of hydroxyl 
 
 
 
Total ion chromatogram(TIC) was extracted for the molecular ion of mephedrone and of each of the 
suggested metabolites. Extracted ion chromatograms (EIC) produced three peaks where one of the 
mass spectra is that of the parent drug mephedrone while the other two mass spectra were suggestive 
to be one of the metabolites of mephedrone. The detected peaks that were suggestive of the 
metabolites of mephedrone had a spectrum with abundant MH+=194 and MH+=166 (Figure 32). 
The detected peak with MH+=178 appeared at 6.6 minutes and has mass spectrum with abundant 
MH+=178 and secondary fragment of m/z= 160 (MH+=178-18) which confirm its identity of as the 
parent drug mephedrone in compare to the previously determined retention time and fragmentation 
pattern of mephedrone (see Figure 30) 
The detected peak with MH+=194 appeared at 5.4 minute and has mass spectrum with abundant 
MH+=194 and secondary fragment of m/z= 176 (MH+=194-18). The detected peak with MH+=166 
appeared at 6.3 minute and has mass spectrum with abundant MH+=166.  Following the suggested 
metabolic pathway, it is proposed that the produced metabolite with MH+=194 is either hydroxytolyl 
mephedrone or 4-carboxy-nor-mephedrone while the other with MH+ =166 is nor-dihydro-
mephedrone (Figure 33). 
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Figure 32: Representative chromatograms and spectra of the detected peaks suggestive of mephedrone 
metabolites after incubation with pig liver microsomes 
A: TIC, B: EIC and C: mass spectrum of detected peak with MH+=194 and D: mass spectrum of detected 
peak with MH+= 166. 
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Figure 33: proposed metabolites of the identified peaks for the drug mephedrone utilizing LC-MS after 
incubation with in-house prepared microsomes 
 
Samples were analysed in both selected ion monitoring (SIM) and selected reaction monitoring 
(SRM) modes. The selected ions were those of the molecular ion of mephedrone (MH+=178) and of 
the suggested metabolites (MH+= 194 and MH+=166). Analysis of the samples in SIM mode with 
selection of ion mass=178 produced a chromatogram with one representative peak at 6.7 min, where 
its mass spectrum contains abundant MH+=178. Analysis of the samples in SRM mode with 
selection of ion mass=178 produced a chromatogram with one representative peak at 6.7 min, where 
its mass spectrum contains the fragment of m/z=160 which is due to neutral loss of water in similar 
way to the one previously observed in MS analysis of mephedrone. Retention time, abundant 
molecular ion and typical fragmentation pattern were confirmative to the identity of the drug 
mephedrone ( Figure 34). 
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Figure 34: Representative chromatograms and spectra produced after Tandem MS. of ion mass=178 
detected after incubation of mephedrone with pig liver microsomes 
A: SIM mode and B: SRM mode. 
                                                                                                                                        Results and Discussion 
118 
 
Similarly, analysis of the samples in SIM mode with selection of ion mass=194 produced a 
chromatogram with one peak at 5.0 min, where its mass spectrum contains abundant MH+=194. 
Analysis of the samples in SRM mode with selection of ion mass=194 produced a chromatogram 
with one peak at 5.0 min. The mass spectrum of the detected peak showed one fragment with m/z= 
176 which is due to neutral loss of water in similar way to the one previously observed in MS analysis 
of mephedrone and the detected peak at retention time =5.0. Two other fragments were detected: 
m/z=158, 146 and 133 ( Figure 35). The fragmentation pattern of the suggested metabolites with 
MH+= 194 could be expected and compared to the detected fragments produced from MS/MS 
analysis (Figure 36) 
 
continued 
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Figure 35: Representative chromatograms and spectra produced after Tandem MS. of ion mass=194 
detected after incubation of mephedrone with pig liver microsomes 
A: SIM mode and B: SRM mode. 
 
 
 
 
Continued 
                                                                                                                                        Results and Discussion 
120 
 
 
Figure 36: expected fragmentation pattern for the suggested metabolites of the peak detected of MH+=194 
after incubation of mephedrone with pig liver microsomes. 
A: hydroxytolyl-mephedrone B: 4-carboxy-nor-mephedrone 
 
 
When the detected fragments in the relevant mass spectra after tandem mass analysis are compared 
to expected fragment of both suggested metabolites, it is more suggestive that the produced 
metabolite is hydroxytolyl mephedrone rather than 4-carboxy-nor-mephedrone. The proposed 
fragmentation pattern of hydroxyl-tolyl-mephedrone ion after tandem MS shows that the fragments 
are a product of one or more fragmentation steps of the parent ion, where the largest fragment of 
m/z=146 is due net loss of one carbon atom and two water molecules. The next fragment of m/z= 158 
is due net loss two water molecules and fragment of m/z= 176 is due to neutral loss of water. 
When performing analysis of the samples in SIM mode with selection of ion mass=166 produced a 
chromatogram with one representative peak at 6.3.0 min, where its mass spectrum contains abundant 
MH+=166. Analysis of the samples in SRM mode with selection of ion mass=166 produced a 
chromatogram with one peak at 6.3 min. 
The mass spectrum of the detected peak showed one major fragment of m/z= 120 and another 
secondary fragment of m/z=149. The detected fragment of m/z = 149 is comparable to the fragments 
produced earlier for mephedrone and the suggested metabolite hydroxytolyl mephedrone. However, 
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the suggested metabolite of m/z= 166 is proposed to be produced by more than one metabolic steps 
where one of them is reduction of the ketone moiety to the corresponding alcohol – nor-dihydro-
mephedrone. In the latter, the major fragment of m/z=149 is a product of neutral loss of hydroxyl 
group compared to neutral loss of water in MS/MS analysis of mephedrone and hydroxytolyl- 
mephedrone (Figure 37). 
The proposed fragmentation pattern through detected shows two main fragments, the largest one due 
to α-cleavage with m/z=120 while the other with m/z=149 is due to neutral loss of water, though 
fragmentation of the peripheral amine functional group is also proposed to produce fragment of 
m/z=149 (Figure 38). 
 
continued 
                                                                                                                                        Results and Discussion 
122 
 
 
Figure 37: Representative chromatograms and spectra produced after Tandem MS. of ion mass=166 
detected after incubation of mephedrone with pig liver microsomes 
A: SIM mode and B: SRM mode. 
 
 
Figure 38: Proposed fragmentation pattern and mass spectrum of the metabolite ion of m/z=166 detected 
for the drug mephedrone after tandem MS utilizing LC-MS with proposed fragments suggestive of nor-
dihydro-mephedrone 
 
                                                                                                                                        Results and Discussion 
123 
 
Suggestively, the proposed metabolic pathway of the detected metabolites is by hydroxylation of the 
methyl group attached to the aromatic ring for hydroxytolyl-mephedrone and a two-step N-
demethylation and reduction of the ketone moiety two steps for nor-dihydro-mephedrone (Figure 
39). 
The detected metabolites in the current research work were described earlier by Meyer et al. and 
recently by Pedersen et.al. both in vitro and in in vivo studies.  Meyer et.al. performed an in vivo 
study and reported some metabolites of mephedrone including the ones detected in the current 
research work, hydroxytolyl mephedrone and nor-dihydro-mephedrone. Pedersen et.al. performed in 
vitro studies utilizing infected insect cell microsomes, human liver microsomes and human liver S9 
fraction. They also analysed forensic cases. Five metabolites of their expected metabolites list were 
detected including the one detected in current research work, hydroxytolyl mephedrone, while nor-
dihydro-mephedrone was not detected neither in vitro or in vivo samples (Meyer et al., 2010; 
Pedersen et al., 2013). Compared to the metabolites described in current research work, two 
metabolites are described to be produced by in vitro metabolism: hydroxytolyl which was described 
earlier in both in vitro and in vivo studies, while nor-dihydro mephedrone was detected only in vivo 
study. 
 
Figure 39: A proposed metabolic pathway through the identified metabolites of mephedrone utilizing LC-
MS 
(1) Mephedrone (2) hydroxytolyl-mephedrone (3) nor-dihydro mephedrone, (*) undetected intermediate 
                                                                                                                                        Results and Discussion 
124 
 
4.2.2.  Methoxetamine 
For methoxetamine, as discussed earlier, MXE is structurally similar to ketamine, which would 
suggest a similar metabolic pathway. Ketamine is metabolized through N-dealkylation to 
norketamine, followed by hydroxylation of norketamine at different locations and the formation of 
5, 6-dehydronorketamine (Figure 40). The same metabolites were observed in vitro as well as in vivo 
in humans and animals’ (Portmann et al., 2010; Schmitz et al., 2010). 
 
Figure 40: Summary metabolic pathway of ketamine 
 
Meyer et al. recently utilised GC-MS for in vivo studies and detection of MXE metabolites in human 
and rat urine. They concluded that MXE may be metabolised through phase I and phase II enzymatic 
system. Phase I enzymatic reactions involves N-demethylation, O-demethylation and hydroxylation 
or a combination of these metabolic steps. It was concluded through their study also that phase II 
metabolic pathways are involved in the metabolism of MXE through sulphontaion or glucuronidation 
of most of these metabolites (Meyer et al., 2013). Menzies et al. performed in vitro studies utilizing 
LC-MS for the analysis of MXE metabolites after incubation with human liver microsomes. Phase I 
and phase II metabolites were detected in their study, where phase I metabolites were the product of 
N-demethylation, O-demethylation, reduction, hydroxylation and dehydrogenation. 
Adapted from published data about MXE and similar drugs, a metabolic pathway can be proposed 
for phase I metabolism of MXE (Figure 41.). This proposed metabolic pathway would be used as 
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predictive tool for detection and analysis of metabolites by tracing specific m/z values and extraction 
the chromatograms for specific ion mass (Table 15) 
 
Figure 41: Suggested phase I metabolic pathway of MXE adapted from published data for the metabolism of 
MXE and similar drugs. 
 
 
 
Table 15: Suggested metabolites produced from phase I metabolism of MXE after incubation with liver 
microsomes and analysis utilizing LC-MS/IOT and the monitored ion masses 
Number1 Name MW2 Extracted MH+ 
1 MXE 247 248 
2 nor-MXE 219 220 
3 O-desmethyl-nor-MXE 205 206 
4 O-desmethyl-dihydro-nor-MXE 207 208 
5 Dihydro-nor-MXE 221 222 
6 Dihydro-MXE 249 250 
7 O-desmethyl- dihydro-MXE 235 236 
8 O-desmethyl - MXE 233 234 
9 O-desmethyl -hydroxy--MXE 249 250 
10 hydroxy-MXE 263 264 
11 hydroxy-nor-MXE 235 236 
12 O-desmethyl-hydroxy- nor-MXE 221 222 
1: molecule number in reference to Figure 41  2: molecular weight 
3: neutral loss of water     4: loss of hydroxyl 
 
Total ion chromatogram(TIC) was extracted for the molecular ion of MXE and of each of the 
suggested metabolites. Extracted ion chromatograms (EIC) produced three peaks where one of the 
mass spectra is that of the parent drug MXE while the other two mass spectra were suggestive to be 
                                                                                                                                        Results and Discussion 
126 
 
one of the metabolites of MXE. The detected peaks that were suggestive to of the metabolites of 
MXE were having a spectrum with abundant MH+=234 and MH+=250 (Figure 42). 
The detected peak with MH+=248 appeared at 7.4 minute and has mass spectrum with abundant 
MH+=248 and secondary fragments of m/z= 203 and m/z=175, similar to the observed mass spectrum 
of MXE control runs., which confirm the identity of the peak to be of MXE (see Figure 30) 
The detected peak with MH+=234 appeared at 6.1 minute and has mass spectrum with abundant 
MH+=234 and secondary fragments of m/z= 189, which are less 14 units than the respective ion 
masses observed in mass spectrum of MXE of m/z=248 and m/z=203. The detected peak with 
MH+=250 appeared at 6.3 minute and has mass spectrum with abundant MH+=250 and secondary 
fragment of m/z=205.  Following the suggested metabolic pathway, it is proposed that the produced 
metabolite with MH+=234 is O-dimethyl MXE, while the other with MH+ =250 is either dihydro-
MXE or O-desmethyl -hydroxy-MXE (Figure 43). 
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Figure 42: Representative chromatograms and spectra of the detected peaks suggestive of MXE 
metabolites after incubation with pig liver microsomes 
A: TIC, B: EIC and C: mass spectrum of detected peak with MH+=234 and D: mass spectrum of detected 
peak with MH+= 250. 
 
 
Figure 43: proposed metabolites of the identified peaks for the drug MXE utilizing LC-MS after 
incubation with in-house prepared pig liver microsomes 
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Samples were analysed through MS/MS analysis using selected reaction monitoring modes The 
selected ions were those of the molecular ion of MXE (MH+=248) and of the suggested metabolites 
(MH+= 250 and MH+=234). Analysis of the samples in SRM mode with selection of ion mass=248 
produced a chromatogram with one representative peak at 7.3 min, where its mass spectrum contains 
the fragments of m/z= 203 and m/z=175 similar to the one previously observed in MS analysis of 
MXE. A new fragment of m/z=230 was detected which is 18 units less than the molecular ion, 
suggestive it is due to neutral loss of water. Analysis of the samples in SRM mode with selection of 
ion mass=234 produced a chromatogram with one representative peak at 6.1 min, where its mass 
spectrum contains the fragments of m/z= 189 and m/z=161. Those observed fragments are similar to 
the one previously observed in MS analysis of the suggested metabolite and comparable to the ones 
observed through MS analysis of MXE. The observed fragments are 14 units less than the respective 
ones observed for MXE. Similar to the observed fragment in case of MXE, a new fragment was 
detected of m/z=216 which is 18 units less than the molecular ion of the suggested metabolite. 
Analysis of the samples in SRM mode with selection of ion mass=250 produced a chromatogram 
with low intensity signal. Tracing TIC at the expected retention time of 5.4 min for the suggested 
metabolite of MH+=250 one representative peak at 5.4 min showed a mass spectrum with one 
fragment of m/z=205. The molecular ion of the suggested metabolite is two units more than the one 
of MXE, and the observed fragment of m/z=205 is comparable to the respective one observed for 
MXE of m/z=203.which is also two units more (Figure 44). 
The mass spectra of the MXE and proposed metabolites showed similar fragmentation pattern 
between each other and in compare with tandem MS data. A proposed fragmentation pattern of the 
drug MXE and comparison with the detected fragments of the suggested metabolites may confirm 
the identity of each detected molecule. Proposed fragmentation pattern of MXE from the identified 
fragment after tandem MS analysis of ion mass=248 shows that the fragment of m/z= 203 is a product 
of net loss of ethyl-amino group, the fragment of m/z=230 is a product of net loss of water and the 
fragment of m/z= 175 is a product of α-cleavage followed by net loss of (C4H8O). Another proposed 
fragmentation pathway to produce the fragment of m/z=203 as by α-cleavage followed by net loss of 
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(C2H4O) that will fragment further to produce the fragment of m/z=175. Other proposed fragments 
were not detected (Figure 45). 
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Figure 44: Representative chromatograms and spectra produced after Tandem MS. of selected ion masses 
detected in EIC after incubation of MXE with pig liver microsomes 
A: MH+=248, B: MH+=234 and C: MH+=250 
 
 
Figure 45: proposed fragmentation pattern of MXE through the detected fragment after MS/MS analysis 
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Similarly, and in comparison to the proposed fragmentation pathway of MXE, the identity of the 
detected metabolite of MH+=234 could be confirmed as O-desmethyl-MXE. Similar fragmentation 
pathway is observed with 14 units less due to O-demethylation (Figure 46). For the detected peak 
with M+=250, two metabolites are suggested. Low intensity signal was recorded and the suggested 
fragmentation pathways of the suggested metabolites were not conclusive for the identity of the 
molecule. The proposed fragmentation pathway of the dihydro-MXE in respect to the one proposed 
and observed for MXE produce a fragment of m/z=205 through different proposed pathway. 
The other suggested metabolite with MH+=250 was O-desmethyl –hydroxy-MXE.  Hydroxylation 
of the cyclohexanone moiety can occur in any site. However, compared to the metabolism of the 
structurally related ketamine, and for the purpose of description, it was assumed hydroxylation will 
take place on the 5 or 6 position. None of the other proposed fragments were detected (Figure 47). 
 
Figure 46: proposed fragmentation pattern of O-desmethyl-MXE in respect to the proposed fragmentation 
of MXE after MS/MS analysis 
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Figure 47: proposed fragmentation pattern of O-desmethyl–hydroxy-MXE in respect to the proposed 
fragmentation of MXE after MS/MS analysis 
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No other metabolites were identified that supported the initial proposal that methoxetamine has a 
similar metabolic pathway to ketamine – i.e. hydroxylation and N-dealkylation. However, the 
proposed O-demethylation pathway for methoxetamine is similar to other metabolic pathways 
described by in vitro studies of other drugs with a similar methoxy functional group attached to the 
benzene ring. Tramadol is a typical example of drugs with very similar structure compared to 
methoxetamine with peripheral methoxy group attached to the benzene ring (Sevcik et al., 1993). 
The major metabolite in the case of tramadol is by O-demethylation to produce O-
desmethyltramadol, the active metabolic product of the tramadol (Figure 48). 
 
Figure 48: Comparison between the structure of MXE and tramadol showing similarity in structure and 
metabolic pathway by O-demethylation 
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4.2.3.  Methcathinone 
To the best of knowledge, limited data are available about the metabolism of methcathinone. 
However, methcathinone, theoretically, could be metabolised into cathinone. (Sorensen, 2011). Very 
recent in 2015, Chen published data about in vitro study of metabolism of designer drugs including 
methcathinone and cathinone was reported as a metabolite for methcathinone through N-
demethylation. (Chen, 2015). 
Compared to mephedrone and depending on the theoretical demethylation of methcathinone, a 
metabolic pathway can be proposed for methcathinone where it could be metabolised into nor-
methcathinone and dihydro-methcathinone by demethylation and reduction pathway, respectively. 
Another metabolite is possible by combination of these pathways to produce nor-dihydro-
methcathinone ( Figure 49) 
 
Figure 49: suggested metabolic pathway of methcathinone 
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Total ion chromatograms were extracted for the following molecular ion of the parent drug 
methcathinone and of the suggested metabolites, i.e.: 164, 150, 166 and 152. It was possible to detect 
the peaks that correspond to the parent drug. However, it was not possible to identify any peak for 
the molecular ion of the suggested metabolites. 
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4.3.  In vitro studies of selected NPS using hepatocytes and analysis utilizing GC-MS 
4.3.1.  analysis of the selected NPS utilizing GC-MS 
The aim of this part of the work is to determine retention times’ and the fragmentation pattern of 
selected NPS utilizing GC-MS as fingerprint for each drug. The results were obtained by preparing 
solutions of NPSs of interest. Mephedrone (4MMC), methcathinone (MCAT), 4-
fluoromethamphetamine (4FMA) and methoxetamine (MXE) were prepared in acetonitrile and 
injected onto the GC-MS system. The retention times, under the specified GC-MS conditions, were 
identified for 4MMC, MCAT, 4FMA and MXE as 7.72, 6.79 5.57 10.41 (± 0.05) minutes 
respectively. The drugs were then derivatized using BSTFA and injected onto the GC-MS system, 
and the produced mass spectra were compared to those of underivatized drugs. 
The drugs 4MMC, MCAT and 4FMA are structurally similar to cathinone and amphetamine. By 
comparison of spectral data of these drugs with each other, and following the general fragmentation 
rules, a fragmentation pattern can be expected for each of these drugs. The mass spectra of 
amphetamine and cathinone show the m/z=44 as the base peak, the mass of the peripheral ethylamine 
group, a product of α–cleavage, one of the favourable fragmentation schemes. (Figure 50) 
 
Continued 
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Figure 50: Mass spectra of the amphetamine and cathinone 
Spectral data source: NIST Chemistry WebBook (http://webbook.nist.gov/chemistry). 
Mass labels and fragmentation pattern added for clarification. 
 
 
4.3.1.1.  Mephedrone 
For mephedrone, standards were injected onto the GC-MS, and resultant mass spectra were analysed. 
Two adjacent peaks were detected, the first peak eluted at 7.72 minutes while the second at 7.80 
minutes (Figure 51). 
 
Figure 51: Chromatogram produced after injection of mephedrone onto GC-MS system 
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Mephedrone is structurally similar to cathinone, both having an (± alkyl) amine group, β-ketone 
moiety and peripheral (±methyl) phenyl moiety. The fragmentation pattern of mephedrone is 
expected to follow the same fragmentation pattern of cathinone, where it will show base peak of 
m/z=58 in compare to the base peak of m/z= 44 due to the presence of extra amine-attached-methyl 
group. Due to the extra methyl group attached to the phenyl moiety in mephedrone, secondary peaks 
of m/z=77 and m/z= 105 in case of cathinone will be shown as mass peaks m/z= 91 and m/z=119 
(Figure 52). 
 
Figure 52: fragmentation pattern of mephedrone (upper) in compare with fragmentation pattern of 
cathinone (lower). 
 
Mass spectrum of the first detected peak showed the molecular ion with m/z 177 in addition to m/z 
values of 162, 147, 119, 91 and 58. The base peak was m/z 58 that corresponds to the peripheral 
ethyl-methyl-amine group, a product of α-cleavage (Figure 53). 
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Figure 53: Mass spectrum of the first detected peak after injection of mephedrone onto GC-MS system and 
the proposed fragmentation pattern 
 
The relative abundance of an ‘m/z value’ and its corresponding isotope were checked against their 
expected natural occurrence, another confirmative tool for the identity of an analyte (Baron et al., 
2011). The corresponding isotope for the m/z values of 147, 162 and 177 were not detected, which 
could be due to the low relative abundance of these m/z values in the produced GC-MS spectrum of 
less than 0.2% 
Table 16: Natural occurrence and relative abundance of m/z value and its corresponding isotope for 
mephedrone. 
m/z vs isotope Natural Occurrence Relative Abundance 
58 vs 59 96.6% vs 3.4% 96.5 vs 3.5 % 
91 vs 92 92.7% vs 7.3% 92.2% vs 7.8% 
119 vs 120 91.8% vs 8.2% 91.4% vs 8.6% 
147 vs 148 90.0% vs 10.0% ND1 
162 vs 163 89.8% vs 10.2% ND 
177 vs 178 88.9% vs 11.1% ND 
1: Not detected 
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The mass spectrum of the second detected peak of mephedrone showed m/z values with a different 
but comparable pattern to the one noticed in the mass spectrum of the first detected peak. The noticed 
pattern was the appearance of m/z values 175, 160 and 56 as the base peak, which are less two mass 
units of the corresponding m/z values =177, 162 and 58 respectively. The other m/z values, i.e. m/z= 
119 and 91 are appearing in both spectra. The noticed pattern is affecting the fragments containing 
the amine group while not affecting the fragments containing the phenyl group which may conclude 
that the fewer mass units is affecting the part of the structure containing the amine group. A possible 
explanation for the source of this additional peak is that it is an impurity, by-product or mephedrone 
related molecule during synthesis. Another possible explanation for the appearance of these less two 
mass units’ fragments is the effect of pyrolysis processes upon injection (Zuba, 2012). Camillery 
et.al. described the observation of m/z=56, when analysing mephedrone utilizing GC-MS, as a minor 
ion caused by the loss of H2. Also, they described the observation of m/z= 42 as a minor ion also 
caused by the loss of CH4 (Camilleri et al., 2010). Further work is needed to confirm the identify this 
less two unit’s molecule (Figure 54) 
 
Figure 54: Mass spectrum of the second detected peak after injection of mephedrone onto GC-MS system 
and the proposed fragmentation pattern 
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After derivatization, the chromatogram showed four identifiable peaks: 7.69, 7.81, 7.89 and 8.84 
minutes, where the mass spectra of the first two peaks was comparable to those previously detected 
for the underivatized mephedrone, while the other two are suggestive of the derivatized mephedrone 
(Figure 55). 
 
Figure 55: Chromatogram recorded for mephedrone after derivatization and injection onto GC-MS system 
 
 
As expected from the molecular structure of mephedrone, the silylation reaction will involve the 
replacement of available active hydrogen of the amine functional group with a trimethylsilyl group 
(Orata, 2012). Mass spectra of each peak was analysed to compare the masses to each other, where 
it shows that the mass spectra of detected peaks 3 and 4 were both having comparable mass spectra 
to each other and to the ones of underivatized drug. Successful derivatization with BSTFA, and 
depending on number of attacked functional group, is expected to produce comparable fragments of 
the parent molecule plus the mass of one or more of trimethylsilyl functional group, i.e. plus 72, 
144...etc. 
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Mass spectrum of peak 4 showed mass spectra comparable with the one of peak 1, where the base 
peak was of m/z= 130 (58+72), corresponding to the base peak of underivatized mephedrone of 
m/z=58, which is produced by the replacement of the available active hydrogen of the amine group 
by the trimethylsilyl functional group (Figure 56). 
 
Figure 56: Mass spectrum of detected peak 4 of derivatized mephedrone after injection onto GC-MS 
system 
Mass spectrum of peak 3 also showed comparable pattern with that of other peaks, but with the 
absence of the expected base peak m/z=130. A possible explanation is that the derivatization reaction 
took place on the enol form mephedrone, replacing the active hydrogen of the hydroxyl group by the 
trimethylsilyl functional group. This appears to be the most satisfactory explanation as the expected 
base peak of m/z=130 that was produced by replacement of active hydrogen of the amine group was 
not detected here in peak 3. In general, the derivatization reaction preferably took place on hydroxyl 
group of the enol form of the molecules, though the availability of active hydrogen on the amine 
group as the reactivity of hydroxyl functional group toward silylation is much more than the 
reactivity of amines (Orata, 2012). However, mass spectra of peak 3 showed base peak of m/z=56, 
same as noticed in the other peak detected in the chromatogram of underivatized mephedrone. 
                                                                                                                                        Results and Discussion 
143 
 
Silylation reactions may produce unexpected artefacts when reacting with some functional groups 
such as ketones and aldehydes, as was described by Little, who suggested the formation of 
trimethylsilyl-enol molecules for ketones with α-hydrogen (Little, 1999). In fact, the derivatization 
of the enol form of ketones is usually considered more troublesome rather than a target, which 
mandate to drive the keto-enol equilibrium toward the ketone or non-enolisable derivatives.  
However, some studies suggested the preference of silylation of the enol form of the ketone, a 
reaction that take place in one-step, as this derivative will elute earlier than the methoxime derivative. 
(Novotny and Wiesler, 1984). This supports the proposal that peak 3 detected for the derivatized 
mephedrone is the product of derivatization of the enol form of mephedrone, as it eluted earlier than 
peak 4, which is proposed to be the derivatized form of the ketone form of mephedrone. Another 
important mass value, m/z= 56, was detected as base peak in the mass spectra of peak 3 of derivatized 
mephedrone, which is comparable to the base peak detected in mass spectra of peak 2 of 
underivatized mephedrone (see Figure 54). This is most probably due to the migration of the double 
C-C bond of the enol from of mephedrone to produce double N-C bond, a possible mechanism during 
GC-MS-ES analysis. 
 
Figure 57: Mass spectrum of detected peak 3 of derivatized mephedrone after injection onto GC-MS 
system 
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4.3.1.2.  Methcathinone 
Applying the same principles followed earlier, the fragmentation pattern of methcathinone was 
studied in this part of the work. Methcathinone is structurally similar to cathinone and mephedrone, 
as mephedrone is the methylated form of methcathinone that in turn is the methylated form of 
cathinone 
Conclusively, the fragmentation pattern of mephedrone is expected to follow the same fragmentation 
pattern of cathinone, where it will show base peak of m/z=58 in compare to the base peak of m/z= 44 
due to the presence of extra amine-attached-methyl group. Other m/z values, i.e. m/z=77 and m/z=105 
will show in case of methcathinone similarly to the ones appeared in case of cathinone (Figure 58) 
 
Figure 58: Expected fragmentation pattern of methcathinone (upper) in compare with fragmentation 
pattern of cathinone (lower). 
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Same as was noticed in case of mephedrone, two adjacent peaks were detected, the first peak 
retention time was 6.79 and the second peak retention time was at 6.90 minutes (Figure 59). 
 
Figure 59: Chromatogram produced after injection of methcathinone onto GC-MS system 
As expected from the proposed fragmentation pattern and in compare with the mass spectra of 
cathinone, mass spectra of the first peak showed the molecular ion with m/z 163 in addition to m/z 
values of 148, 133, 119, 91 and 58.  The base peak was m/z 58 that corresponds to the peripheral 
ethyl-methyl-amine group, a product of α-cleavage (Figure 60) 
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Figure 60: Mass spectrum of the first detected peak after injection of methcathinone onto GC-MS system 
and the proposed fragmentation pattern 
Checking the relative abundance of each detected m/z value and its corresponding isotope, they were 
relatively close to the expected natural occurrence for the m/z values of 58, 77, and 105 (Table 17). 
Table 17: Natural occurrence and relative abundance of m/z value and its corresponding isotope for 
methcathinone. 
m/z vs isotope Natural Occurrence Relative Abundance 
58 vs 59 96.8% vs 3.2% 96.5% vs 3.5% 
77 vs 78 93.7% vs 6.3% 92.8% vs 7.2% 
105 vs 106 92.7% vs 7.3% 92.6% vs 7.4% 
 
Again, and same as noticed for mephedrone, the second detected peak for methcathinone showed 
comparable mass spectrum, mainly with the appearance of the base peak as less two masses in 
compare to the one detected for the first peak. Same explanations may be suggested: impurity, by-
product, and methcathinone related molecule during synthesis, effect of pyrolysis processes upon 
injection or most likely formation of double N-C bond producing ketamine molecules. The repetition 
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of the same phenomenon – the appearance of the less two mass units in different occasion for 
different drugs - is more likely supportive for the assumption that it is due to ‘analytical conditions 
‘or sample preparation steps leading to the same pattern, i.e. pyrolysis or the formation of the double 
bond producing ketoiminie molecules (Figure 61). 
 
Figure 61: Mass spectrum of the second detected peak after injection of methcathinone onto GC-MS 
system and the proposed fragmentation pattern 
More through studies are needed for the determination of this phenomenon, which may include study 
of other similar dugs – cathinones and synthetic cathinones. The importance of future such study is 
that these drugs are possible by-products or drug related chemicals that are underestimated by the 
scientific community, as those ‘proposed chemicals’ are potentially having psychoactive effects. The 
clinical and toxic effects of any drug may be related to other impurities or adulterants that may cause 
or augment toxic effects. 
The derivatization of methcathinone produced a chromatogram with only one identifiable peak for 
the derivatized drug. Mass spectrum of this peak showed the base peak of m/z=130, the corresponding 
base peak of m/z=58 for the underivatized molecule, in addition to another peak of m/z= 220 
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confirming successful derivatization of methcathinone through replacement the active hydrogen of 
the amine group by the trimethylsilyl functional group (Figure 62). No other identifiable peaks were 
detected that were suggestive or confirmative of the derivatization of the enol form of methcathinone 
in a similar way to what was observed for mephedrone. 
 
Figure 62: Mass spectrum of the second detected peak after injection of derivatized methcathinone onto 
GC-MS system 
 
4.3.1.3.  4-fluoromethamphetamine (4-FMA) 
4 –Fluromethamphetamine (4-FMA) is structurally similar to amphetamine, both having an (± alkyl) 
amine group and peripheral phenyl moiety. The fragmentation pattern of 4-FMA is expected to 
follow the same fragmentation pattern of amphetamine, where it will show base peak of m/z=58 in 
comparison to the base peak of m/z= 44 due to the presence of extra amine-attached-methyl group.  
Due to the presence of fluorine attached to the phenyl moiety in 4-fluoromethamphetamine, 
secondary peaks of m/z=77 and m/z= 91 in case of amphetamine will be shown as mass peaks m/z= 
95 and m/z=109 respectively (Figure 63). 
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Figure 63: Expected fragmentation pattern of 4-FMA (upper) in compare with fragmentation pattern of 
amphetamine (lower). 
Standard of the 4-FMA were injected onto the GC-MS system, and resultant mass spectra was 
compared with the proposed fragmentation pattern. One peak was detected with retention time of 
5.52 minutes. As expected from the proposed fragmentation pattern and in comparison with the mass 
spectra of amphetamine, in addition to the base peak of m/z 58 that corresponds to the peripheral 
ethyl-methyl-amine group, a product of α-cleavage, mass spectra showed m/z values of 152, 137, and 
109. 
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Figure 64: Chromatogram and Mass spectrum of the detected peak after injection of 4-FMA onto GC-MS 
system and the proposed fragmentation pattern 
 
Another indicative tool, similar to what was applied previously, is to check that the relative 
abundance of each detected m/z value, against its corresponding isotope values of 58 and 109, were 
relatively close to the detected relative abundance. The corresponding isotope value of 95 was not 
detected (Table 18). 
Table 18: Natural occurrence and relative abundance of m/z value and its corresponding isotope for 4-FMA. 
m/z vs isotope Natural Occurrence Relative Abundance 
58 vs 59 96.8% vs 3.2% 96.2% vs 3.8% 
109 vs 110 92.7% vs 7.3% 93.1% vs 6.9% 
 
The derivatization of 4-FMA produced a chromatogram with only one identifiable peak for the 
derivatized drug. Mass spectrum of this peak showed the base peak of m/z=130, the corresponding 
base peak of m/z=58 of the underivatized molecule (Figure 65). 
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Figure 65: Mass spectrum of the detected peak after injection of derivatized 4-FMA onto GC-MS system 
 
4.3.1.4.  Methoxetamine (MXE) 
Methoxetamine, as discussed earlier, is structurally similar to Ketamine and belongs to the 
arylcyclohexylamine family, and so expected both to have similar fragmentation pattern. 
Fragmentation of ketamine and its metabolite was studied utilizing LC/MS, and the authors proposed 
a pattern where the ketamine shows neutral loss of H2O and a loss of ethylamine followed by loss of 
carboxyl or H2O (Wang et al., 2005). Another recent study for the characterization of methoxetamine, 
with comparison to ketamine utilizing different instrumentation, including mass spectrometry, 
proposed a comprehensive fragmentation pathway for methoxetamine (Hays et al., 2012). The latter 
study presented both spectra of ketamine and methoxetamine, and suggested that the major 
fragmentation of methoxetamine would be similar to ketamine due to the similarity of structure. We 
expected this similarity in pattern earlier in our work, and suggested this similarity in structure would 
produce a similar fragmentation pattern as well as to be metabolized in a relatively similar pattern. 
Standard of MXE were injected onto the GC-MS system, and resultant mass spectra was compared 
with the proposed fragmentation pattern. One signal was detected with retention time of 10.40 
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minutes. The mass spectrum of the detected peak for MXE produced m/z=190 as the base peak and 
the following m/z values that were suggestive to be the fragments of MXE: 219 and 176 (Figure 66). 
 
 
Figure 66: Chromatogram produced and Mass spectrum of the detected peak after injection of derivatized 
MXE onto GC-MS system 
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As proposed earlier by Hays et al, MXE goes into α-cleavage and loss of the ketone part as CO and 
following ring closure (Hays et al., 2012). In this part of the study, fragment ions at m/z 134, 147, 
176,177, 190, 218, and 276 were also characteristic for MXE. As shown in spectrum 2, ring 
degradation by further loss of carbon atoms led to fragment ion at m/z 134 and 121. Meyer et al 
studied later metabolism and toxicological detectability of MXE using GC-MS and similar results 
were observed (Meyer et al., 2013). Combining the previous and later studies, with the detected mass 
spectrum of MXE, a possible fragmentation pathway of MXE can be proposed (Figure 67). 
 
Figure 67: Predominant fragments structure and proposed fragmentation pathway of MXE after injection 
onto GC-MS 
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The derivatization of MXE produced a chromatogram with only one identifiable peak for the 
derivatized drug. Analysis of the detected m/z values was confirmative for successful derivatization 
by replacement of active hydrogen of amine by trimethylsilyl group. Mass spectra showed 
characteristic m/z values of 319, 304 and 73 (Figure 68) 
 
Figure 68: Mass spectrum of the detected peak after injection of derivatized 4-FMA onto GC-MS system 
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4.3.2.  In vitro metabolism studies of selected NPS using HepaRG™ followed by 
analysis utilizing GC-MS 
Following the analysis of the selected NPS utilizing GC-MS (section 4.3.1), HepaRG™ Cells were 
used as in vitro model for the study of the metabolism of the selected NPS (section 3.3.3.5). Each 
drug was studied at different concentrations (10, 20, 40, 60, 80 and 100 µM), and each concentration 
was studied at the following specified times (0, 90 minutes and 24 hrs).  The chromatograms obtained 
in the experiment were studied for the presence of the parent drug and new peaks when compared to 
blank samples. Retention times and fragmentation patterns for each drug were used to confirm drug 
identity. 
Parent drugs were detected in all samples and the identity of the drug was confirmed using retention 
times and mass spectra (see section 4.3.1. ). For different concentrations of each drug used, peak 
areas were proportional to the drug concentrations, where higher concentration was reflected by 
larger peak areas (Figure 69). 
 
                                                                                                                                        Results and Discussion 
156 
 
 
 
                                                                                                                                        Results and Discussion 
157 
 
 
Figure 69: chromatograms of selected NPS of different concentration at zero time after incubation with 
HepaRG™. 
Squared peaks are of the parent drug, where: A: mephedrone, B: methcathinone, C: 4-
fluoromethaphetamine and D: methoxetamine 
 
Peak areas were plotted against concentration for linearity, and for all selected NPS showed to be 
linear with R2 > 0.96 (Figure A.74, p. 186). The data collected were plotted as percentage of drug 
concentration in relation to the primary drug concentration at zero time, reflected by average peak 
area (n=2), and the resultant relative concentrations were plotted against time. Mephedrone, 
methcathinone and 4-fluoromethamphetamine showed comparable trend of drugs concentration over 
time of incubation with HepaRG™ cell line. These drugs showed continuous decrease in drugs 
concentration over time, while methoxetamine showed a sharp decrease in drug concentration 
followed by an increase. 
For mephedrone, the drug concentrations relative to the primary drug concentration dropped to an 
average of 37% (32-44%) after 90 minutes of incubation with HepaRG™, and then there was another 
decrease down to an average of 12% (9-18%) after 24 hrs. In a comparable trend, methcathinone and 
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4-fluoromrthamphetamine concentrations dropped to averages of 88% (82-93%) and 85% (80-93%), 
respectively, after 90 minutes of incubation with HepaRG™. This decrease was followed by another 
decrease down to 74% (67-79%) and 76% (70-82%) for methcathinone and 4-
fluoromethamphetamine, respectively (Figure 70). 
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Figure 70: relative drug concentrations of selected NPS to the primary drug concentration after 90 minutes 
and 24 hours of incubation with HepaRG™. 
A: mephedrone, B: methcathinone, C: 4-fluoromethamphetamine and D: methoxetamine. 
 
The structural similarity of mephedrone, methcathinone and 4-fluoromethamphetmaine may suggest 
similar physicochemical properties, which may explain why these drugs behave similarly in 
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biological systems in terms of, for example, transcellular transport, protein affinity and metabolism. 
Protein binding is one major component that affect drug’s efficacy, as it is only the free unbound 
fraction of the drug that is available to be transported to the intracellular space for further biological 
action, e.g. metabolism. In comparison, methoxetamine showed different concentrations over time, 
which could be explained by the different structural backbone in comparison to the other selected 
NPS. However, the increase in methoxetamine concentration after 24 hours of incubation after the 
sharp decrease after 90 minutes could be due to cell death and lysis, which caused the intracellular 
content of methoxetamine to pool into the extracellular space. This general trend of lower available 
extracellular drug concentration is a strong evidence that drugs are being used or consumed by the 
cells, most likely through metabolism. 
By studying the chromatograms of the selected NPS, at different concentrations and different 
incubation times, for new peaks, in comparison to blank controls, it was possible to detect one new 
peak in mephedrone samples and one new peak in methcathinone samples. In both cases the new 
peaks appeared earlier before the parent drug. It is expected that any potential metabolites of the drug 
would be more polar than the parent drug, and would appear earlier in the chromatogram when using 
reversed mode chromatography, the one used through this thesis work. 
Studying the chromatograms of mephedrone after incubation with HepaRG™, a new peak was 
detected, before the parent drug, at 6.39 minutes. The mass spectrum of these new peak showed a 
comparable mass spectrum to that of mephedrone. The mass spectrum of this peak showed both m/z 
values of 119 and 91. These two m/z values are the common masses appearing in the mass spectrum 
of mephedrone together with the base peak with m/z value of 58 (see Figure 53). This pattern may 
suggest that the new peak is related to the parent drug with structural change affecting the amine 
group (Figure 71). In fact, N-demethylation is one of the most reported pathways for metabolism of 
mephedrone and structurally similar drugs, which may suggest the detected peak is the product of N-
demethylation. However, it was not possible to detect the expected m/z value of 44, a product of the 
suggested N-demethylation pathway. 
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Figure 71: sample chromatogram (A) and mass spectrum of newly appearing peak of samples of 
mephedrone after incubation with HepaRG™. 
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In a similar approach, chromatograms for methcathinone showed a new peak at 5.24 minutes when 
compared to blank controls. The mass spectrum of this peak was also comparable to that of 
methcathinone. The mass spectrum showed both m/z values of 105 and 77. These two m/z values are 
common masses appearing in mass spectrum of methcathinone together the base peak with m/z value 
of 58 (see Figure 60). This is a similar pattern to the one observed for mephedrone, suggesting this 
new peak to be related to methcathinone with structural change affecting the amine group (Figure 
72). This may suggest that methcathinone, similar to mephedrone, underwent N-demethylation. The 
structural similarity between mephedrone and methcathinone, both being β-ketoamines, may explain 
the correlation observed in the analysis of mephedrone and methcathinone analysing samples of these 
drugs after incubation with HepaRG™. 
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Figure 72: sample chromatogram (A) and mass spectrum of newly appearing peak of samples of 
mephedrone after incubation with HepaRG™. 
 
In chromatograms obtained for 4-fluoromethamphetamine and methoxetamine after incubation with 
HepaRG™, no new peaks were detected. 
In general, though these drugs were successfully analysed utilizing GCMS, any potentially produced 
metabolites are expected to be more polar, less volatile and less stable when analysed utilizing 
GCMS, which makes LCMS a better option for analysis of any potentially metabolites. However, 
derivatization of the samples is expected to increase volatility and stability of the compounds, which 
increases detectability of potentially produced metabolites utilizing GCMS. 
All samples of drugs after incubation with HepaRG™ were derivatized using BSTFA, but it was not 
possible to detect new peaks that could be correlated to any potentially produced metabolites. 
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4.3.3.  Cytotoxicity studies of selected NPSs using MTT Assay utilizing HepaRG™ 
Mephedrone (4MMC), methcathinone (MCAT), 4-fluoromethamphetamine (4-FMA) and 
methoxetamine (MXE) were the selected NPS for this part of the study. 4MMC, MCAT and 4FMA 
are amphetamine related drugs with currently no available data about their cytotoxic effects. 
However, amphetamines, cathinones and related drugs have been studied, both in vitro and in vivo, 
for their cytotoxic effects. Cytotoxicity caused by amphetamines mainly affects the liver, the organ 
most at risk in general for drug related toxicity, and specifically amphetamines (Da Silva et al., 
2013a). No similar data are available for MXE, the ketamine analogue belonging to the 
Arylcyclohexylamine, or other drugs of the same class, for comparison. 
The potency of the drug to cause the effect is evaluated by EC50 value, which is defined as: ‘the 
concentration of the agonist required to provoke a response halfway between the baseline and 
maximal response’ (Motulsky and Christopoulos, 2004). In the current part of the work, the agonist 
is one of the selected NPS’s and the provoked response is percentage cell death. 
For cytotoxicity study using HepaRG™ cells, the data were collected from the three independent 
experiments using 11 different concentrations of each drug in the range of (4.0x10-2-1.6x101 mM). 
The collected data about percentage of cell death were normalized on a scale of zero – µ%, where 
the blanks were considered as having zero percentage cell death. Adapted from normalization 
equation, the following equation was used to normalize the data on the desired scale of zero-100%: 
Yn = Y/Ymax 
Where Yn: Normalized value, Y: original value and Ymax: maximum value in the series. 
 
The collected data were plotted as percentage of cell death normalized to maximum response versus 
concentration, and the resultant normalized data were analysed using curve fitting with non-linear 
regression best-fit approach using ‘GraphPad Prism version 6.00 for Windows, GraphPad Software, 
La Jolla California USA, www.graphpad.com [free trial] ‘. The graph for all drugs showed increase 
in the response with increasing concentration (Figure 73) 
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Figure 73 …... continued 
                                                                                                                                        Results and Discussion 
166 
 
 
 
Figure 73: Normalized cell death percentage of HepaRG cells induced by selected NPS 48 h after 
incubation under specified conditions 
 
 
All tested selected NPSs showed reproducible response that is dependent on concentration, where 
increasing the concentration increases the percentage of cell death. Within the concentration range 
used, 4MMC, 4FMA and MXE showed nearly similar average maximal percentage cell death of 
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about 84%, 78% and 73% respectively, while MCAT showed average maximal percentage cell death 
of about 45%. 
In this part of the work, under the specified condition and within the specified range, 4FMA showed 
the most potent effect with EC50 value of 0.2323 mM (39 µg/ml). This is compared to MXE with 
EC50 value of 0.3211 mM (79 µg/ml), MCAT with EC50 value of 0.3687 mM (60 µg/ml) and 4MMC, 
which obtained the least cytotoxic profile, with EC50 value of 0.6297 mM (111 µg/ml). 
Compared to published data about cell death cytotoxic effect and other cytotoxic effects, the EC50 
values of 4MMC, MCAT and 4FMA in the current work ranged between 0.2323 and 0.6297 mM. 
These values are lower than reported EC50 for amphetamines, cathinones, and related drugs in in vitro 
studies, where EC50 values ranged between 0.74 and 5.26 mM (Da Silva et al., 2013b). While no data 
is available for MXE or related drugs for the in vitro EC50 values for comparison The calculated 
molarity values were converted into the equivalent SI to compare with available reported toxic values 
through in vivo, post-mortem or clinical samples. Equivalent concentrations were 111, 60, 79 and 39 
µg/ml for 4MMC, MCAT, 4FMA and MXE respectively (Table 19). 
Those obtained EC50 values in this part of the work are many fold higher than the reported toxic peak 
concentration in either clinical intoxicated patients’ samples or post-mortem samples. The reported 
concentration of mephedrone, as an example, in post-mortem biological samples in four fatalities in 
Scotland, ranged between 0.50-22 μg/mL (Torrance and Cooper, 2010). Compared to the obtained 
EC50 value of 0.6297 mM for mephedrone, which is equivalent to 111 μg/mL, is about 5-22 times 
more than the reported values in biological samples. In fact, it has been reported that tissue levels of 
amphetamine related drugs can be up to 18-30 times higher than blood concentrations. This 
discrepancy between in vitro and in vivo data, in case of amphetamines and related drugs, is partially 
due to their low protein binding affinity, which make their diffusion into tissues from plasma more 
favourable. In addition, post-mortem samples are most of the times from victims who have received 
emergency care in their pre-mortem intoxicated interval (Da Silva et al., 2013b). 
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In this part of the work, none of the selected NPS yielded 100% cell death. However, 4MMC, MCAT 
and MXE caused at least the death of 75% of the cells, while 4FMA at maximum used dose caused 
less than 50% of cell death. While one major effect– i.e. cell death – is studied here – is studied here, 
other cytotoxic effects with wider range needs further future studies to elaborate more about the toxic 
effects NPS in general, and the selected ones specifically (Table 19). 
Table 19: MTT of selected NPS summary. 
Drug Max cell death1 EC50 (mM)2 Equivalent [] (µg/ml) Reported Toxic [] (µg/ml)3 
4MMC 84% 0.6297 111 0.5-22 
MCAT 45% 0.3687 60 NA 
MXE 78% 0.3211 79 NA 
4FMA 73% 0.2323 39 NA 
1: Max death cell induced under the specified condition and within the specified range (4x10-2 – 
1.6x102 mM) 
1: EC50 the concentration required to cause cell death a halfway between the baseline and maximal 
response 
3: reported toxic values through in vivo, postmortem or clinical samples 
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Chapter 5  Summary and conclusion 
The development of new analytical methods to detect NPS represents a significant challenge for 
forensic analysts, mainly due to the lack of reference standards and to the rapidly appearance of these 
diverse NPS.  Moreover, their variability, easy availability and relatively easy synthesis, are all extra 
challenges to the authorities and scientific community.  Most of these drugs are marketed as ‘legal 
highs’ or research chemicals to bypass the legal consequences. Most of the time, these chemicals 
cause many fatalities and morbidities before being legally framed as ‘drugs of abuse’. In fact, the 
scientific community is the one responsible for developing novel approaches for the detection of 
these NPS at the earliest possible time and submitting solid data for the legal authorities at the point 
of appearance of these NPS. This responsibility is not limited to the analytical methods, but also 
anticipated clinical and toxicological profile studies that could provide evidence about the danger 
and possible risks of these chemicals. NPS are changing continuously, and the forensic chemists will 
be in the forefront of developing new analytical methods for detecting these drugs in forensic cases.  
Drugs of abuse from around the world are available nowadays through the internet. 
Synthetic cathinones is a subgroup of NPS which is commonly abused for its euphoric effects, where 
Mephedrone, Methoxetamine, Methcathinone are examples. Upon performing an extensive literature 
survey, it was concluded that the currently available methods of analysis of these drugs and their 
metabolites in biological fluids did not fulfil the critical need of such methods in the field of forensic 
chemistry.  4-fluoromethamphetamine is an amphetamine-like drug of abuse with only one published 
method of analysis, and no metabolic studies, until now and to the best of our knowledge. NPS are 
commonly traded as mixtures, so our decision to analyse the drugs of interest concomitantly may be 
helpful for analysts who are interested in the analysis of these drugs and any other related drug. 
In the first part of the thesis, HPLC was utilized for qualitative and quantitative analysis of 
mephedrone, alone and concomitantly with methcathinone. A method was developed and fully 
validated for analysis by HPLC-DAD after LLE from spiked blood and serum samples. The LLE 
protocol was optimized by experimentation of different extraction solvents and pH modifications to 
avoid emulsion formation which is a problem often appeared in this type of extraction. LLE 
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efficiency was improved reflected in the satisfactory validation parameters. The method showed 
simplicity to apply, robustness, repeatability, rapidity and validity over the specified range. The 
analytical method was shown to be linear over the specified range of 0.1-10 µg/ml, repeatable with 
RSD values of 3.37-3.98% and 4.05-6.45% for intraday and intraday repeatability respectively, with 
accuracy represented by extraction fraction of 83-109%, specific for the analytes and with LOD and 
LOQ of 0.011-0.014 and 0.036-0.043 µg/ml respectively. These values are comparable to those 
published data utilizing HPLC-DAD or other analytical techniques. For example, LOQ in one study 
for mephedrone in biological fluids was determined to be 0.1 µg/mL (Torrance and Cooper, 2010), 
and in another study LOD and LOQ were determined to be 0.010 and 0.025 µg/mL respectively 
(Dickson et al., 2010). The values are comparable to published similar HPLC-DAD data for analysis 
of mephedrone after LLE from blood, where LOD and LOQ were determined to be 0.039 and 0.078 
µg/mL respectively (Maskell et al., 2011). The working range is also comparable to other published 
data and cover the range of observed clinically toxic concentration. In conclusion, the use of solvent 
mixture with the addition of alcohol seems to work more efficiently for the extraction of drugs from 
biological samples. In addition, due to the basic nature of most of drugs of abuse, we buffered the 
samples with a buffer solution of pH 10, as this will present the drugs in their non-ionisable form. 
Similarly, important, this will minimize emulsion formation, where extreme pH seems practically to 
be one of the predisposing factors. The developed valid HPLC-DAD analytical method for the 
quantitative analysis of mephedrone alone and with methcathinone presented in this chapter can be 
considered as a reference argument for future analysis of these designer drugs and any related drugs 
utilizing such instrumentation. 
In the second part of thesis, in vitro studies on the metabolism of selected NPS using pig liver 
microsomes and a qualitative LC/MS analysis were successfully performed. Liver microsomes were 
prepared by a conventional ultracentrifugation method and used for performing metabolism of the 
selected drugs. The in vitro study was applied to mephedrone and methcathinone as a continuation 
of the previous work. MXE was added after it appears just as this in vitro work was started, using 
liver microsomes. Samples were analysed utilizing LC-MS under the specified conditions and parent 
drugs and detected metabolites separated with good resolution in less than10 minutes total run time. 
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The products of the metabolic study were prepared by filtration and injected onto LC-MS. After 
initial runs under M/S conditions, chromatograms were extracted for the molecular ions of the parent 
drug and expected metabolites. Two of the detected peaks from the MS study were suggestive as 
being metabolites for the drug mephedrone, while another two were suggestive as being metabolites 
for the drug MXE. 
Detected mass ions were then analysed under MS/MS conditions using SIM and SRM mode. The 
produced chromatograms after MS/MS analysis showed peaks in concordance with detected peaks 
of the MS study. Mass spectra of the detected peaks were confirmative for the identity of the 
suggested metabolites of mephedrone and for one of the suggested metabolites of MXE, while other 
peaks were not inclusive for the identity of other suggestive metabolite of MXE. 
The detected peaks for mephedrone metabolism were those of the parent drug (MH+=178), one with 
MH+=194 and another peak with MH+=166. The detected peak with MH+194 was suggested to be 
either hydroxytolyl-mephedrone as a product of hydroxylation of the tolyl moiety or 4-carboxy-nor-
mephedrone as a product of demethylation and two steps of hydroxylation. Comparative 
fragmentation pattern of both possible metabolites with the detected fragments after MS/MS analysis 
using SRM mode were confirmative for the identity of the detected metabolite to be hydroxytolyl-
mephedrone. The other detected with MH+=166 was suggestive to be dihydro-nor-mephedrone as a 
product of two steps of N-demethylation and reduction of the ketone moiety. Compared to the 
expected fragmentation pattern, with the detected fragment after MS/MS was inclusive for the 
identity of the other metabolite to be dihydro-nor-mephedrone.  None of the other suggested 
metabolites were detected, most probably due to the presence of these metabolites as intermediates 
or in concentration below the limit of detection. These findings are consistent with previously and 
recently published data about the detected metabolites of mephedrone as presented by Meyer et al. 
and Pedersen et al., though more numbered metabolites were reported. Meyer et al. reported both 
metabolites presented here, while Pedersen et al. reported only hydroxytolyl mephedrone but not the 
dihydro-nor-mephedrone. To the best of our knowledge, the detected metabolite dihydro-nor-
mephedrone was only reported by Meyer et al. as through in vivo study, while its reported here in an 
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in vitro study (Meyer et al., 2010; Pedersen et al., 2013). Though variation of the in vivo and in vitro 
system are taken into consideration, these findings are supportive for the power of in vitro metabolic 
studies as a predictive tool for the metabolic profile of NPS. 
For MXE, the detected peaks were those of the parent drug (MH+=248), one with MH+=234 and 
another peak with MH+=250. The detected peak with MH+=234 was suggestive to be O-desmethyl 
MXE as product of O-demethylation Compared to the expected fragmentation pattern, with the 
detected fragment after MS/MS, data were confirmative for the identity of the metabolite to be O-
desmethyl MXE. The other detected peak with (MH+=250) was suggestive to be either dihydro-
MXE or O-desmethyl -hydroxy--MXE. Comparative fragmentation patterns of both possible 
metabolites with the detected fragments after MS/MS analysis using SRM mode were not conclusive 
for the identity of the molecule. 
For methcathinone, we were not able to detect any of the expected metabolites. Most probably none 
were produced. In fact, potentially and theoretically methcathinone would be metabolised in a similar 
way to mephedrone. Limited data are available about the metabolism of methcathinone for 
comparison. 
Tandem MS analysis was helpful to support the proposed fragmentation pattern of the parent drugs 
and detected metabolites. Mass spectrometry and LC/MS in particular is a powerful tool for 
identification and structure elucidation, compared to the limited application of LC/DAD 
instrumentation for elucidation purposes. Analysis showed successful in vitro metabolism and 
microsomes preparation, demonstrated by the production of hydroxytolyl-mephedrone and nor-
dihydro mephedrone. For MXE, two first-time reported metabolites were presented, produced by the 
O-demethylation and the reduction of the ketone moiety to the corresponding alcohol, respectively. 
The third part of the work moved to another level of in vitro studies utilizing hepatocytes. To 
complete the spectrum of the most frequently used analytical instrumentation in forensic laboratories, 
GC-MS was utilized for the analysis of selected NPS and potentially produced metabolites. As a 
continuation of the previous work, the in vitro studies were applied to mephedrone, methcathinone 
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and methoxetamine.  4-fluoromethamphetmine, which appeared as a NPS when this work 
commenced was added to the analysis.  Up to the present time, no similar data are available about 
the metabolic profile of 4-fluoromethamphetamine. In addition, up to the present time, no similar 
data about cytotoxic effects of any of the selected NPS are available. 
Studying the selected NPS utilizing GC-MS, mephedrone and methcathinone showed nearly similar 
fragmentation patterns, comparable to each other and to the confirmed fragmentation pattern of 
cathinones. The fragmentation pattern described here is relatively similar to the published data, 
specifically about mephedrone. However, we did not find a similar description for the fragments 
produced by the loss of N-methyl group producing (M+ -15) fragments. 
For mephedrone and methcathinone, an additional peak appeared in both cases with base peak of 56. 
Previous published data described the appearance of m/z=56 as a consequence of loss of H2 of the 
iminium ion. However, the suggestion is that the identification of a molecule with base peak of 
m/z=56 is truly due to net loss of the loss of H2 and formation of ketoimine molecule at some stage 
through analysis, but not as part of the fragmentation pathway. The fragmentation pattern of 
methoxetamine is similar to previously published data, while no similar data for comparison was 
available for 4-fluoromethamphetamine. 
Utilizing HepaRG and hepatocytes for metabolic studies, we were able to identify the parent 
molecules utilizing GC-MS. It was possible to detect new peaks when studying the chromatograms 
of mephedrone and methcathinone, where in both cases the mass spectra of theses peaks were   
However, we were unable to identify any of the potential metabolites or identify any of the analysed 
peaks to be of the metabolites. Compared to previous work using microsomes as an in vitro metabolic 
system, we were able to detect metabolites of some of the selected drugs, indicating success of this 
in vitro model. However, we could not detect any metabolites using the purchased primary human 
hepatocytes and HepaRG cell lines. That is most probably due to the previously discussed drawbacks 
of these in vitro metabolizing models. 
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Primary human hepatocytes, being currently isolated from surgically dissected liver with tumour or 
other liver diseases leads to deficiency of some liver specific functions, especially P450 enzymatic 
activity and also they may lose some of their metabolizing functions when they are in the suspension 
form as they lose their naturally occurring polarity. HepaRG cell lines which are originally taken 
from a liver tumour of a human donor with chronic hepatitis C also has limitations, mainly being of 
a particular genotype affecting the type of produced drug-metabolizing enzymes. Some genotypes 
such as CYP1A2, CYP2A6 and even CYP2D6 are poorly expressed in HepaRG cells which in turn 
leads to reduction in their metabolic capacity of the selected drugs. 
HepaRG cell line was utilized for the assessment of cytotoxic effects of the selected NPS, 
demonstrated by cell death. Collected data showed that, within the specified range, 4FMA showed 
the most potent effect with EC50 value of 0.2323 mM (39 µg/ml) while mephedrone showed the least 
toxic effects with EC50 value of 0.6297 mM (111 µg/ml). This is compared to methoxetamine with 
EC50 value of 0.3211 mM (79 µg/ml) and methcathinone with EC50 value of 0.3687 mM (60 µg/ml). 
No similar data was available for comparison of methoxetamine toxic effects, while for other drugs, 
results were comparably lower than reported EC50 for amphetamines, cathinones, and related drugs 
in in vitro studies.
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Future work 
Drugs abuse is a serious and historical problem that needs continuous close observation and 
multidisciplinary work to dry its resources. The sharp skills and knowledge acquired through this 
research together with my medical background and close work with drug abuse prevention authorities 
in my home country are believed to strengthen my intention and future plans to integrate all efforts 
and focus them toward the benefit of society. 
As an of the thesis research work, further research work is needed to keep pace with the rapidly 
appearing ‘NPS’. Success of the in vitro system as a predictive tool for the toxicological profile of 
NPS, either through detecting the metabolites or their cytotoxic effects, mandate more consideration 
and optimization for this kind of non-invasive, relatively cheap, informative and ethically acceptable 
approach. Though this kind of approach is well established in the pharmaceutical industry compared 
with their use in forensic sciences, they are not less useful for the prediction of clinical and 
toxicological profiles of drugs of abuse. 
Through this thesis, the phenomenon of keto-enol tauterism was raised as an issue when analysing 
the selected beta-ketoamine selected NPS using GC-MS. Keto-enol tauterism is well discussed in 
literature, but limited information is available about it regarding drugs of abuse in general. Thermal 
instability of these molecules was an issue raised as well, represented by production of different, yet 
comparable, fragmentation patterns.  The importance of this phenomenon is the different 
fragmentation pattern that will arise which may –if not considered – affect the interpretation of data 
and quality of results.   Further studies are needed to estimate and quantify the effect of these 
phenomena for the selected NPS and related NPS. 
In vitro cytotoxicity studies using HepaRG cell lines were informative about the cytotoxic effects 
that selected NPS may have on cells resembled by cell death. This type of studies is helpful as 
preliminary evaluation step. Future studies may include study of the cytotoxic effects selectively on 
different type of cells (i.e. brain, liver, etc. …) as a predictive tool for local and systematic effects of 
NPS. 
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Wide selection of NPS is intended, with continually updating the list of included drugs to keep pace 
with newly appearing one. This climate of the emergence of new drugs of abuse mandates robust, 
easy to prepare and relatively cheap optimised analytical approaches.   
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Figure A.74: linearity curves for selected NPS at zero time incubation with HepaRG after LLE. 
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